HTTP 200 OK
Allow: GET, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept
{
"count": 1453,
"next": "https://mitotox.org/api/compounds/list?format=api&page=11",
"previous": "https://mitotox.org/api/compounds/list?format=api&page=9",
"results": [
{
"compound_ID": "D0926",
"name": "fenchlorphos",
"synonyms": "Fenchlorphos; RONNEL; Fenclofos; Dermafos; Fenchlorfos; 299-84-3; Phenchlorfos; Ectoral; Etrolene; Korlane; Nanchor; Trolene; Viozene; Blitex; Korlan; Nanker; Nankor; Remelt; Rovan; Trichlorometafos; Gesektin K; Fenchloorfos; Dermaphos; Trolene 20L; Trichlormetaphos; Dow ET 14; Dow ET 57; Fenchlorfosu; Fenchlorophos; Dermafosu; Smear; Moorman's Medicated Rid-Ezy; Dermafosu [Polish]; OMS 123; ET 14; ET 57; Ronnel [ANSI]; Ronnel [USAN]; Fenchlorphos [ISO]; Fenchloorfos [Dutch]; Caswell No. 724; Fenchlorfosu [Polish]; Trolen; ENT 23,284; Fenclofosum [INN-Latin]; UNII-89RAG7SB3B; Dimethyl trichlorophenyl thiophosphate; HSDB 667; Phosphorothioic acid, O,O-dimethyl O-(2,4,5-trichlorophenyl) ester; NSC 8926; EINECS 206-082-6; EPA Pesticide Chemical Code 058301; BRN 1885571; Dimethyl (2,4,5-trichlorophenyl) phosphorothionate; 89RAG7SB3B; AI3-23284; O,O-Dimethyl O-(2,4,5-trichlorophenyl) phosphorothioate; CHEBI:82125; JHJOOSLFWRRSGU-UHFFFAOYSA-N; Fenclofos (INN); Fenclofos [INN]; Phenol, 2,4,5-trichloro-, O-ester with O,O-dimethyl phosphorothioate; O,O-Dimethyl O-(2,4,5-trichlorophenyl)thiophosphate; Ronnel (USAN); O,O-Dimethyl-O-(2,4,5-trichlorphenyl)-thionophosphat; O-(2,4,5-Tricloro-fenil)-O,O-dimetil-monotiofosfato; O-(2,4,5-Trichloor-fenyl)-O,O-dimethyl-monothiofosfaat; O-(2,4,5-Trichlor-phenyl)-O,O-dimethyl-monothiophosphat; NCGC00163886-02; NCGC00163886-03; O,O-Dimethyl-O-(2,4,5-trichlorphenyl)-thionophosphat [German]; O-(2,4,5-Tricloro-fenil)-O,O-dimetil-monotiofosfato [Italian]; O-(2,4,5-Trichloor-fenyl)-O,O-dimethyl-monothiofosfaat [Dutch]; O-(2,4,5-Trichlor-phenyl)-O,O-dimethyl-monothiophosphat [German]; Thiophosphate de o,o-dimethyle et de o-(2,4,5-trichlorophenyle); Phenol, 2,4,5-trichloro-, O-ester with O,O-dimethylphosphorothioate; Thiophosphate de O,O-dimethyle et de O-(2,4,5-trichlorophenyle) [French]; DSSTox_CID_14885; DSSTox_RID_79218; DSSTox_GSID_34885; Fenclofosum; Fenclos; CAS-299-84-3; dimethoxy-sulfanylidene-(2,4,5-trichlorophenoxy)-?^{5}-phosphane; Trichlorometaphos; FENCLORFOS; Ronnel, analytical standard; SCHEMBL19438; Moor Man's Medicated Rid-Ezy; CHEMBL1871418; DTXSID2034885; NSC8926; HMS2093B20; HY-B1093; NSC-8926; Tox21_113416; Tox21_113425; Tox21_301334; O,4,5-trichlorophenyl) thiophosphate; AKOS015888330; Tox21_113416_1; CCG-213503; CS-4660; DB11456; O,4,5-trichlorophenyl) phosphorothioate; Phosphorothioic acid, O,O-dimethyl O-(2,4,5-trichlorophenyl) ester (8CI)(9CI); NCGC00163886-01; NCGC00163886-05; NCGC00255659-01; Fenchlorphos 10 microg/mL in Cyclohexane; Thiophosphate de O,4,5-trichlorophenyle); Fenchlorphos 100 microg/mL in Cyclohexane; SBI-0206816.P001; WLN: GR BG DG EOPS & O1 & O1; LS-108887; C18986; D05753; AB01563101_01; Dimethyl (2,5-trichlorophenyl) phosphorothionate; Fenchlorphos, PESTANAL(R), analytical standard; Dimethyl O-(2,4,5-trichlorophenyl) thiophosphate; J-017721; O-(2,5-Tricloro-fenil)-O,O-dimetil-monotiofosfato; Q1853255; O,O-Dimethyl O-(2,4,5-trichlorophenyl) thiophosphate; O-(2,5-Trichloor-fenyl)-O,O-dimethyl-monothiofosfaat; O-(2,5-Trichlor-phenyl)-O,O-dimethyl-monothiophosphat; O,O-Dimethyl O-(2,4,5-trichlorophenyl) phosphorothionate; methyl 2,4,5-trichlorophenyl methoxy(sulfanylidene)phosphonite; Phosphorothioic acid,O-dimethyl O(2,4,5-trichlorophenyl) ester; dimethoxy-sulfanylidene-(2,4,5-trichlorophenoxy)-$l^{5-phosphane; Phenol,4,5-trichloro-, O-ester with O,O-dimethyl phosphorothioate; Phosphorothioic acid,O-dimethyl O-(2,4,5-trichlorophenyl) ester; Phosphorothioic acid, O,O-dimethyl O-(2,4,5-trichlorophenyl) ester (8CI); phosphorothioic acid, O-(2,4,5-trichlorphenyl)-, O,O-dimethyl ester;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C8H8Cl3O3PS",
"molecular_weight": "321.5",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "9298",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01937",
"RC02558",
"RC03179"
]
},
{
"compound_ID": "D0927",
"name": "fendiline hydrochloride",
"synonyms": "Fendiline hydrochloride; 13636-18-5; Fendiline HCl; Fendiline (hydrochloride); MLS000069570; 3,3-diphenyl-N-(1-phenylethyl)propan-1-amine hydrochloride; NCGC00094891-01; SMR000058827; DSSTox_CID_25860; DSSTox_RID_81180; DSSTox_GSID_45860; SR-01000003123; NCGC00018223-06; 3,3-diphenyl-N-(1-phenylethyl)propan-1-amine;hydrochloride; Prestwick_568; Sensit (TN); fendiline-hydrochloride; Fendiline(hydrochloride); Opera_ID_555; CAS-13636-18-5; MLS001076126; MLS002222223; SCHEMBL666530; SPECTRUM1501026; CHEMBL1405922; DTXSID2045860; CTK8F9736; REGID_for_CID_5702162; HMS1568F22; HMS1921D11; Pharmakon1600-01501026; HY-B0984; KS-00001F9U; Tox21_111351; CCG-40224; NSC757826; s5279; AKOS030526089; Tox21_111351_1; API0008517; CS-4475; NSC-757826; NCGC00094891-02; NCGC00094891-03; NCGC00094891-04; DB-042340; FT-0630407; D07943; A807067; C-20665; J-006837; SR-01000003123-3; SR-01000003123-4; Q27279890; N-(3,3-Diphenylpropyl)-?-methylbenzylamine hydrochloride; 3,3-diphenyl-N-(1-phenylethyl)-1-propanamine hydrochloride; Benzenepropanamine, gamma-phenyl-N-(1-phenylethyl)-, hydrochloride (1:1);",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C23H26ClN",
"molecular_weight": "351.9",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5702162",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01938",
"RC02559",
"RC03180"
]
},
{
"compound_ID": "D0928",
"name": "fenhexamid",
"synonyms": "Fenhexamid; 126833-17-8; N-(2,3-Dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide; Elevate; Teldor; Fenhexamide; KBR 2738; Fenhexamid [ISO:BSI]; UNII-Q68C3C9P1U; Cyclohexanecarboxamide, N-(2,3-dichloro-4-hydroxyphenyl)-1-methyl-; HSDB 7273; Q68C3C9P1U; CHEBI:81853; N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexane-1-carboxamide; N-(2,3-dichloro-4-hydroxy-phenyl)-1-methyl-cyclohexanecarboxamide; Q63395375; KBR-2738; DSSTox_CID_12549; DSSTox_RID_78978; DSSTox_GSID_32549; SCHEMBL23092; CHEMBL1688541; DTXSID3032549; VDLGAVXLJYLFDH-UHFFFAOYSA-N; ZINC2384330; Tox21_301042; AKOS015903660; Fenhexamid 10 microg/mL in Cyclohexane; KS-000017Q3; NCGC00163791-01; NCGC00163791-02; NCGC00163791-03; NCGC00254944-01; LS-56568; AX8130220; CAS-126833-17-8; F0967; FT-0668488; Fenhexamid, PESTANAL(R), analytical standard; C18593; J-005440; 2',3'-dichloro-4'-hydroxy-1-methylcyclohexanecarboxanilide;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C14H17Cl2NO2",
"molecular_weight": "302.2",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "213031",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01939",
"RC02560",
"RC03181"
]
},
{
"compound_ID": "D0929",
"name": "fenobam",
"synonyms": "Fenobam; 57653-26-6; NCGC00092384-02; McN-3377-98; N-(3-Chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazol-2-yl)urea; DSSTox_CID_26770; DSSTox_RID_81892; DSSTox_GSID_46770; UNII-078RCY7I27; CHEMBL239800; Fenobamum; Fenobamum [INN-Latin]; fenobam anhydrous; Fenobam [INN]; CAS-57653-26-6; 078RCY7I27; Urea, N-(3-chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazol-2-yl)-; 1-(3-chlorophenyl)-3-(1-methyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl)urea; DTXSID5046770; CHEBI:92728; HMS3413I16; HMS3677I16; NPL 2009; Tox21_112624; Tox21_113516; Tox21_500842; BDBM50105838; BN0209; MFCD00868019; AKOS022488647; Tox21_112624_1; DB12931; MCULE-9260864714; MCN 3377-98; NCGC00092384-01; NCGC00092384-03; NCGC00261527-01; CC-28382; HY-101478; LS-193274; B7035; CS-0021515; C-16725; BRD-K41160163-001-01-9; n-(3-chlorophenyl)-n'-(1-methyl-4-oxo-4,5-dihydro-1h-imidazol-2-yl)urea; 1-(3-Chloro-phenyl)-3-(1-methyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl)-urea; N-(3-Chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazole-2-yl)urea;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C11H11ClN4O2",
"molecular_weight": "266.68",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "135659063",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01940",
"RC02561",
"RC03182"
]
},
{
"compound_ID": "D0930",
"name": "fenretinide",
"synonyms": "FENRETINIDE; 65646-68-6; 4-HPR; N-(4-Hydroxyphenyl)retinamide; 4-hydroxyphenylretinamide; 4-Hydroxyphenyl retinamide; Retinoic acid p-hydroxyanilide; all-trans-4'-Hydroxyretinanilide; Fenretinida; Fenretinidum; McN-R-1967; 4-hydroxy(phenyl)retinamide; N-(4-Hydroxyphenyl)all-Trans Retinamide; Fenretinidum [Latin]; Fenretinida [Spanish]; 4HPR; Retinoic acid p-hydroxyphenylamide; Fenretinide [USAN:INN]; Retinamide, N-(4-hydroxyphenyl)-; UNII-187EJ7QEXL; 4-(hydroxyphenyl)retinamide; 15-[(4-hydroxyphenyl)amino]retinal; CCRIS 3260; BRN 5769490; 187EJ7QEXL; CHEMBL7301; MLS002701698; CHEBI:42588; AKJHMTWEGVYYSE-FXILSDISSA-N; MFCD00792674; NSC-374551; HPR; NCGC00090752-03; DSSTox_CID_12005; DSSTox_RID_78900; DSSTox_GSID_32005; (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide; Fenretinimide; (2E,4E,6E,8E)-N-(4-Hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenamide; SMR001456303; CAS-65646-68-6; SR-01000075917; (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide; SYT-101; ST-602; N-(4-Hydroxyphenyl)-trans-Retinamide; Fenretinide (4-HPR); N-(4-Hydroxyphenyl)-all-trans Retinamide; p-Hydroxyphenylretinamide; Spectrum5_001939; Fenretinide (USAN/INN); 4 HPR; Lopac0_000625; SCHEMBL11703; SCHEMBL11704; BSPBio_001419; MLS001055399; MLS006010811; BML2-E08; N-(4-hydroxyphenyl)-retinamide; DTXSID2032005; SCHEMBL15703189; CHEBI:92493; AOB6402; 15-(4-Hydroxyanilino)retinal #; HMS1361G21; HMS1791G21; HMS1989G21; HMS2089B17; HMS3261N12; HMS3402G21; HMS3412M06; HMS3676M06; Pharmakon1600-01505602; 4-HPR;(4-Hydroxyphenyl)retinamide; BCP06908; ZINC3871023; Tox21_111007; Tox21_200989; Tox21_500625; 1-enyl)nona-2,4,6,8-tetraenamide; 3670AH; BDBM50092055; HSCI1_000112; LS-282; NSC374551; NSC760419; s5233; AKOS024456572; Tox21_111007_1; CCG-204713; CS-0789; DB05076; LP00625; MK-4016; N-(4-hydroxyphenyl)retinamide, 4-HPR; NSC-760419; all-trans-n-(4-hydroxyphenyl)retinamide; dimethyl-9-(2,6,6-trimethylcyclohex-; IDI1_033889; Retinoic acid p-hydroxyanilide, >=95%; NCGC00090752-01; NCGC00090752-02; NCGC00090752-04; NCGC00090752-05; NCGC00090752-06; NCGC00090752-07; NCGC00090752-09; NCGC00090752-10; NCGC00090752-11; NCGC00090752-12; NCGC00258542-01; NCGC00261310-01; (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenamide; AS-59667; BP-13369; HY-15373; SC-76490; SMR000677938; AB0109574; EU-0100625; FT-0081247; A12163; D04162; H 7779; W-5119; (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-; 33819-EP2275420A1; 33819-EP2295055A2; 33819-EP2295406A1; 33819-EP2295416A2; 33819-EP2295426A1; 33819-EP2295427A1; 33819-EP2298748A2; 33819-EP2298764A1; 33819-EP2298765A1; 33819-EP2305642A2; 33819-EP2311453A1; 33819-EP2311808A1; 33819-EP2311829A1; AB00172992-07; 646F686; A835178; Q5443576; SR-01000075917-1; SR-01000075917-4; 4-(HYDROXYPHENYL)-RETINAMIDE (SEE RETINOID PROJECTS 1 AND 2.); RETINOID PROJECT 6 (4-HPR) (SEE RETINOID PROJECTS 1,2,3,4,5); RETINOID PROJECT 2 (4-(HYDROXYPHENYL)RETINAMIDE) (SEE RETINOID PROJECT 1,3,4, 5,6); RETINOID PROJECT 4 (4-HYDROXYPHENYL)RETINAMIDE (SEERETINOID PROJECT 1, 2, AND 3); RETINOID PROJECT 5 (4-HYDROXYPHENYL)RETINAMIDE (SEERETINOID PROJECT 1, 2, 3, 4); (2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenoic acid (4-hydroxy-phenyl)-amide; 2,6,8-Nonatetraenamide, N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl-, (all-E)-; 3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenoic acid (4-hydroxy-phenyl)-amide; N-(4-Hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraeneamide;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C26H33NO2",
"molecular_weight": "391.5",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5288209",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01941",
"RC02562",
"RC03183"
]
},
{
"compound_ID": "D0931",
"name": "fentiazac",
"synonyms": "FENTIAZAC; Donorest; Flogene; 18046-21-4; Norvedan; BR 700; UNII-0YHF6E6NLS; Fentiazacum [INN-Latin]; Fentiazaco [INN-Spanish]; 2-(4-(4-chlorophenyl)-2-phenylthiazol-5-yl)acetic acid; 4-(p-Chlorophenyl)-2-phenyl-5-thiazoleacetic acid; EINECS 241-958-1; CH 800; 0YHF6E6NLS; NSC 282191; C17H12ClNO2S; 4-(4-Chlorophenyl)-2-phenyl-5-thiazoleacetic acid; BRN 1083610; 5-Thiazoleacetic acid, 4-(p-chlorophenyl)-2-phenyl-; 5-Thiazoleacetic acid, 4-(4-chlorophenyl)-2-phenyl-; MLS003115545; WY 21,894; CHEMBL589092; NCGC00182976-01; NCGC00183868-01; 2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]acetic acid; DSSTox_CID_3050; DSSTox_RID_76852; DSSTox_GSID_23050; Fentiazaco; Fentiazacum; CAS-18046-21-4; SR-05000001476; Fentiazac [USAN:BAN:INN:JAN]; Fentiazac [USAN:INN:BAN:JAN]; SCHEMBL24355; Fentiazac (JAN/USAN/INN); ZINC1444; DTXSID8023050; CHEBI:94523; JIEKMACRVQTPRC-UHFFFAOYSA-; HMS2089J20; HMS3713O10; Tox21_111788; Tox21_113218; Tox21_113219; BDBM50309254; MFCD00866039; NSC282191; Tox21_111788_1; API0002696; CCG-220474; DB13217; NSC-282191; ACM18046214; NCGC00183868-02; CC-28404; SMR001831119; WY-21894; DB-044397; LS-150718; WY-21,894; FT-0630446; D01975; AB01087413-03; C-19991; 2-phenyl-4-(p-chlorophenyl)thiazol-5-ylacetic acid; Q3742491; SR-05000001476-1; SR-05000001476-2; 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid; [4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]acetic acid; InChI=1/C17H12ClNO2S/c18-13-8-6-11(7-9-13)16-14(10-15(20)21)22-17(19-16)12-4-2-1-3-5-12/h1-9H,10H2,(H,20,21);",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C17H12ClNO2S",
"molecular_weight": "329.8",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "28871",
"classification": "M",
"indications": "",
"side_effects": "",
"atc_codes": "M02AA14; M01AB10",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01942",
"RC02563",
"RC03184"
]
},
{
"compound_ID": "D0932",
"name": "fenticlor",
"synonyms": "Fenticlor; 97-24-5; 2,2'-THIOBIS(4-CHLOROPHENOL); Bis(2-hydroxy-5-chlorophenyl) sulfide; Fentichlor; Novex; Phentichlorum; Meflorin; Ovitrol; Bis(2-hydroxy-5-chlorophenyl)sulfide; Oksid; Fenticloro; Fenticlorum; D 25-Antimykotikum; Phenol, 2,2'-thiobis[4-chloro-; S 7 (antimycotic); 2,2'-Dihydroxy-5,5'-dichlorodiphenyl sulfide; 2,2'-Dihydroxy-5,5'-dichlorophenyl sulfide; Ph 549; 5,5'-Dichloro-2,2'-dihydroxydiphenyl sulfide; Caswell No. 851; CR 305; 2,2'-sulfanediylbis(4-chlorophenol); HL 1050; D 25; Fenticlorum [INN-Latin]; Fenticloro [INN-Spanish]; NSC55636; NSC 55636; 2,2'-Thiobis4-chlorophenol; Fenticlor [USAN:INN:BAN]; UNII-D61659OVD0; CCRIS 4731; S 7 (VAN); CHEBI:556580; D 25 (VAN); Phenol, 2,2'-thiobis(4-chloro-; NSC 4112; EINECS 202-568-7; S 7; EPA Pesticide Chemical Code 064209; BRN 2057140; C12H8Cl2O2S; AI3-08456; MLS002415676; 2,2'-Thiobis[4-chlorophenol]; ANUSOIHIIPAHJV-UHFFFAOYSA-N; D61659OVD0; component of Banish; NSC-4112; NSC-55636; NCGC00013679-02; SMR000145265; DSSTox_CID_6137; DSSTox_RID_78031; 2,5'-dichlorophenyl sulfide; 4-chloro-2-(5-chloro-2-hydroxyphenylthio)phenol; DSSTox_GSID_26137; 2,5'-dichlorodiphenyl sulfide; 4-chloro-2-[(5-chloro-2-hydroxyphenyl)thio]phenol; Phenol,2'-thiobis[4-chloro-; WLN: QR DG BSR BQ EG; 5,2'-dihydroxydiphenyl sulfide; 2,2 -thiobis(4-chlorophenol); CAS-97-24-5; 4-chloro-2-(5-chloro-2-hydroxyphenyl)sulfanylphenol; PubChem15318; Fenticlor (USAN/INN); ACMC-209s8a; Epitope ID:131793; cid_7329; NCIStruc1_000386; NCIStruc2_000549; TimTec1_002292; Oprea1_024834; Oprea1_589846; SCHEMBL23276; 4-06-00-05645 (Beilstein Handbook Reference); ARONIS001661; CHEMBL473535; 4-chloro-2-(5-chloro-2-hydroxy-phenyl)sulfanyl-phenol; 4-chloro-2-[(5-chloro-2-hydroxyphenyl)sulfanyl]phenol; component of Banish (Salt/Mix); DTXSID4026137; ANUSOIHIIPAHJV-UHFFFAOYSA-; BDBM80984; CTK8B2784; NSC4112; HMS1540I04; KUC106499N; ZINC136146; 4,4'-dichloro-2,2'-thiodiphenol; ALBB-012859; KS-00003V2Q; NCI55636; Tox21_110031; Tox21_200961; ANW-40856; BBL003411; CCG-37773; NCGC00013679; STK048543; AKOS000491331; Tox21_110031_1; Bis(5-chloro-2-hydroxyphenyl) Sulfide; KSC-19-058; LS-2024; MCULE-9101515986; VZ35833; bis-(2-hydroxy-5-chlorophenyl) sulfide; KS-0000134I; NCGC00013679-03; NCGC00013679-04; NCGC00013679-06; NCGC00091879-01; NCGC00091879-02; NCGC00258514-01; AS-13478; I412; NCI60_004363; ST029256; 2,2'-THIOBIS(4-CHLORO- PHENOL); AB0013676; DB-022656; TR-031067; B0850; FT-0683643; R1614; ST24027234; D04164; SR-01000878241; Q5443595; SR-01000878241-2; W-100113; 4-chloro-2-[(5-chloro-2-hydroxy-phenyl)thio]phenol; BRD-K19439093-001-01-0; 4-chloranyl-2-(5-chloranyl-2-oxidanyl-phenyl)sulfanyl-phenol; InChI=1/C12H8Cl2O2S/c13-7-1-3-9(15)11(5-7)17-12-6-8(14)2-4-10(12)16/h1-6,15-16H;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C12H8Cl2O2S",
"molecular_weight": "287.2",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "7329",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01943",
"RC02564",
"RC03185"
]
},
{
"compound_ID": "D0933",
"name": "fenuron",
"synonyms": "FENURON; 1,1-Dimethyl-3-phenylurea; 101-42-8; Falisilvan; Urea, N,N-dimethyl-N'-phenyl-; N,N-Dimethyl-N'-phenylurea; Electrum; Fenidin; Dibar; Dybar; Amicure UR; PUD (herbicide); Omicure 94; Fikure 62U; Quintex; 3-Phenyl-1,1-dimethylurea; Croptex Chrome; Herbon Yellow; Croptex Ruby; Dyhard RU 300; Dyhard UR 300; N-Phenyl-N',N'-dimethylurea; 1-Phenyl-3,3-dimethylurea; Caswell No. 457; Urea, 1,1-dimethyl-3-phenyl-; Fenuron [ANSI:BSI:ISO]; UNII-O7L040435W; HSDB 6639; EINECS 202-941-4; EPA Pesticide Chemical Code 035507; BRN 2208535; CHEBI:5013; XXOYNJXVWVNOOJ-UHFFFAOYSA-N; Fenuron;1,1-Dimethyl-3-phenylurea; O7L040435W; PUD; (dimethylamino)-N-benzamide; 1,1-Dimethyl-3-phenylurea, analytical standard; 3,3-dimethyl-1-phenylurea; Fenulon; 1,1-dimethyl-3-phenyl-urea; Maybridge4_003841; DSSTox_CID_17551; DSSTox_RID_79334; DSSTox_GSID_37551; SCHEMBL62004; MLS000861661; N-phenyl-N',N'-dimethyl urea; CHEMBL1492698; DTXSID7037551; SCHEMBL21049119; ZINC97471; HMS1531O13; HMS2809O05; BCP30318; Tox21_300902; 0384AA; CCG-54419; MFCD00025662; SBB058215; STK399737; Fenuron 10 microg/mL in Acetonitrile; AKOS001178467; MCULE-4375507264; NCGC00163883-01; NCGC00163883-02; NCGC00163883-03; NCGC00254806-01; AS-59690; CAS-101-42-8; SMR000460445; Fenuron, PESTANAL(R), analytical standard; LS-160027; TR-000379; FT-0631536; ST24036606; ST50410378; C11224; 33330-EP2305655A2; 33330-EP2311815A1; 33330-EP2371823A1; J-000390; Q3742493; SR-01000643516-1; BRD-K32813024-001-01-3;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C9H12N2O",
"molecular_weight": "164.2",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "7560",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01944",
"RC02565",
"RC03186"
]
},
{
"compound_ID": "D0934",
"name": "fenvalerate",
"synonyms": "fenvalerate; 51630-58-1; Pydrin; Phenvalerate; Sumicidin; Belmark; Aqmatrine; Phenoxin; Agrofen; Ectrin; Fenaxin; Fenkem; Fenkill; Fenoxin; Fenval; Tirade; Furitrothion; Insectral; Sanmarton; Sumibac; Sumifleece; Sumifly; Sumipower; Sumitick; Sumkidin; Tribute; Evercide 2362; Gold crest tribute; Sumicidin 20E; Cyano(3-phenoxyphenyl)methyl 2-(4-chlorophenyl)-3-methylbutanoate; Caswell No. 077A; Fenvalerate [BSI:ISO]; C25H22ClNO3; Fenvalerate-d5; CCRIS 311; Asana; alpha-Cyano-3-phenoxybenzyl alpha-(4-chlorophenyl)isovalerate; WL 43775; HSDB 6640; EPA Shaughnessy Code: 109301; OMS-2000; EINECS 257-326-3; S-5602; BRN 2025982; SD 43775; AI3-29235; alpha-Cyano-3-phenoxybenzyl 2-(4-chlorophenyl)isovalerate; CHEBI:5014; NYPJDWWKZLNGGM-UHFFFAOYSA-N; S 5602; Fenvalerate A-beta; 4-Chloro-alpha-(1-methylethyl)benzeneacetic acid cyano(3-phenoxyphenyl)methyl ester; alpha-Cyano-3-phenoxybenzyl-2-(4-chlorophenyl)-3-methylbutyrate; alpha-Cyano-3-phenoxybenzyl alpha-isopropyl-4-chlorophenylacetate; DSSTox_CID_621; S 5602A-beta; (+)-alpha-Cyano-3-phenoxybenzyl-(+)-alpha-(4-chlorophenyl)isovalerate; [cyano-(3-phenoxyphenyl)methyl] 2-(4-chlorophenyl)-3-methylbutanoate; (Cyano(3-phenoxyphenyl)methyl-4-chloro-alpha-(1-methylethyl)phenylacetate); (RS)-alpha-Cyano-3-phenoxybenzyl (RS)-2-(4-chlorophenyl)-3-methylbutyrate; alpha-Cyano-(3-phenoxyphenyl)methyl-4-chloro-alpha-(1-methylethyl)benzeneacetate; Cyano(3-phenoxyphenyl)methyl 4-chloro-alpha-(1-methylethyl)benzeneacetate; Benzeneacetic acid, 4-chloro-.alpha.-(1-methylethyl)-, cyano(3-phenoxyphenyl)methyl ester; DSSTox_RID_75696; DSSTox_GSID_20621; Halmark; W-111022; Sumi-alfa; fenvalarate; Asana XL; Sumi-.alpha.; Cyano(3-phenoxybenzyl)methyl 2-(4-chlorophenyl)-3-methylbutyrate; Fenvalerate .alpha.; cyano[3-(phenyloxy)phenyl]methyl 2-(4-chlorophenyl)-3-methylbutanoate; (RS)-alpha-Cyano-3-phenoxybenzyl (RS)-2-(4-chloro-phenyl)-3-methylbutyrate; Sumicidin A .alpha.; Benzeneacetic acid, 4-chloro-alpha-(1-methylethyl)-, cyano(3-phenoxyphenyl)methyl ester; BRN 5857755; Fenvalerate A .alpha.; Benzeneacetic acid, 4-chloro-.alpha.-(1-methylethyl)-, (S)-cyano(3-phenoxyphenyl)methyl ester, (.alpha.S)-; Benzeneacetic acid, 4-chloro-.alpha.-(1-methylethyl)-, cyano (3-phenoxyphenyl)methyl ester,(S-(R*,R*))-; CAS-51630-58-1; Fenvalerate (pydrin); S 5602 A .alpha.; S 5602B-alpha; 67614-33-9; Fenvalerate [INN:BAN]; S 5602B-beta; fenvaierate; OMS 3023; pydrin, (R-(R*,S*))-isomer; Fenvalerate E.C.; 67614-32-8; Benzeneacetic acid, 4-chloro-alpha-(1-methylethyl)-, cyano(3-phenoxyphenyl)methyl ester, (R-(R*,S*))-; Acadrex (TN); Fenvalerate (BAN); (+-)-Fenvalerate; S 1844; Fenvalerate, >=97%; SCHEMBL26911; (S)-alpha-Cyano-3-phenoxybenzyl(S)-2-(4-chlorophenyl)isovalerate; Cyano(3-phenoxyphenyl)methyl 2-(4-chlorophenyl)-3-methylbutanoate #; BMK1-H10; CHEMBL492491; (S)-.alpha.-Cyano-3-phenoxybenzyl(S)-2-(4-chlorophenyl)-3-methylbutyrate; DTXSID3020621; NIOSH/CY1576360; CTK8E5624; alpha-Cyano-3-phenoxybenzyl-alpha-(4-chlorophenyl)isovalerate; Cyano (3-phenoxybenzyl)-2-(4-chlorophenyl)-3-methylbutyrate; alpha-cyano-3-phenoxybenzyl 2-(4-chlorophenyl)-3- methylbutyrate; alpha-cyano-3-phenoxybenzyl alpha-isopropyl-4-chlorophenyl acetate; Tox21_201838; Tox21_302957; GL6974; HSCI1_000043; MFCD00055324; AKOS015904814; Fenvalerate 10 microg/mL in Isooctane; LS-7394; Fenvalerate 100 microg/mL in Isooctane; NCGC00163508-01; NCGC00163508-02; NCGC00163508-03; NCGC00256483-01; NCGC00259387-01; AC-22281; AS-49365; Benzeneacetic acid, 4-chloro-.alpha.-(1-methylethyl)-, (R)-cyano(3-phenoxyphenyl)methyl ester, (.alpha.S)-; Benzeneacetic acid, 4-chloro-alpha-(1-methylethyl)-, cyano(3-phenoxyphenyl)methyl ester, (R-(R*,R*))-; Benzeneacetic acid, 4-chloro-alpha-(1-methylethyl)-, cyano(3-phenoxyphenyl)methyl ester, (S-(R*,S*))-; CC-28411; Fenvalerate 10 microg/mL in Acetonitrile; H653; LS-28682; LS-28683; LS-28685; SC-18544; ACM1246815008; AX8021157; TR-018390; 533-EP2274983A1; 533-EP2275422A1; 533-EP2280009A1; 533-EP2292608A1; 533-EP2305658A1; 533-EP2308857A1; 533-EP2308858A1; 533-EP2311816A1; 533-EP2311817A1; 533-EP2314583A1; CY15763600; FT-0630648; C10988; D07952; Fenvalerate, PESTANAL(R), analytical standard; 630F581; C-22054; Q412010; Fenvalerate, certified reference material, TraceCERT(R); a-Cyano-3-phenoxybenzyl 2-(4-chlorophenyl)-3-methylbutyrate; alpha-Cyano-3-phenoxybenzyl alpha-(4-chlorophenyl)-iso-valerate; alpha-cyano-m-phenoxybenzyl 2-(p-chlorophenyl)-3-methylbutyrate; alpha-cyano-3-phenoxy-benzyl 2-(p-chlorophenyl)-2-isopropyl-acetate; alpha-cyano-3-phenoxybenzyl 2-(4-chlorophenyl)-3-methylbutanoate; alpha-cyano-3-phenoxybenzyl 2-(4-chlorophenyl)-3-methylbutyrate; Cyano(3-phenoxyphenyl)methyl 4-chloro-a-(1-methylethyl)benzeneacetate, 9CI; (+-)-4-Chloro-alpha-(1-methylethyl)benzeneacetic acid cyano(3-phenoxyphenyl)methyl ester; [(S)-cyano-(3-phenoxyphenyl)methyl] (2R)-2-(4-chlorophenyl)-3-methylbutanoate; Cyano(3-phenoxyphenyl)methyl ester, 4-chloro-alpha-(1-methylethyl)benzeneacetic acid; Benzeneacetic acid, 4-chloro-alpha-(1-methylethyl)-, cyano(3-phenoxyphenyl)methyl ester, (+-)-; Benzeneacetic acid, 4-chloro-alpha-(1-methylethyl)-, cyano(3-phenoxyphenyl)methyl ester,(R-(R*,S*))-;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C25H22ClNO3",
"molecular_weight": "419.9",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "3347",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01945",
"RC02566",
"RC03187"
]
},
{
"compound_ID": "D0935",
"name": "flopropione",
"synonyms": "flopropione; 2295-58-1; 2',4',6'-Trihydroxypropiophenone; Phloropropiophenone; Cospanon; Phloropropionone; Propiophloroglucine; Flopropion; Argobyl; Chlonarin; Ecapron; Gasstenon; Labroda; Labrodax; Supanate; Supazlun; Labrodax supanate; 1-(2,4,6-trihydroxyphenyl)propan-1-one; Propionylphloroglucinol; 1-Propanone, 1-(2,4,6-trihydroxyphenyl)-; 1-(2,4,6-Trihydroxyphenyl)-1-propanone; 2,4,6-Trihydroxypropiophenone; RP 13907; Flopropionum [INN-Latin]; Flopropiona [INN-Spanish]; UNII-05V5NVB5Y1; NSC 97909; Flopropione [INN:DCF:JAN]; 13907 R. P.; PROPIOPHENONE, 2',4',6'-TRIHYDROXY-; EINECS 218-942-8; BRN 2096799; AI3-36955; 05V5NVB5Y1; PTHLEKANMPKYDB-UHFFFAOYSA-N; NCGC00094817-01; AK161699; DSSTox_CID_25851; DSSTox_RID_81173; DSSTox_GSID_45851; Flopropiona; Flopropionum; Profenon; CAS-2295-58-1; Gallepronin; Flopion; Spamorin; Spasmoril; Pasmus; Phlopropiophenone; Ephtanon (TN); propanoyl-phloroglucinol; Spectrum_000563; ACMC-209fzy; Spectrum2_000954; Spectrum3_000579; Spectrum4_000391; Spectrum5_001471; 13907 R.P.; Flopropione (JP17/INN); 2,6-Trihydroxypropiophenone; SCHEMBL26316; BSPBio_001998; KBioGR_000941; KBioSS_001043; 3-08-00-03413 (Beilstein Handbook Reference); DivK1c_000482; SPECTRUM1500629; SPBio_000948; 2',6'-Trihydroxypropiophenone; ZINC1454; CHEMBL1605835; DTXSID3045851; CHEBI:31614; CTK8B1247; HMS501I04; KBio1_000482; KBio2_001043; KBio2_003611; KBio2_006179; KBio3_001498; NINDS_000482; Propiophenone,4',6'-trihydroxy-; HMS1921M05; HMS3652F21; Pharmakon1600-01500629; NSC97909; Tox21_111340; 2413AH; ANW-25004; CCG-40074; NSC-97909; NSC757392; s4249; AKOS016357612; Tox21_111340_1; CS-8184; FCH1118903; MCULE-8049309136; NSC-757392; VZ21793; IDI1_000482; NCGC00094817-02; NCGC00094817-03; NCGC00094817-05; CC-07168; SC-47917; SBI-0051564.P002; 13907 R.P; AX8006713; DB-019834; HY-100562; LS-125515; TC-113749; 13907 R. P; FT-0609878; ST24047208; SW219253-1; 1-[2,4,6-tris(oxidanyl)phenyl]propan-1-one; A16550; D01259; AB00052131_02; A816445; C-06961; SR-01000872776; Q5460218; SR-01000872776-1; BRD-K43383936-001-02-9; Glycine, L-?cysteinyl-?L-?asparaginylglycyl-?L-?arginyl-?L-?cysteinyl-; InChI=1/C9H10O4/c1-2-6(11)9-7(12)3-5(10)4-8(9)13/h3-4,10,12-13H,2H2,1H;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C9H10O4",
"molecular_weight": "182.17",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "3362",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01946",
"RC02567",
"RC03188"
]
},
{
"compound_ID": "D0936",
"name": "fluazuron",
"synonyms": "Fluazuron; 86811-58-7; UNII-VB0PV6I7L6; Fluazuron [INN]; VB0PV6I7L6; N-[[4-chloro-3-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]carbamoyl]-2,6-difluorobenzamide; CHEBI:39374; Fluazuron (INN); NCGC00166205-01; AK161763; Acatak; 1-(4-Chloro-3-((3-chloro-5-(trifluoromethyl)-2-pyridyl)oxy)phenyl)-3-(2,6-difluorobenzoyl)urea; Fluazuronum; N-((4-chloro-3-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)carbamoyl)-2,6-difluorobenzamide; N-[(4-chloro-3-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)carbamoyl]-2,6-difluorobenzamide; Fluazuronum [INN-Latin]; C20H10Cl2F5N3O3; DSSTox_CID_26556; DSSTox_RID_81716; DSSTox_GSID_46556; SCHEMBL64358; MLS004712078; CHEMBL1164608; DTXSID1046556; CTK8F9777; YOWNVPAUWYHLQX-UHFFFAOYSA-N; BCP12637; EBD48504; KS-00000G9H; ZINC2570819; Acatak Pour-ON (TN) [veterinary]; Tox21_112346; AKOS015895051; DB15583; NCGC00166205-02; AS-15518; CC-28450; P696; SMR003475024; AX8130446; CAS-86811-58-7; FT-0630946; ST24047209; Fluazuron, PESTANAL(R), analytical standard; D07964; 31388-EP2274983A1; 31388-EP2275422A1; 31388-EP2292608A1; 31388-EP2308858A1; 31388-EP2311816A1; 31388-EP2311817A1; 811F587; A841834; C-22977; Q27119837; N-(((4-Chloro-3-((3-chloro-5-(trifluoromethyl)-2-pyridinyl)oxy)phenyl)amino)carbonyl)-2,6-difluorobenzamide; 1-[4-Chloro-3-(3-chloro-5-trifluoromethyl-2-pyridyloxy)phenyl]-3-(2,6-difluorobenzoyl)urea; N-(4-chloro-3-(3-chloro-5-(trifluoromethyl)pyridin-2-yloxy)phenylcarbamoyl)-2,6-difluorobenzamide; N-[[4-chloranyl-3-[3-chloranyl-5-(trifluoromethyl)pyridin-2-yl]oxy-phenyl]carbamoyl]-2,6-bis(fluoranyl)benzamide; N-[[4-chloro-3-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]oxy]anilino]-oxomethyl]-2,6-difluorobenzamide;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C20H10Cl2F5N3O3",
"molecular_weight": "506.2",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "65651",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01947",
"RC02568",
"RC03189"
]
},
{
"compound_ID": "D0937",
"name": "flubendiamide",
"synonyms": "flubendiamide; 272451-65-7; 3-Iodo-N2-(2-methyl-1-(methylsulfonyl)propan-2-yl)-N1-(2-methyl-4-(perfluoropropan-2-yl)phenyl)phthalamide; UNII-GEV84ZI4K6; GEV84ZI4K6; CHEBI:38798; ZGNITFSDLCMLGI-UHFFFAOYSA-N; 1-N-[4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-2-methylphenyl]-3-iodo-2-N-(2-methyl-1-methylsulfonylpropan-2-yl)benzene-1,2-dicarboxamide; N(2)-[1,1-dimethyl-2-(methylsulfonyl)ethyl]-3-iodo-N(1)-{2-methyl-4-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]phenyl}benzene-1,2-dicarboxamide; N(2)-[1,1-dimethyl-2-(methylsulfonyl)ethyl]-3-iodo-N(1)-{2-methyl-4-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]phenyl}phthalamide; Flubendiamide [ISO]; HSDB 7883; DSSTox_CID_27672; DSSTox_RID_82490; DSSTox_GSID_47672; SCHEMBL27362; CHEMBL563789; DTXSID4047672; CTK8C3876; Tox21_303432; ANW-70746; ZINC43065317; AKOS016007707; ACN-053737; TRA0044303; NCGC00257277-01; 3-iodo-N-(2-methanesulfonyl-1,1-dmethylethyl)-N'-(2-methyl-4-(1,2,2,2-tetrafluoro-1-trifluoromethylethyl)phenyl)phthalamide; AX8239278; RT-012731; CAS-272451-65-7; 31423-EP2274983A1; 31423-EP2308858A1; 31423-EP2311816A1; 31423-EP2311817A1; Flubendiamide, PESTANAL(R), analytical standard; J-016707; Q17300229; 1,2-Benzenedicarboxamide, N2-[1,1-dimethyl-2-(methylsulfonyl)ethyl]-3-iodo-N1-[2-methyl-4-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]phenyl]-;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C23H22F7IN2O4S",
"molecular_weight": "682.4",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "11193251",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01948",
"RC02569",
"RC03190"
]
},
{
"compound_ID": "D0938",
"name": "flucythrinate",
"synonyms": "FLUCYTHRINATE; 70124-77-5; Fluorocythrin; CyBolt; Pay-Off; Cythrin; Guardian; Funchiong jujr; Stock Guard; Pay Off; Caswell No. 002AA; AC 222705; Flucythrinate [ANSI:BSI:ISO]; HSDB 6647; EINECS 274-322-7; EPA Pesticide Chemical Code 118301; BRN 2195795; GBIHOLCMZGAKNG-UHFFFAOYSA-N; [cyano-(3-phenoxyphenyl)methyl] 2-[4-(difluoromethoxy)phenyl]-3-methylbutanoate; alpha-Cyano-3-phenoxybenzyl 4-difluoromethoxy-alpha-isopropylphenylacetate; Cyano(3-phenoxyphenyl)methyl 4-(difluoromethoxy)-alpha-(1-methylethyl)benzeneac; (+-)-alpha-Cyano-m-phenoxy-benzyl (+)-2-(p-difluoromethoxy)phenyl-3-methylbutyrate; (+-)-Cyano(3-phenoxyphenyl)methyl (+)-(4-difluoromethoxy)-alpha-(1-methylethyl)benzeneacetate; (+-)-Cyano(3-phenoxyphenyl)methyl(+)-4-(difluoromethoxy)-alpha-(1-methylethyl)benzeneacetate; (+-)-cyano-(3-phenoxyphenyl)methyl (+)-4-(difluoromethoxy)-alpha-(methylethyl)benzeneacetate; (RS)-alpha-Cyano-3-phenoxybenzyl (S)-2-(4-difluoromethoxyphenyl)-3-methylbutyrate; (RS)-Cyano-(3-phenoxyphenyl)methyl (S)-4-(difluoromethoxy)-alpha-(1-methylethyl)benzeneacetate; 4-(Difluoromethoxy)-alpha-(1-methylethyl)benzeneacetic acid cyano(3-phenoxy-phenyl)methyl ester; Benzeneacetic acid, 4-(difluoromethoxy)-.alpha.-(1-methylethyl)-, cyano(3-phenoxyphenyl)methyl ester; Benzeneacetic acid, 4-(difluoromethoxy)-alpha-(1-methylethyl)-, cyano(3-phenoxyphenyl)methyl ester; Cyano(3-phenoxyphenyl)methyl 2-(4-(difluoromethoxy)phenyl)-3-methylbutyrate; (+-)-Cyano-(3-phenoxyphenyl)methyl (+)-4-(difluoromethoxy)-alpha-(1-methylethyl)benzeneacetate; Fludioxanil; cyano(3-phenoxyphenyl)methyl 2-(4-(difluoromethoxy)phenyl)-3-methylbutanoate; Cyano(3-phenoxyphenyl)methyl 2-[4-(difluoromethoxy)phenyl]-3-methylbutanoate; Flucythrinate E.C.(10%); Fluorocythrin E.C.(10%); SCHEMBL682196; CHEMBL2289397; CTK8E5623; AKOS015902545; Cyano(3-phenoxyphenyl)methyl 2-[4-difluoromethoxy)phenyl]-3-methylbutyrate; AC-12669; Flucythrinate 100 microg/mL in Isooctane; LS-28745; SC-74644; Flucythrinate 10 microg/mL in Cyclohexane; DB-055378; TR-023263; FT-0630796; C14524; Flucythrinate, PESTANAL(R), analytical standard; Q1430580; alpha-Cyano-m-phenoxybenzyl alpha-Isopropyl-4-difluoromethoxyphenylacetate; (+)-alpha-cyano-m-phenoxybenzyl (+)-alpha-isopropyl-4-difluoromethoxyphenylacetate; [cyano-(3-phenoxyphenyl)methyl] 2-[4-(difluoromethoxy)phenyl]-3-methyl-butanoate; Cyano(3-phenoxyphenyl)methyl 2-[4-(difluoromethoxy)phenyl]-3-methylbutanoate #; cyano[3-(phenyloxy)phenyl]methyl 2-{4-[(difluoromethyl)oxy]phenyl}-3-methylbutanoate; Flucythrinate solution, 10 mug/mL in cyclohexane, PESTANAL(R), analytical standard;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C26H23F2NO4",
"molecular_weight": "451.5",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "50980",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01949",
"RC02570",
"RC03191"
]
},
{
"compound_ID": "D0939",
"name": "flunixin meglumine",
"synonyms": "FLUNIXIN MEGLUMINE; 42461-84-7; Flunixin meglumin; Banamine; finadyne; Flumeglumine; Flunixin-S; Sch 14714 meglumine; Flunixin N-methylglucanine; Flunixin (meglumine); Banamine (Veterinary); UNII-8Y3JK0JW3U; Sch-14714 meglumine; EINECS 255-836-0; 8Y3JK0JW3U; CHEBI:76144; 1-Deoxy-1-(methylamino)-D-glucitol 2-(2-methyl-3-(perfluoromethyl)anilino)nicotinate; 2-[[2-Methyl-3-(trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic acid meglumine salt; 2-(alpha(sup 3),alpha(sup 3),alpha(sup 3)-Trifluoro-2,3-xylidino)nicotinic acid compound with 1-deoxy-1-(methylamino)-D-glucitol (1:1); 2-((2-Methyl-3-(trifluoromethyl)-phenyl)amino)-3-pyridinecarboxylic acid with meglumine compounded; 3-Pyridinecarboxylic acid, 2-((2-methyl-3-(trifluoromethyl)phenyl)amino)-, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1); D-Glucitol, 1-deoxy-1-(methylamino)-, 2-((2-methyl-3-(trifluoromethyl)phenyl)amino)-3-pyridinecarboxylate (salt); SMR000875279; SR-05000001901; Flunixin Meglumine [USAN]; flunixin-meglumin; Flunixin meglumine [USAN:USP]; (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol;2-[2-methyl-3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid; C14H11F3N2O2.C7H17NO5; PubChem15394; Flunixin meglumine (USP); Banamine [vetarynary] (TN); SCHEMBL43691; BSPBio_002558; MLS001333159; MLS002153985; SPECTRUM1505113; CHEMBL1733447; CTK8F9789; C21H28F3N3O7; MGCCHNLNRBULBU-WZTVWXICSA-N; HMS2093I10; HMS2234K05; Pharmakon1600-01505113; HY-B0386; NSC759583; s2108; Flunixin meglumine, >=98% (HPLC); AKOS015895954; AC-6012; API0025954; CCG-213338; CS-2460; KS-5126; NSC-759583; KS-000010G2; NCGC00180889-01; 2-((2-methyl-3-(trifluoromethyl)- phenyl)amino)-3-pyridinecarboxylic acid with meglumine compounded; LS-71360; SC-18614; AB2000512; FT-0626443; SW196448-3; D04216; K-8817; AB00920714_05; AB00920714_06; 461F847; C-22876; Q-201124; SR-05000001901-1; SR-05000001901-3; Q27145782; Flunixin meglumine, European Pharmacopoeia (EP) Reference Standard; Flunixin meglumine, United States Pharmacopeia (USP) Reference Standard; Flunixin Meglumine, Pharmaceutical Secondary Standard; Certified Reference Material; (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-(2-methyl-3-(trifluoromethyl)phenylamino)nicotinate; 1-deoxy-1-(methylazaniumyl)-D-glucitol 2-{[2-methyl-3-(trifluoromethyl)phenyl]amino}nicotinate; 2-{[2-methyl-3-(trifluoromethyl)phenyl]amino}nicotinic acid--1-deoxy-1-(methylamino)-D-glucitol (1/1);",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C21H28F3N3O7",
"molecular_weight": "491.5",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "39212",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01951",
"RC02572",
"RC03193"
]
},
{
"compound_ID": "D0940",
"name": "fluocinonide",
"synonyms": "fluocinonide; 356-12-7; Lidex; Fluocinolide; Metosyn; Vanos; Fluocinolide acetate; Fluocinolone acetonide acetate; Fluonex; LIDEX-E; Lonide; Lyderm; Lidex E; Fluocinonidum [INN-Latin]; Fluocinonide Emulsified Base; Fluocinonido [INN-Spanish]; Topsyn; Fluocinolone acetonide 21-acetate; Bestasone; Biscosal; Cortalar; Straderm; Topsymin; Synalar acetate; C26H32F2O7; UNII-2W4A77YPAN; Fluocinonide(Vanos); Fluocinonide, micronised; EINECS 206-597-6; NSC 101791; 2W4A77YPAN; MLS000028476; 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone, 21-acetate; Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-6,9-difluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6alpha,11beta,16alpha)-; Fluocinonido; Fluocinonidum; SMR000058331; Fluocinonide FAPG; DSSTox_CID_25307; DSSTox_RID_80793; DSSTox_GSID_45307; Pregna-1,4-diene-3,20-dione, 6-alpha, 9-difluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic17-acetal with acetone, 21-acetate; Fluocinonide [USAN:BAN:INN:JAN]; (6ALPHA,11BETA,16ALPHA)-21-(ACETYLOXY)-6,9-DIFLUORO-11-HYDROXY-16,17-[(1-METHYLETHYLIDENE)BIS(OXY)]-PREGNA-1,4-DIENE-3,20-DIONE; Vanos (TN); Fluocinonide [USAN:INN:BAN:JAN]; LIDEX (TN); NCGC00016436-01; CAS-356-12-7; Prestwick_1066; Fluocinonide (Vanos); Fluocinonide(Vanos)/; Fluocinonide [USAN:USP:INN:BAN:JAN]; Opera_ID_1780; Prestwick0_000774; Prestwick1_000774; Prestwick2_000774; Prestwick3_000774; FLUOCINOMIDE ACETATE; SCHEMBL4262; CHEMBL1501; BSPBio_000848; SPBio_002787; BPBio1_000934; CHEBI:5109; GTPL7078; DTXSID8045307; Fluocinonide (JP17/USP/INN); Fluocinonide, >=98% (HPLC); HMS1570K10; HMS2097K10; HMS2234H04; HMS3259N05; HMS3714K10; HY-B0485; ZINC3977978; Tox21_110438; ABP000638; MFCD00079302; s2608; AKOS015896516; Tox21_110438_1; AC-2071; API0002731; BCP9000697; CCG-220774; CS-2601; DB01047; NC00621; YF10077; FLUOCINONIDE ACETONIDE 21-ACETATE; NCGC00022398-03; NCGC00022398-05; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone, 21-acetate; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone, 21-acetate (8CI); SC-78862; Fluonex;Lidex;Lidex-E;Lonide;Lyderm;Vanos; AB2000697; LS-118446; C07007; D00325; 20527-EP2371811A2; 356F127; SR-01000003097; Q5462791; SR-01000003097-3; W-106660; BRD-K57886322-001-03-4; BRD-K57886322-001-12-5; Fluocinonide, United States Pharmacopeia (USP) Reference Standard; 1,4-PREGNADIEN-6ALPHA,9ALPHA-DIFLUORO-11BETA,16ALPHA,17,21-TETROL-3,20-DIONE 16,17-ACETONIDE 21-ACETATE; 2-((2S,6aS,6bR,7S,8aS,8bS,11aR,12aS,12bS)-2,6b-difluoro-7-hydroxy-6a,8a,10,10-tetramethyl-4-oxo-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-2-oxoethyl acetate; 2-[(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-6,6,9,13-tetramethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-8-yl]-2-oxoethyl acetate;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C26H32F2O7",
"molecular_weight": "494.5",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.",
"protein_binding": "",
"half_life": "",
"absorption": "The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. In general, percutaneous absorption is minimal.",
"cid": "9642",
"classification": "D; C",
"indications": "",
"side_effects": "",
"atc_codes": "D07CC05; C05AA11; D07AC08",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01952",
"RC02573",
"RC03194"
]
},
{
"compound_ID": "D0941",
"name": "fluorodifen",
"synonyms": "Fluorodifen; Preforan; Fluorodiphen; Soyex; 15457-05-3; Fluorodifene; 2-Nitro-1-(4-nitrophenoxy)-4-(trifluoromethyl)benzene; Caswell No. 462AA; Fluordifen; Fluorodifen [BSI:ISO]; Benzene, 2-nitro-1-(4-nitrophenoxy)-4-(trifluoromethyl)-; 2,4-Dinitro-p-trifluoromethyl phenyl ether; 4-Trifluoromethyl-2,4'-dinitrophenyl ether; Fluorodifene [ISO-French]; UNII-H4154A0WOP; NSC 58415; C 6989; 4-Nitrophenyl 4-(trifluoromethyl)-2-nitrophenyl ether; p-Nitrophenyl 2-nitro-4-(trifluoromethyl)phenyl ether; Ether, 2,4'-dinitro-4-trifluoromethyldiphenyl; EINECS 239-474-0; EPA Pesticide Chemical Code 085001; BRN 2018474; p-Nitrophenyl 2-nitro-4-(trifluoromethyl) phenyl ether; CHEBI:5116; H4154A0WOP; 2,4'-Dinitro-4-trifluoromethyl-diphenyl ether; 2,4'-Dinitro-4-(trifluoromethyl)diphenyl ether; 4-(Trifluoromethyl)-2,4'-dinitrodiphenyl ether; C-6989; HHMCAJWVGYGUEF-UHFFFAOYSA-N; 4-Nitrophenyl alpha,alpha,alpha-trifluoro-2-nitro-p-tolyl ether; p-Nitrophenyl alpha,alpha,alpha-trifluoro-2-nitro-p-tolyl ether; 4-Trifluoromethyl-2,4'-dinitrodiphenyl ether; Ether, (p-nitrophenyl) (alpha,alpha,alpha-trifluoro-2-nitro-p-tolyl); DSSTox_CID_17553; DSSTox_RID_79335; NCIOpen2_007883; DSSTox_GSID_37553; SCHEMBL39283; WLN: WNR DOR BNW BXFFF; CHEMBL1892429; DTXSID7037553; NSC58415; ZINC1532140; Tox21_301354; NSC-58415; AKOS015903714; Ether, p-nitrophenyl .alpha.,.alpha.,.alpha.-trifluoro-2-nitro-p-tolyl; NCGC00163842-01; NCGC00255525-01; LS-67878; Ether,4'-dinitro-4-trifluoromethyldiphenyl; CAS-15457-05-3; C6989; C 6929; C11064; Fluorodifen, PESTANAL(R), analytical standard; Ether,.alpha.,.alpha.-trifluoro-2-nitro-p-tolyl; Ether,.alpha.,.alpha.-trifluoro-2-nitro-p-tolyl); J-009119; 2,4'-DINITRO-4-TRIFLUOROMETHYLDIPHENYL ETHER; Q15809890; 2-Nitro-1-(4-nitrophenoxy)-4-(trifluoromethyl) benzene; 4-Nitrophenyl 2-nitro-4-(trifluoromethyl)phenyl ether #; 4-nitrophenyl 4-(trifluoro methyl)-2-nitrophenyl ether; p-Nitrophenyl .alpha.,.alpha.-trifluoro-2-nitro-p-tolyl ether; 4-Nitrophenyl .alpha.,.alpha.,.alpha.-trifluoro-2-nitro-p-tolyl ether; p-Nitrophenyl .alpha.,.alpha.,.alpha.-trifluoro-2-nitro-p-tolyl ether;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C13H7F3N2O5",
"molecular_weight": "328.2",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "27295",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01953",
"RC02574",
"RC03195"
]
},
{
"compound_ID": "D0942",
"name": "fluorosalan",
"synonyms": "FLUOROSALAN; Flusalan; Fluorophene; Fluorsalan; Vancide FP; 4776-06-1; Flusalanum; Fluorosalan [USAN]; Caswell No. 290; Flusalanum [INN-Latin]; UNII-80OFG3WPYD; 3,5-Dibromo-3'-(trifluoromethyl)salicylanilide; 80OFG3WPYD; CHEMBL283552; 3,5-Dibromo-2-hydroxy-N-(3-(trifluoromethyl)phenyl)benzamide; Flusalan (INN); Flusalan [INN]; EINECS 225-322-0; NSC166520; Fluorosalan (USAN); EPA Pesticide Chemical Code 027601; NSC 166520; BRN 1155294; NCGC00181143-01; 3,5-Dibromo-3'-trifluoromethylsalicylanilide; 3,5-Dibromo-3'-(triflouromethyl)salicylanilide; DSSTox_CID_21985; DSSTox_RID_79896; DSSTox_GSID_41985; 3,5-Dibromo-alpha,alpha,alpha-trifluoro-m-salicylotoluidide; 3,5-dibromo-2-hydroxy-N-[3-(trifluoromethyl)phenyl]benzamide; m-Salicylotoluidide, 3,5-dibromo-alpha,alpha,alpha-trifluoro-; Benzamide, 3,5-dibromo-2-hydroxy-N-(3-(trifluoromethyl)phenyl)-; CAS-4776-06-1; Benzamide, 3,5-dibromo-2-hydroxy-N-[3-(trifluoromethyl)phenyl]-; SCHEMBL374268; 3'-TRIFLUOROMETHYL-3,5-DIBROMO SALICYLANILIDE; DTXSID0041985; CTK5I6206; CHEBI:135715; ZINC537744; Tox21_112749; Tox21_302424; BDBM50027790; NSC-166520; NCGC00181143-02; NCGC00255963-01; NCI60_001302; LS-144425; FT-0750585; D04222; 3,.alpha.,.alpha.-trifluoro-m-salicylotoluidide; SR-01000944883; SR-01000944883-1; Q27269166; 3,5-Dibromo-2-hydroxy-N-(3-trifluoromethyl-phenyl)-benzamide; Benzamide,5-dibromo-2-hydroxy-N-[3-(trifluoromethyl)phenyl]-; 3,5-Dibromo-.alpha.,.alpha.,.alpha.-trifluoro-m-salicylotoluidide; m-Salicylotoluidide,5-dibromo-.alpha.,.alpha.,.alpha.-trifluoro-; 3,5-Dibromo-2-hydroxy-N-(3-trifluoromethyl-phenyl)-benzamide(fluorophen); Benzamide, 3, {5-dibromo-2-hydroxy-N-[3-(trifluoromethyl)phenyl]-}; m-Salicylotoluidide, 3,5-dibromo-.alpha.,.alpha., .alpha.-trifluoro-;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C14H8Br2F3NO2",
"molecular_weight": "439.02",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "20906",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01954",
"RC02575",
"RC03196"
]
},
{
"compound_ID": "D0943",
"name": "fluoxastrobin",
"synonyms": "Fluoxastrobin; 361377-29-9; Fluoxastrobin [ISO]; (Z)-fluoxastrobin; UNII-XQ43WY091Y; HEC 480 SC; XQ43WY091Y; CHEBI:83253; (1E)-(2-((6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinyl)oxy)phenyl)(5,6-dihydro-1,4,2-dioxazin-3-yl)methanone O-methyloxime; Disarm; (E)-1-(2-{[6-(2-chlorophenoxy)-5-fluoropyrimidin-4-yl]oxy}phenyl)-1-(5,6-dihydro-1,4,2-dioxazin-3-yl)-N-methoxymethanimine; (E)-1-[2-[6-(2-chlorophenoxy)-5-fluoropyrimidin-4-yl]oxyphenyl]-1-(5,6-dihydro-1,4,2-dioxazin-3-yl)-N-methoxymethanimine; Evito; HSDB 7880; DSSTox_CID_14625; DSSTox_RID_79180; DSSTox_GSID_34625; SCHEMBL18719; SCHEMBL350134; CHEMBL1902591; DTXSID2034625; Tox21_300824; ZINC36533692; AKOS015909404; NCGC00168310-01; NCGC00168310-02; NCGC00254728-01; ACM361377299; Fluoxastrobin 10 microg/mL in Acetonitrile; LS-183689; CAS-361377-29-9; J2.975.310E; J3.642.606C; Fluoxastrobin, PESTANAL(R), analytical standard; Q27269858; (E)-(2-{[6-(2-chlorophenoxy)-5-fluoropyrimidin-4-yl]oxy}phenyl)(5,6-dihydro-1,4,2-dioxazin-3-yl)methanone O-methyloxime; (Z)-[2-[[6-(2-Chlorophenoxy)-5-fluoropyrimidine-4-yl]oxy]phenyl](5,6-dihydro-1,4,2-dioxazine-3-yl)-N-methoxymethaneimine;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C21H16ClFN4O5",
"molecular_weight": "458.8",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "11048796",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01955",
"RC02576",
"RC03197"
]
},
{
"compound_ID": "D0944",
"name": "fluticasone propionate",
"synonyms": "FLUTICASONE PROPIONATE; Flovent; Cutivate; Flixotide; Flonase; 80474-14-2; Flixonase; Flovent HFA; Flunase; Flusonal; Fluspiral; Flutide; atemur; Flutivate; Asmatil; Axotide; Brethal; Fluinol; Flovent Diskus 50; Flixotide Disks; Flixotide Disk; Flovent Diskus; Flovent Diskus 100; Flovent Diskus 250; Flixotide Inhaler; Cultivate; Inalacor; Rinosone; Trialona; Ubizol; Zoflut; Flixonase Nasal Spray; Flonase Aq; Fluticasonpropionat Allen; Fluticasone (propionate); UNII-O2GMZ0LF5W; CCI-18781; CCI 18781; O2GMZ0LF5W; CHEBI:31441; [(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate; Fluticasone propionate (Flonase, Veramyst); S-(Fluoromethyl) 6alpha,9-difluoro-11beta,17-dihydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta-carbothioate, 17-propionate; C25H31F3O5S; Flovent-hfa; Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, (6alpha,11beta,16alpha,17alpha)-S-(fluoromethyl) ester; Fluxonal; Skyron; Xhance; Fluticasone propionate [USAN]; Flovent Rotadisk; Cutivate (TN); Fluticasone propionate [USAN:USP]; ArmonAir RespiClick; Flonase (TN); Flovent (TN); MFCD00866007; ArmonAir RespiClickTM; Flonase Allergy Relief; Fluticasone Impurity B; Prestwick0_000997; Prestwick1_000997; Prestwick2_000997; Prestwick3_000997; SCHEMBL4068; CHEMBL1473; BSPBio_001093; MLS001424085; SPBio_002984; BPBio1_001203; GTPL7080; BIF0710; WMWTYOKRWGGJOA-CENSZEJFSA-N; FN-25; HMS1571G15; HMS2051N19; HMS2098G15; HMS3413A19; HMS3677A19; HMS3715G15; Fluticasone propionate (JAN/USAN); HY-B0154; ZINC3920027; AC-457; BDBM50354849; s1992; AKOS015895220; CCG-100981; CS-1986; DB00588; KS-1173; NC00231; NCGC00179308-01; NCGC00179308-05; BR-72799; LS-19323; SC-19333; SMR000469159; AB1010912; ST2407016; AB00513992; FT-0082893; PF-00241939; D01708; AB00513992-06; AB00513992_08; Fluticasone propionate, >=98% (HPLC), powder; 474F142; AN-584/43505443; SR-01000763355; Q-101393; Q8564098; SR-01000763355-3; BRD-K62310379-001-03-0; Fluticasone propionate, European Pharmacopoeia (EP) Reference Standard; Fluticasone propionate, United States Pharmacopeia (USP) Reference Standard; Fluticasone Propionate, Pharmaceutical Secondary Standard; Certified Reference Material; (1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-difluoro-14-{[(fluoromethyl)sulfanyl]carbonyl}-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-14-yl propanoate; (6?,11?,16?,17?)-6,9-Difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid fluoromethyl ester; (6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid S-(fluoromethyl) ester; 6alpha,9-difluoro-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-11beta-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17alpha-yl propanoate; Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, S-(fluoromethyl) ester, (6-alpha,11-beta,16-alpha,17-alpha)-; Fluticasone propionate for impurity C identification, EuropePharmacopoeia (EP) Reference Standard; Fluticasone propionate for impurity G identification, EuropePharmacopoeia (EP) Reference Standard;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C25H31F3O5S",
"molecular_weight": "500.6",
"state": "solid",
"clearance": "1093mL/min for fluticasone propionate[F4358]. A study of 24 healthy Caucasian males showed a clearance of 63.9L/h following intravenous administration[A7490].",
"volume_of_distribution": "The volume of distribution of intravenous fluticasone propionate is 4.2L/kg[F4358][FDA Label]. A study of 24 healthy Caucasian males showed a volume of distribution at steady state of 577L following intravenous administration[A7490].",
"route_of_elimination": "Fluticasone propionate is mainly eliminated in the feces with <5% eliminated in the urine[F4358,A176918][FDA Label].",
"protein_binding": "Fluticasone propionate is 99% protein bound in serum[F4358]. Topical fluticasone propionate is only 91% protein bound in serum however[F4355].",
"half_life": "7.8 hours for intravenous fluticasone propionate[F4358][FDA Label]. A study of 24 healthy Caucasian males shows a half life of 14.0 hours following intravenous administration and 10.8 hours following inhalation[A7490].",
"absorption": "Intranasal bioavailability of fluticasone propionate is <2%, and oral bioavailability is <1%[F4358][FDA Label]. Intranasal exposure results in the majority of the dose being swallowed[A177118]. Topical absorption of fluticasone propionate is very low but can change depending on a number of factors including integrity of the skin and the presence of inflammation or disease[F4355]. A study of 24 healthy Caucasian males showed an inhaled bioavailability of 9.0%[A7490].",
"cid": "444036",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01956",
"RC02577",
"RC03198"
]
},
{
"compound_ID": "D0945",
"name": "fluvastatin",
"synonyms": "fluvastatin; 93957-54-1; Lescol; Cranoc; (+)-(3R,5S)-fluvastatin; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S)-fluvastatin; Fluvastatin [INN:BAN]; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; Canef; XU 62320; XU-62320; EN300-51915; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; C24H26FNO4; (3R,5S,E)-7-(3-(4-Fluorophenyl)-1-isopropyl-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoic acid; Fluvastatin & Primycin; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (-)-fluvastatin; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-isopropyl-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid; PubChem10727; DSSTox_CID_636; Prestwick2_000859; SCHEMBL2846; 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate; DSSTox_RID_75707; DSSTox_GSID_20636; (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid; SCHEMBL556754; GTPL2951; DTXSID2020636; BDBM86704; CHEBI:38565; CHEBI:93160; FJLGEFLZQAZZCD-MCBHFWOFSA-N; HMS2089P06; HMS3259J15; Pharmakon1600-01504911; 6-Heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)- 3,5-dihydroxy-, (3R,5S,6E)-rel-; 6-Heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)- 3,5-dihydroxy-, (R*,S*-(E))-(+-)-; ACT03305; ZINC1886617; Tox21_302765; DL-108; NSC758896; API0002749; CCG-213323; CS-1226; LS-7404; NC00659; NSC-758896; (3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; NCGC00256490-01; CPD001453708; HY-14664; SAM002548940; CAS-93957-54-1; CAS_93957-54-1; W-5176; 957F541; Q417942; SR-05000001489-1; BRD-K66296774-001-02-0; UNII-4L066368AS component FJLGEFLZQAZZCD-MCBHFWOFSA-N; (E)-(3R,5S)-7-[3-(4-Fluoro-phenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid; 6-Heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-, (R*,S*-(E))-(+-)-; 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, (3R,5S,6E)-; Fluvastatin sodium L1483;",
"trade_name": "Lescol",
"abbrev_name": "",
"description": "statin; antilipemic; competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase ( conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis); reduce plasma cholesterol levels",
"molecular_formula": "C24H26FNO4",
"molecular_weight": "411.5",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "446155",
"classification": "C",
"indications": "",
"side_effects": "",
"atc_codes": "C10AA04",
"group": "Compound",
"drug_type": "",
"target": [
"T387"
],
"function": [
"F010401",
"F0108",
"F0504"
],
"references": [
"RC01957",
"RC02578",
"RC03199",
"RC04660",
"RC04674",
"RC04689"
]
},
{
"compound_ID": "D0946",
"name": "folpet",
"synonyms": "Folpet; 133-07-3; Faltan; Orthophaltan; Phthaltan; Folpel; Acryptan; Spolacid; Folnit; Folpan; Ftalan; Intercide TMP; PHALTAN; Fungitrol 11; Fungitrol; Vinicoll; Faltex; N-(Trichloromethylthio)phthalimide; Cosan I; Phaltane; Thiophal; Fungitrol II; Ortho phaltan 50W; Troysan anti-mildew O; Trichloromethylthiophthalimide; Murphy's rose fungicide; Folpel [French]; 2-[(Trichloromethyl)thio]-1H-isoindole-1,3(2H)-dione; Folpet [ANSI:BSI:ISO]; Caswell No. 464; Folpex; 2-(Trichloromethylsulfanyl)isoindole-1,3-dione; N-(Trichloromethanesulphenyl)phthalimide; N-(Trichlormethylthio)phthalimide; N-(Trichlor-methylthio)-phthalamid; N-[(Trichloromethyl)thio]phthalimide; N-(Trichloromethylmercapto)phthalimide; 1H-Isoindole-1,3(2H)-dione, 2-[(trichloromethyl)thio]-; UNII-X5NFK36917; CCRIS 1036; HSDB 2651; EINECS 205-088-6; ENT 26539; Trichlormethylthioimid kyseliny ftalove; EPA Pesticide Chemical Code 081601; BRN 0193373; 2-((Trichloromethyl)thio)-1H-isoindole-1,3(2H)-dione; AI3-26539; Trichloromethyl(thio)phthalimide; N-(Trichlor-methylthio)-phthalamid [German]; CHEBI:82019; Trichlormethylthioimid kyseliny ftalove [Czech]; 2-((Trichloromethyl)thio)isoindoline-1,3-dione; HKIOYBQGHSTUDB-UHFFFAOYSA-N; X5NFK36917; Phthalimide, N-((trichloromethyl)thio)-; Phthalimide, N-[(trichloromethyl)thio]-; Trifol; DSSTox_CID_1385; Cosan T; DSSTox_RID_76127; DSSTox_GSID_21385; PHTHALIC ACID,IMIDE,N-TRICHLOROMETHYL SULFENYL; 1H-Isoindole-1,3(2H)-dione, 2-((trichloromethyl)thio)-; 2-[(Trichloromethyl)sulfanyl]-1H-isoindole-1,3(2H)-dione; N-((Trichloromethyl)thio)-Phthalimide; N-[(Trichloromethyl)thio]-Phthalimide; CAS-133-07-3; C9H4Cl3NO2S; Phalton; N-(trichloromethyl)-thiophthalimide; N-(TRICHLOROMETHYL)THIOPHTHALIMIDE; SCHEMBL19853; 5-21-11-00118 (Beilstein Handbook Reference); CHEMBL1883819; DTXSID0021385; HY-B1878; ZINC2041008; Folpet 10 microg/mL in Cyclohexane; Tox21_201987; Tox21_301077; AC-997; MFCD00047303; Folpet 100 microg/mL in Cyclohexane; AKOS015895774; N-(trichloromethanesulfenyl)phthalimide; FCH2709964; LS-7733; MCULE-7604769697; NCGC00168313-01; NCGC00168313-02; NCGC00168313-03; NCGC00254978-01; NCGC00259536-01; CC-28811; O669; Folpet, PESTANAL(R), analytical standard; 2-(trichloromethylthio)isoindole-1,3-dione; CS-0013944; FT-0659392; 2-(trichloromethylthio)isoindoline-1,3-dione; C18860; 133F073; A806547; C-34942; Q426485; J-006303; 2-[(Trichloromethyl)sulfanyl]-1H-isoindole-1,3(2H)-dione #; 2-[(Trichloromethyl)thio]-1H-isoindole-1,3(2H)-dione, 9CI; 2-[(trichloromethyl)sulfanyl]-2,3-dihydro-1H-isoindole-1,3-dione; InChI=1/C9H4Cl3NO2S/c10-9(11,12)16-13-7(14)5-3-1-2-4-6(5)8(13)15/h1-4;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C9H4Cl3NO2S",
"molecular_weight": "296.6",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "8607",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01958",
"RC02579",
"RC03200"
]
},
{
"compound_ID": "D0947",
"name": "forchlorfenuron",
"synonyms": "Forchlorfenuron; 68157-60-8; 1-(2-chloropyridin-4-yl)-3-phenylurea; 1-(2-Chloro-4-pyridyl)-3-phenylurea; CPPU; 4PU30 cpd; Urea, N-(2-chloro-4-pyridinyl)-N'-phenyl-; N-(2-Chloro-4-pyridyl)-N'-phenylurea; UNII-K62IP7463J; CHEBI:81861; GPXLRLUVLMHHIK-UHFFFAOYSA-N; K62IP7463J; Forchlorfenuron, 98%; AK-51740; Q-201133; Forchlorfenuron [ISO]; 4-CPPU; Forchlorfenuron [ANSI:ISO]; HSDB 7983; KT-30; Forchlorfenuron (KT-30); DSSTox_CID_14634; DSSTox_RID_79182; DSSTox_GSID_34634; KSC496O4F; SCHEMBL119685; ACMC-209o29; CHEMBL1229826; DTXSID1034634; CTK3J6742; KS-00000GBE; BIC0279; Forchlorfenuron (KT-30, CPPU); ZX-AFC000639; ZINC402792; HY-B1841; Tox21_301094; ANW-35455; CF-003; MFCD00059898; s5306; AKOS015895398; N-(2-Chloro-4-pyridinyl)-N;-phenyl; CM10941; CS-6276; LS41254; MCULE-6325790412; RTR-022810; N-(2-chloro-4-pyridyl)-N`-phenylurea; 1-(2-chloro-4-pyridinyl)-3-phenylurea; 3-(2-chloropyridin-4-yl)-1-phenylurea; NCGC00164383-01; NCGC00164383-02; NCGC00164383-03; NCGC00254994-01; AC-11699; AS-14155; BR-51740; CC-28817; Forchlorfenuron 10 microg/mL in Methanol; K126; SC-12211; AB0014042; AX8131481; CAS-68157-60-8; DB-055112; LS-159608; ST2403101; TR-022810; 1-(2-chloranylpyridin-4-yl)-3-phenyl-urea; 4CH-018034; FT-0626521; N-(2-Chloro-4-pyridinyl)-N'-phenylurea #; ST51039313; 57F608; C18604; M-1619; N-(2-chloro(4-pyridyl))(phenylamino)carboxamide; A836038; C-15151; Forchlorfenuron, PESTANAL(R), analytical standard; Q408770; N-(2-Chloro-4-pyridyl)-N'-phenylurea, applicable for cell culture, BioReagent;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C12H10ClN3O",
"molecular_weight": "247.68",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "93379",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01959",
"RC02580",
"RC03201"
]
},
{
"compound_ID": "D0948",
"name": "formononetin",
"synonyms": "formononetin; 485-72-3; Biochanin B; Formononetol; 7-hydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one; 7-Hydroxy-4'-methoxyisoflavone; 7-hydroxy-3-(4-methoxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-methoxyphenyl)-; 4'-O-methyldaidzein; UNII-295DQC67BJ; 7-Hydroxy-3-(4-methoxyphenyl)-4-benzopyrone; NSC 93360; 7-Hydroxy-3-(4-methoxyphenyl)chromone; CHEBI:18088; Isoflavone, 7-hydroxy-4'-methoxy-; EINECS 207-623-9; NSC-93360; 295DQC67BJ; HKQYGTCOTHHOMP-UHFFFAOYSA-N; NSC93360; AK106172; 7-hydroxy-3-(4-methoxyphenyl)-4H-benzopyran-4-one; Q-100540; SMR000470932; SR-01000765510; formononetine; 7-hydroxy-4'-methoxy-isoflavone; Formononetin,(S); MFCD00016948; Formononetin, 98%; PubChem9850; Spectrum_000373; SpecPlus_000223; Daidzein 4-methyl ether; Spectrum2_000560; Spectrum3_000660; Spectrum4_001429; Spectrum5_000258; Formononetin(Formononetol); DSSTox_CID_2311; Formononetin (Formononetol); DSSTox_RID_76544; NCIOpen2_005983; DSSTox_GSID_22311; Oprea1_139748; Oprea1_815287; SCHEMBL62915; BSPBio_002299; KBioGR_001878; KBioSS_000853; SPECTRUM102007; MLS000697593; MLS006011897; BIDD:ER0119; DivK1c_006319; SPBio_000639; CHEMBL242341; 7-Hydroxy-3-(4-methoxyphenyl)-4H-1-benzopyran-4-one; DTXSID4022311; CTK8C4788; Formononetin, analytical standard; KBio1_001263; KBio2_000853; KBio2_003421; KBio2_005989; KBio3_001519; KS-00000HZV; 7-Hydroxy-3-(4′-methoxyphenyl)-4H-benzopyran-4-one; HMS1922N18; HMS2231I04; HMS3369C07; HMS3655N22; ALBB-030789; BCP29929; Formononetin, >=99.0% (TLC); HY-N0183; TNP00176; Tox21_301848; ANW-73131; BBL010458; BDBM50021398; CCG-38727; CF0045; LMPK12050037; s2299; SBB016445; STK801612; ZINC18847036; AKOS000270811; AC-8001; CS-3081; DB15335; MCULE-4171151967; SDCCGMLS-0066428.P001; 7-hydroxy-4'-methoxy-Isoflavone (8CI); NCGC00017269-01; NCGC00017269-02; NCGC00017269-03; NCGC00017269-04; NCGC00017269-05; NCGC00017269-06; NCGC00017269-07; NCGC00095207-01; NCGC00095207-02; NCGC00095207-03; NCGC00178715-01; NCGC00255167-01; 4CN-0880; AS-11642; CAS-485-72-3; CC-28828; LS-39701; NCI60_042081; SC-04770; ST024713; AB0010475; AX8016260; Isoflavone, 7-hydroxy-4'-methoxy- (8CI); Neochanin; Flavosil;NEOCHANIN;Formononetol; F0868; FT-0626540; FT-0632204; K-080; N1625; SW219915-1; 3-(4-methoxyphenyl)-7-oxidanyl-chromen-4-one; C00858; AB00052676-07; 485F723; A827555; AE-641/01968055; C-16842; Q408859; 7-hydroxy-3-(4-methoxyphenyl)-1-benzopyran-4-one; SR-01000765510-3; SR-01000765510-4; BRD-K55567017-001-02-4; BRD-K55567017-001-06-5; F3139-1207; 7-hydroxy-3-(4-methoxyphenyl)-4H-benzopyran-4-one(9CI); 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-methoxyphenyl)- (9CI); Formononetin, United States Pharmacopeia (USP) Reference Standard; 7-Hydroxy-3-(4-methoxyphenyl)chromone, 7-Hydroxy-4'-methoxyisoflavone; Biochanin B; Flavosil; Formononetol; NSC 93360; NSC93360; NSC-93360;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C16H12O4",
"molecular_weight": "268.26",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5280378",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01960",
"RC02581",
"RC03202"
]
},
{
"compound_ID": "D0949",
"name": "fulvestrant",
"synonyms": "Fulvestrant; 129453-61-8; Faslodex; Ici 182780; ICI 182,780; ICI-182780; ZM 182780; ZM-182780; ZD-9238; ZD 182780; C32H47F5O3S; Fulvestrant (Faslodex); ZD 9238; CHEMBL1358; (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; CHEBI:31638; 7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; DSSTox_CID_2369; DSSTox_RID_76561; DSSTox_GSID_22369; (7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; Fulvestrant [USAN]; ZD9238; Faslodex (TN); (7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10),2,4-triene-3,17-diol; (7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol; 7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol; Estra-1,3,5(10)-triene-3,17-diol, 7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-, (7alpha,17beta)-; Estra-1,3,5(10)-triene-3,17-diol, 7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-, (7alpha,17beta)-; CAS-129453-61-8; fulvestrantum; Fluvestrant; Falsodex; Fulvestrant (JAN/USAN/INN); CCRIS 8741; Faslodex(ICI 182,780); HSDB 7658; NCGC00024964-02; Fulvestrant [USAN:USP:INN:BAN]; ICI182780; PubChem24291; ZD-182780; SCHEMBL8209; BIDD:PXR0136; MLS006010187; BIDD:ER0348; Fulvestrant, >98% (HPLC); GTPL1015; DTXSID4022369; CTK8F0501; EX-A959; HMS2090N22; HMS3260G10; HMS3712A06; Tox21_110939; Tox21_202604; Tox21_303656; Tox21_500114; ABP001070; BDBM50169743; MFCD00903953; NSC719276; AKOS015895669; Tox21_110939_1; AC-4693; ACN-029814; BCP9000707; CCG-220082; CCG-221418; CS-1267; DB00947; LP00114; NSC-719276; ICI 182 780; ICI 182,789; NCGC00164789-02; NCGC00164789-04; NCGC00257357-01; NCGC00260152-01; NCGC00260799-01; (7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; AS-13024; CC-28864; H046; HY-13636; LS-64781; SC-19202; SMR001456109; BCP0726000227; AB0012854; RT-013311; S1191; Fulvestrant, Vetec(TM) reagent grade, >98%; D01161; W-5207; AB01273957-01; AB01273957-02; AB01273957-03; AB01273957_04; 453F618; C-23331; J-005680; Q5508491; BRD-A85667082-001-12-7; Fulvestrant, European Pharmacopoeia (EP) Reference Standard; Fulvestrant, United States Pharmacopeia (USP) Reference Standard; Fulvestrant for system suitability, European Pharmacopoeia (EP) Reference Standard; (13S,17S)-13-Methyl-7-[9-(4,4,5,5,5-pentafluoro-pentane-1-sulfinyl)-nonyl]-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; (7?,17?)-7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol; (7a,17b)-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol; (7a,17b)-7-[9-[(4,4,5,5,5pentafluoropentyl)Sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol; (7alpha,17beta)-7-[9-(4,4,5,5,5-Pentafluoropentane-1-sulfinyl)nonyl]estra-1,3,5(10)-triene-3,17-diol; (7R,13S,17S)-13-Methyl-7-[9-(4,4,5,5,5-pentafluoro-pentane-1-sulfinyl)-nonyl]-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentyldihydrosulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; (7R,8R,9S,13S,14S,17S)-13-Methyl-7-[9-(4,4,5,5,5-pentafluoro-pentane-1-sulfinyl)-nonyl]-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; 13-Methyl-7-[9-(4,4,5,5,5-pentafluoro-pentane-1-sulfinyl)-nonyl]-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; 13-Methyl-7-[9-(4,5,5,5-pentafluoropentylsulfinyl)nonyl]-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; 7alpha-[9-(4,4,5,5,5-pentafluoro-pentylsulfinyl)nonyl]estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-[9-[(RS)-(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10),2,4-triene-3,17beta-diol; Estra-1,5(10)-triene-3,17-diol, 7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-, (7.alpha.,17.beta.)-;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C32H47F5O3S",
"molecular_weight": "606.8",
"state": "solid",
"clearance": "",
"volume_of_distribution": "* 3 to 5 L/kg",
"route_of_elimination": "Fulvestrant was rapidly cleared by the hepatobiliary route with excretion primarily via the feces (approximately 90%).\nRenal elimination was negligible (less than 1%).",
"protein_binding": "99% (mainly VLDL, LDL, and HDL)",
"half_life": "40 days",
"absorption": "",
"cid": "104741",
"classification": "L",
"indications": "",
"side_effects": "",
"atc_codes": "L02BA03",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01961",
"RC02582",
"RC03203"
]
},
{
"compound_ID": "D0950",
"name": "geliomycin",
"synonyms": "Resistomycin; Heliomycin; Geliomycin; Croceomycin; Itamycin; 20004-62-0; Antibiotic A 3733A; Geliomitsin; Heliomycin [INN]; Heliomycine [INN-French]; Heliomycinum [INN-Latin]; Heliomicina [INN-Spanish]; UNII-7N3A092A5X; A 3733A; BRN 2187224; CHEBI:29671; 7N3A092A5X; 2H-Benzo(cd)pyrene-2,6(1H)-dione, 3,5,7,10-tetrahydroxy-1,1,9-trimethyl-; NCGC00160275-02; DSSTox_CID_26101; DSSTox_RID_81339; DSSTox_GSID_46101; Heliomicina; Heliomycine; Heliomycinum; 3,5,7,10-Tetrahydroxy-1,1,9-trimethyl-2H-benzo[cd]pyrene-2,6(1H)-dione; Antibiotic obtained from cultures of Actinomyces flavochromogenes var. heliomycini or the same substance obtained by any other means; CAS-20004-62-0; Heliomycin (Salt/Mix); 11029-70-2; 4-08-00-03704 (Beilstein Handbook Reference); SCHEMBL2134180; CHEMBL1320139; DTXSID4046101; CTK8G2929; ABLACSIRCKEUOB-UHFFFAOYSA-N; NP285; Tox21_111753; BBL016487; STK177255; 3,5,7,10-Tetrahydroxy-1,1,9-trimethyl-1H-benzo[cd]pyrene-2,6-dione; AKOS000715231; Tox21_111753_1; ZINC100150837; MCULE-5498366880; ACM20004620; NCGC00160275-01; NCGC00160275-03; NCGC00160672-01; LS-40015; LS-74106; NCGC00160275-01!RESISTOMYCIN; ST50338003; X-340; C12080; SR-01000318568; J-012937; SR-01000318568-1; BRD-K64517075-001-01-9; Q27110219; 1,2-Dihydro-1,1,9-trimethyl-3,5,7,10-tetrahydroxy-6H-benzo[c,d]pyrene-2,6-dione; 2H-Benzo[cf]pyrene-2,6(1H)-dione,3,5,7,10-tetrahydroxy-1,1,9-trimethyl-; 3,5,7,10-Tetrahydroxy-1,1,9-trimethyl-2H-benzo[cd]pyrene-2,6(1H)-dione #;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C22H16O6",
"molecular_weight": "376.4",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "135430323",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01962",
"RC02583",
"RC03204"
]
},
{
"compound_ID": "D0951",
"name": "genistein",
"synonyms": "genistein; 446-72-0; Prunetol; Genisteol; 4',5,7-Trihydroxyisoflavone; Genisterin; Sophoricol; 5,7,4'-Trihydroxyisoflavone; 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; Bonistein; Differenol A; Genestein; NPI 031L; 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)-; C.I. 75610; SIPI 807-1; UNII-DH2M523P0H; NSC 36586; CCRIS 7675; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; NSC36586; CHEMBL44; EINECS 207-174-9; BRN 0263823; ISOFLAVONE, 4',5,7-TRIHYDROXY-; MLS000738127; DH2M523P0H; CHEBI:28088; TZBJGXHYKVUXJN-UHFFFAOYSA-N; NSC-36586; GEN; NCGC00015479-09; DSSTox_CID_2308; DSSTox_RID_76542; Genistein, 99%, synthetic; DSSTox_GSID_22308; CAS-446-72-0; Lactoferrin-genistein; 4',5, 7-Trihydroxyisoflavone; SR-01000075498; PTI G4660 (Genistein); STO514; HSDB 7475; PTI G4660; PTI-G4660; SIPI-9764-I; 3kgt; 3kgu; Genistein, 8; Genistein,(S); PTI-G 4660; 4′,5,7-Trihydroxyisoflavone; TNP00151; Genistein [USAN]; MFCD00016952; GENISTEIN (ENDOCRINE DISRUPTER); Genistein (flavonoid); PubChem9852; Spectrum_000320; Tocris-1110; 1x7r; 2qa8; Genistein 85% HPLC; SpecPlus_000305; Spectrum2_000638; Spectrum3_000678; Spectrum4_001543; Spectrum5_000106; Lopac-G-6649; 4',7-Trihydroxyisoflavone; MolMap_000022; UPCMLD-DP096; G 6649; Bio 300; 4,5,7-Trihydroxyisoflavone; Isoflavone,5,7-trihydroxy-; Lopac0_000520; Oprea1_224620; Oprea1_437815; SCHEMBL19166; BSPBio_002375; KBioGR_002006; KBioGR_002564; KBioSS_000800; KBioSS_002573; SPECTRUM210296; 5-18-04-00594 (Beilstein Handbook Reference); BIDD:ER0113; DivK1c_006401; Genistein, analytical standard; SPBio_000636; 4',5,7-trihydroxy-Isoflavone; GTPL2826; MEGxp0_000568; NPI-031L; 4,5,7-Trihydroxy Iso-Flavone; DTXSID5022308; UPCMLD-DP096:001; ACon1_001065; BDBM19459; cid_5280961; KBio1_001345; KBio2_000800; KBio2_002564; KBio2_003368; KBio2_005132; KBio2_005936; KBio2_007700; KBio3_001595; KBio3_003042; AOB5073; CHEBI: 28088; cMAP_000086; Bio1_000445; Bio1_000934; Bio1_001423; HMS2271K09; HMS3261H21; HMS3267K14; HMS3412I13; HMS3428M01; HMS3649B22; HMS3654D17; HMS3676I13; HMS3742I07; SIPI-807-1; ACT05962; ALBB-015886; BCP07581; KS-00000MH8; Tox21_110161; Tox21_201428; Tox21_300585; Tox21_500520; AC-472; BBL010484; CCG-38551; CG-009; FW-635I-2; LMPK12050218; s1342; SBB066115; STK801619; WHO 11073; ZINC18825330; AKOS001590147; ENDOCRINE DISRUPTOR (GENISTEIN) (SEE ALSO GENISTEIN (446-72-0)); Tox21_110161_1; CS-1534; DB01645; KS-5128; LP00520; LS-1266; MCULE-4857649752; SB17235; SMP1_000133; Genistein; 4',5,7-Trihydroxyisoflavone; NCGC00015479-01; NCGC00015479-02; NCGC00015479-04; NCGC00015479-05; NCGC00015479-06; NCGC00015479-07; NCGC00015479-08; NCGC00015479-10; NCGC00015479-11; NCGC00015479-12; NCGC00015479-13; NCGC00015479-14; NCGC00015479-15; NCGC00015479-16; NCGC00015479-17; NCGC00015479-18; NCGC00015479-19; NCGC00015479-20; NCGC00025005-01; NCGC00025005-02; NCGC00025005-03; NCGC00025005-04; NCGC00025005-05; NCGC00025005-06; NCGC00025005-07; NCGC00169711-01; NCGC00169711-02; NCGC00254275-01; NCGC00258979-01; NCGC00261205-01; 690224-00-1; AK161745; HY-14596; NCI60_003369; SC-04581; SMR000112580; ST056352; SY050124; AB1004490; EU-0100520; FT-0603395; G0272; N1861; SW203763-2; 46G720; C06563; G-2535; Genistein, synthetic, >=98% (HPLC), powder; J10015; K00046; S-7751; US8552057, 2; AB00052696_09; AB00052696_12; A826657; Q415957; Genistein, primary pharmaceutical reference standard; Q-100484; SR-01000075498-1; SR-01000075498-3; SR-01000075498-6; 3-(4-hydroxyphenyl)-5,7-bis(oxidanyl)chromen-4-one; BRD-K43797669-001-02-3; BRD-K43797669-001-03-1; BRD-K43797669-001-10-6; Genistein, from Glycine max (soybean), ~98% (HPLC); SR-01000075498-10; 5,7-dihydroxy-3-(4-hydroxyphenyl)-1-benzopyran-4-one; F0001-2388; 4H-1-Benzopyran-4-one,7-dihydroxy-3-(4-hydroxyphenyl)-; UNII-71B37NR06D component TZBJGXHYKVUXJN-UHFFFAOYSA-N; Genistein, United States Pharmacopeia (USP) Reference Standard; Genistein, Pharmaceutical Secondary Standard; Certified Reference Material; 4 inverted exclamation marka,5,7-Trihydroxyisoflavone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-DIHYDROXY-3-(4-HYDROXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; 4',5,7-TRIHYDROXYISOFLAVONE; PRUNETOL; GENISTEOL;",
"trade_name": "",
"abbrev_name": "",
"description": "flavonoid",
"molecular_formula": "C15H10O5",
"molecular_weight": "270.24",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5280961",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Drug",
"drug_type": "",
"target": [
"T001",
"T002",
"T019",
"T205",
"T408"
],
"function": [
"F0108",
"F0201",
"F020103",
"F02110301",
"F0303",
"F030501"
],
"references": [
"RC01451",
"RC01452",
"RC01963",
"RC02584",
"RC03205",
"RC03563",
"RC03734",
"RC04068",
"RC04192",
"RC04316",
"RC04440",
"RC04564"
]
},
{
"compound_ID": "D0952",
"name": "gentian violet",
"synonyms": "Crystal violet; gentian violet; 548-62-9; Basic violet 3; Hexamethylpararosaniline chloride; Aniline Violet; Methylrosaniline chloride; Hexamethyl Violet; Methyl Violet 10B; Gentiaverm; Pyoktanin; Adergon; Atmonil; Avermin; Axuris; Vianin; Viocid; Badil; Bismuth Violet; Basic Violet BN; methylrosanilinium chloride; Gentioletten; Genticid; Oxiuran; Oxycolor; Oxyozyl; Vermicid; Calcozine Violet C; Meroxyl-Wander; Brilliant Violet 5B; Meroxylan-Wander; Calcozine Violet 6BN; Hecto Violet R; Crystal Violet O; Violet CP; Paper Blue R; Crystal Violet chloride; Violet XXIII; Crystal Violet AO; Crystal Violet BP; Crystal Violet FN; Crystal Violet SS; Violet 5BO; Violet 6BN; Gentianaviolett; C.I. Basic violet 3; Crystal Violet 6B; Gentersal; Meroxylan; Crystal Violet AON; Crystal Violet BPC; Crystal Violet USP; Genapax; Meroxyl; Methyl Violet 5BO; Aizen Crystal Violet; Crystal Violet 5BO; Crystal Violet 6BO; Crystal Violet HL2; HEXAMETHYL-P-ROSANILINE CHLORIDE; Hectograph Violet SR; Methyl Violet 5BNO; Crystal Violet 10B; Hidaco crystal Violet; Methyl Violet 10BD; Methyl Violet 10BK; Methyl Violet 10BN; Methyl Violet 10BO; Mitsui Crystal Violet; Methyl Violet 10BNS; Plastoresin Violet 5BO; Crystal Violet Technical; 12416 Violet; Aniline Violet Pyoktanine; Crystal Violet Pure DSC; Crystal Violet Extra Pure; Pyoverm; CI Basic Violet 3; C.I. 42555; Crystal Violet chloride salt; Blaues pyoktanin; Violet cristallise; Crystal Violet Extra Pure APN; Methylrosanilini chloridum; Hidaco Brilliant Crystal Violet; 39393-39-0; Aizen Crystal Violet Extra Pure; Crystal Violet Extra Pure APNX; Methylrosanilinii chloridum; Methylrosanilinum chloratum; Crystal Violet Pure DSC Brilliant; Caswell No. 264A; Methylviolett [German]; Gentianaviolett [German]; Cloruro de metilrosanilina; CI 42555; Crystal Violet Base; Blaues pyoktanin [German]; Kristall-violett [German]; NCI-C55969; Violet gencianova [Czech]; Violet krystalova [Czech]; Violet zasadita 3 [Czech]; Hexamethyl p-rosaniline hydrochloride; C.I.Basic Violet 11:1; UNII-J4Z741D6O5; CCRIS 2464; Methylrosanilinchlorid [German]; Metilrosanilinio cloruro [DCIT]; Hexamethyl pararosaniline chloride; HSDB 4366; Gentian violet [USP]; GV-Eleven; Basic Violet-3; NSC 3090; EINECS 208-953-6; Methyl Violet 6B (biological stain); MFCD00011750; EPA Pesticide Chemical Code 039502; Methylrosanilinii chloridum [INN-Latin]; Cloruro de metilrosanilina [INN-Spanish]; Chlorure de methylrosanilinum [INN-French]; GVS; CHEBI:41688; J4Z741D6O5; NSC-3090; Hexamethyl-p-rosaniline hydrochloride; Methanaminium, N-(4-(bis(4-(dimethylamino)phenyl)methylene)-2,5-cyclohexadien-1-ylidene)-N-methyl-, chloride; Crystal violet solution; Gentian violet (USP); NCGC00091112-02; Methylviolett; Pararosaniline, N,N,N',N',N'',N''-hexamethyl-, chloride; DSSTox_CID_653; Crystal Violet, certified; C-8650; C-8651; C-8652; (4-(Bis(p-(dimethylamino)phenyl)methylene)-2,5-cyclohexadien-1-ylidene)dimethylammonium chloride; DSSTox_RID_75713; Crystal violet, ACS reagent; DSSTox_GSID_20653; (4-(4,4'-Bis(dimethylamino)benzhydrylidene)cyclohexa-2,5-dien-1-ylidene)dimethylammonium chloride; Crystal Violet, pure, indicator; Metilrosanilinio cloruro; Kristall-violett; Violet gencianova; Violet krystalova; GNF-PF-880; Violet zasadita 3; NSC3090; [4-[bis[4-(dimethylamino)phenyl]methylidene]cyclohexa-2,5-dien-1-ylidene]-dimethylazanium;chloride; Ammonium, (4-(bis(p-(dimethylamino)phenyl)methylene)-2,5-cyclohexadien-1-ylidene)dimethyl-, chloride; CAS-548-62-9; Methanaminium, N-[4-[bis[4-(dimethylamino)phenyl]methylene]-2,5-cyclohexadien-1-ylidene]-N-methyl-, chloride; N-(4-{bis[4-(dimethylamino)phenyl]methylidene}cyclohexa-2,5-dien-1-ylidene)-N-methylmethanaminium chloride; brilliant violet 58; Crystal Violet, pure, high purity biological stain; meroxylanwander; Chlorure de methylrosanilinum; Andergon; C25H30ClN3; genetian violet; Crystal-violet; C25H30N3.Cl; Hectograph violet; Axur is; Methylrosanilinium chloride [INN]; cryst al violet fn; (4-{bis[4-(dimethylamino)phenyl]methylene}cyclohexa-2,5-dienylidene)dimethylam ine, chloride; Methanaminium, N-(4-(bis(4-(dimethylamino)phenyl)methylene)-2,5-cyclohexadien-1-ylidene)-N-methyl-, chloride (1:1); Methanaminium, N-[4-[bis[4-(dimethylamino)phenyl]methylene]-2,5-cyclohexadien-1-ylidene]-N-methyl-, chloride (1:1); Genapax (TN); Gentian Violet solution; M ethyl Violet 10BNS; C .I. basic violet 3; Crystal Violet, micronized; Sentry aq mardel quick aid; EC 208-953-6; SCHEMBL9171; C25H30N3Cl; chlorure de methylrosanilinium; ARONIS27044; CHEMBL64894; SPECTRUM1500315; hexamethylparaosaniline chloride; Gram's Crystal Violet Solution; DTXSID5020653; Crystal Violet, SAJ first grade; HMS500B13; HY-B0324A; KS-00000YEO; C.I. Basic Violet 3 (8CI); Crystal Violet, A.C.S. reagent; ZXJXZNDDNMQXFV-UHFFFAOYSA-M; Crystal Violet, JIS special grade; Crystal Violet, SAJ special grade; Gram-Hucker's stain solution (I); HMS1920B11; HMS2091H15; HMS3655D03; Pharmakon1600-01500315; 548-62-9 (comp.); KS-000048JJ; Gentian violet, 95.0-105.0%; Tox21_111084; Tox21_201762; Tox21_300571; CCG-39763; Crystal Violet, 97.0-103.0%; GA9809; NSC757050; s1917; SBB009016; AKOS000282988; AKOS015901288; Crystal Violet, Dye content >=90 %; Tox21_111084_1; CS-2365; Gentian Violet solution, for microscopy; LS-1348; MCULE-6095016251; NSC-757050; ACM39393390; Methylrosanilinium chloride (JP17/INN); NCGC00091112-01; NCGC00091112-09; NCGC00094687-01; NCGC00094687-02; NCGC00254524-01; NCGC00259311-01; AC-12933; AS-49338; M211; AB2000374; Basic Violet 3 100 microg/mL in Methanol; FT-0628821; ST50411633; SW219351-1; Crystal violet solution, 1%, aqueous solution; A10245; D01046; EN300-113977; Gentian violet, for microscopy (Bact., Hist.); tris(4-(dimethylamino)phenyl)methylium chloride; Gentian Violet, meets USP testing specifications; Gentian Violet; Hexamethylpararosaniline chloride; Gentian violet;Hexamethyl pararosaniline chloride; Q420705; SR-05000001923; Crystal Violet, VETRANAL(TM), analytical standard; SR-05000001923-1; Crystal Violet, ACS reagent, >=90.0% anhydrous basis; Pararosaniline,N,N',N',N'',N''-hexamethyl-, chloride; Z2786051713; UNII-H2G44K8M7S component ZXJXZNDDNMQXFV-UHFFFAOYSA-M; Crystal Violet, certified by the Biological Stain Commission; WLN: L6Y DYJ AUYR DN1&1&R DN1&1& DUK1&1 &Q &G; Gentian Violet, United States Pharmacopeia (USP) Reference Standard; Methylrosanilinium chloride, European Pharmacopoeia (EP) Reference Standard; 4-{bis[4-(dimethylamino)phenyl]methylene}-N,N-dimethylcyclohexa-2,5-dien-1-iminium chloride; Basic Violet 3;Gentian Violet;Hexamethylpararosaniline chloride;Methyl Violet 10B; Crystal Violet, for microscopy (Bact., Bot., Hist., Vit.), indicator (pH 0.1-2.0); Crystal Violet, indicator for the determination of the redox potential, S. No.: 785; Methylrosanilinium for system suitability, European Pharmacopoeia (EP) Reference Standard; ((4-bis(p-(dimethylamino)phenyl)methylene)-2,5-cyclohexadien-1-ylidene)dimethylammonium chloride; (4-{bis[-(dimethylamino)phenyl]methylene}-2,5-cyclohexadien-1-ylidene)dimethylammonium chloride; 4-{bis[4-(dimethylamino)phenyl]methylidene}-N,N-dimethylcyclohexa-2,5-dien-1-iminium chloride; Methanaminium, N-[4-[bis[4-(dimethylamino)phen yl]methylene]-2,5-cyclohexadien-1-ylidene]-N-methyl-, chloride; Methanaminium,N-[4-[bis[4-(dimethylamino)phenyl]methylene]-2,5-cyclohexadien-1-ylidene]-N-methyl-, chloride; Methanaminium,N-[4-[bis[4-(dimethylamino)phenyl]methylene]-2,5-cyclohexadien-1-ylidene]-N-methyl-,chloride; N-(-4-{bis[4-(dimethylamino)phenyl]methylene}2,5-cyclohexadien-1-ylidene)-N-methyltrimethanaminium chloride; N-(4-(Bis(4-(dimethylamino)phenyl)methylene)cyclohexa-2,5-dien-1-ylidene)-N-methylmethanaminium chloride; N-(4-(bis(4-(dimethylamino)phenyl)methylene)cyclohexa-2,5-dienylidene)-N-methylmethanaminium chloride; N-(4-{bis[4-(dimethylamino)phenyl]methylene}-2,5-cyclohexadien-1-ylidene)-N-methylmethanaminium chloride; N-(4-{bis[4-(dimethylamino)phenyl]methylene}cyclohexa-2,5-dien-1-ylidene)-N-methylmethanaminium;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C25H30ClN3",
"molecular_weight": "408",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "11057",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01964",
"RC02585",
"RC03206"
]
},
{
"compound_ID": "D0953",
"name": "glycyrrhetinic acid",
"synonyms": "enoxolone; GLYCYRRHETINIC ACID; 471-53-4; 18-beta-Glycyrrhetinic acid; Glycyrrhetic acid; Uralenic acid; Glycyrrhetin; Jintan; Rhetinic Acid; 18beta-Glycyrrhetinic acid; Arthrodont; Biosone; alpha-Glycyrrhetinic acid; 3beta-Hydroxy-11-oxoolean-12-en-30-oic acid; Enoxolonum [INN-Latin]; Enoxolona [INN-Spanish]; 18-beta-Glycyrrhetic acid; UNII-P540XA09DR; Enoxolone [INN:BAN:DCF]; CCRIS 3962; 18beta-Glycyrrhetic acid; EINECS 207-444-6; NSC 35347; 3-Glycyrrhetinic acid; BRN 2229654; MLS000028748; CHEMBL230006; P540XA09DR; Enoxolone (Glycyrrhetinic acid); (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; CHEBI:30853; 3-beta-Hydroxy-11-oxoolean-12-en-30-oic acid; C30H46O4; Glycyrrhetinate; (3beta)-3-hydroxy-11-oxoolean-12-en-30-oic acid; NSC-35347; 18b-Glycyrrhetic acid; NCGC00017244-03; SMR000058239; DSSTox_CID_669; Olean-12-en-29-oic acid, 3-hydroxy-11-oxo-, (3beta,20beta)-; 18|A-Glycyrrhetinic acid; Glycyrrhetinic acid (JAN); Glycyrrhetinic acid [JAN]; DSSTox_RID_75722; DSSTox_GSID_20669; (2S,4aS,6aS,6bR,8aR,10S,12aS,12bR,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid; Olean-12-en-30-oic acid, 3-beta-hydroxy-11-oxo-; Enoxolonum; (3beta,20beta)-3-Hydroxy-11-oxo-olean-12-en-29-oic acid; Enoxolona; Glyciram; (3beta,5beta,14beta)-3-Hydroxy-11-Oxoolean-12-En-29-Oic Acid; 18-beta-Glycyrrhetinic acid, 98+%; 1449-05-4; (5S,8S,15S,18S,1R,2R,10R,14R,20R)-18-hydroxy-1,2,5,8,15,19,19-heptamethyl-13-o xopentacyclo[12.8.0.0<2,11>.0<5,10>.0<15,20>]docos-11-ene-8-carboxylic acid; CAS-471-53-4; SR-01000721867; Enoloxone; NSC-35350; Hidermart (TN); Enoxolone (INN); NCGC00181115-01; CBW; MFCD00003706; Enoxolone (Glycyrrhetin); Opera_ID_1048; SCHEMBL18540; 18 beta-Glycyrrhetintic Acid; 4-10-00-03775 (Beilstein Handbook Reference); MLS001146949; MLS002207101; Enoxolone, Glycyrrhetinic acid; DTXSID9020669; STX-352; CHEBI: 30853; 18beta-Glycyrrhetinic acid, 97%; HMS2233P23; HY-N0180; Tox21_110804; Tox21_112726; Tox21_200799; BDBM50233538; s2296; SBB006496; ZINC19203131; AKOS015960428; AKOS016036757; HMDB: 0011628; AC-1925; AC-8906; API0002854; CCG-208506; CS-W020624; DB13089; GM-1658; KS-1262; LMPR0106150014; LS-7417; MCULE-4676598997; NCGC00017244-04; NCGC00017244-06; NCGC00142473-03; NCGC00258353-01; ST056310; FT-0082445; G0149; ST24038257; 3beta-hydroxy-11-oxoolean-12-en-29-oic acid; C02283; D00156; S00284; 130100-EP2269977A2; 130100-EP2295411A1; 471G534; A827163; (3?)-3-Hydroxy-11-oxoolean-12-en-30-oic acid; 18beta-Glycyrrhetinic acid, purum, >=97.0% (T); Olean-12-en-30-oic acid, 3beta-hydroxy-11-oxo-; Q-201057; Q5948038; SR-01000721867-3; SR-01000721867-4; SR-01000721867-5; SR-01000721867-6; BRD-K96137854-001-17-1; Enoxolone, European Pharmacopoeia (EP) Reference Standard; Olean-12-en-30-oic acid, 3beta-hydroxy-11-oxo- (8CI); 3beta-Hydroxy-11-oxo-18beta,20beta-olean-12-en-29-oic acid; (3alpha,5xi,8alpha,9xi,17alpha,18xi)-3-hydroxy-11-oxoolean-12-en-29-oic acid; (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-2,4a,6a,6b,9,9,12a-heptamethyl-10-oxidanyl-13-oxidanylidene-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; Enoxolone; 18beta-Glycyrrhetinic acid; 3?-Hydroxy-11-oxo-18?,20?-olean-12-en-29-oic acid;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C30H46O4",
"molecular_weight": "470.7",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "10114",
"classification": "D",
"indications": "",
"side_effects": "",
"atc_codes": "D03AX10",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01965",
"RC02586",
"RC03207"
]
},
{
"compound_ID": "D0954",
"name": "gramicidin",
"synonyms": "GRAMICIDIN; Gramicidinum; Gramicidina; Gramicidine; 1405-97-6; garamicidin D; Gramicidin [USP:INN:BAN]; UNII-5IE62321P4; SCHEMBL163104; ZWCXYZRRTRDGQE-SORVKSEFSA-N; NSC183503; AKOS026750031; 5IE62321P4; HCO-Val-Gly-D-Leu-Ala-D-Val-Val-D-Val-[Trp-D-Leu]3-Trp-NH2-CH2CH2OH;",
"trade_name": "",
"abbrev_name": "",
"description": "ionophore; antibiotic",
"molecular_formula": "C99H140N20O17",
"molecular_weight": "1882.3",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "16130140",
"classification": "R",
"indications": "",
"side_effects": "",
"atc_codes": "R02AB30",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F010602",
"F0108"
],
"references": [
"RC01966",
"RC02587",
"RC03208",
"RC03488"
]
},
{
"compound_ID": "D0955",
"name": "halobetasol propionate",
"synonyms": "HALOBETASOL PROPIONATE; 66852-54-8; Ulobetasol propionate; Ultravate; Halobetasol (propionate); UNII-91A0K1TY3Z; BMY-30056; CGP-14458; 91A0K1TY3Z; Miracorten; BMY 30056; Halobetasol propionate (USAN); Ultravate (TN); NCGC00167451-01; Halobetasol propionate [USAN:USP]; 21-Chloro-6alpha,9-difluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate; Halobetasolpropionate; halobetasol-propionate; BMY-30056;CGP-14458;Ulobetasol propionate; DSSTox_CID_26636; DSSTox_RID_81782; DSSTox_GSID_46636; SCHEMBL33858; CHEMBL1200908; DTXSID6046636; CTK8G0126; BDSYKGHYMJNPAB-LICBFIPMSA-N; CHEBI:135782; (6S,8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl propionate; HY-B0878; Pregna-1,4-diene-3,20-dione, 21-chloro-6,9-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-, (6alpha,11beta,16beta)-; ZINC3920028; Tox21_112455; s4089; AKOS025310143; API0002882; CGP-14,458; CS-4305; NCGC00373230-02; [(6S,8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate; SC-18329; AB2000750; CAS-66852-54-8; D04409; AB01566925_01; 852H548; SR-01000942239; SR-01000942239-1; (6|A,11|A,16|A)-21-Chloro-6,9-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)pregna-1,4-diene-3,20-dione; Miracorten; Ulobetasol propionate; Ultravate;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C25H31ClF2O5",
"molecular_weight": "485",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "6918178",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01967",
"RC02588",
"RC03209"
]
},
{
"compound_ID": "D0956",
"name": "heptachlor",
"synonyms": "heptachlor; Heptachlorane; Heptamul; 3-Chlorochlordene; 76-44-8; Rhodiachlor; Aahepta; Agroceres; Heptagran; Hepta; Velsicol heptachlor; GPKh; Technical heptachlor; Eptacloro; Heptachloor; Heptachlore; Heptox; Velsicol 104; Arbinex 30TN; Heptagranox; Basaklor; Heptamak; Heptasol; Soleptax; Rcra waste number P059; NCI-C00180; Eptacloro [Italian]; Heptachloor [Dutch]; Heptachlore [French]; Caswell No. 474; Latka 104; ENT 15,152; Heptachlor [BSI:ISO]; Heptachlorotetrahydro-4,7-methanoindene; Latka 104 [Czech]; H-34; Heptachlore [ISO-French]; NSC 8930; Gold Crest H-60, Termide; Heptachlor (technical grade); CCRIS 324; 4,7-Methano-1H-indene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro-; E 3314; HSDB 554; Drinox H-34; H-60; OMS 193; 1,4,5,6,7,8,8-Heptachloro-3a,4,7,7a-tetrahydro-4,7-methanoindene; 3,4,5,6,7,8,8a-Heptachlorodicyclopentadiene; EINECS 200-962-3; Heptachlor and metabolites; RCRA waste no. P059; EPA Pesticide Chemical Code 044801; Dicyclopentadiene, 3,4,5,6,7,8,8a-heptachloro-; 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro-1H-4,7-methanoindene; 1,4,5,6,7,8,8-Heptachloro-3a,4,7,7a-tetrahydro-4,7-methano-1H-indene; AI3-15152; CHEBI:34785; 1,4,5,6,7,10,10-Heptachloro-4,7,8,9-tetrahydro-4,7-methyleneindene; 1,4,5,6,7,8,8a-Heptachloro-3a,4,7,7a-tetrahydro-4,7-methanoindane; 4,7-Methanoindene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro-; 1(3a),4,5,6,7,8,8-Heptachloro-3a(1),4,7,7a-tetrahydro-4,7-methanoindene; alpha-Dicyclopentadiene, 3,4,5,6,7,8,8A-heptachloro-; 1,4,5,6,7,8,8-Heptachlorotetrahydro-4,7-methanoindene; DSSTox_CID_679; 1,4,5,6,7,8,8-Eptacloro-3a,4,7,7a-tetraidro-4,7-endo-metano-indene; 1,4,5,6,7,10,10-Heptachloro-4,7,8,9-tetrahydro-4,7-endomethyleneindene; 1,4,5,6,7,8,8-Heptachloor-3a,4,7,7a-tetrahydro-4,7-endo-methano-indeen; 1,4,5,6,7,8,8-Heptachlor-3a,4,7,7,7a-tetrahydro-4,7-endo-methano-inden; 1,4,5,6,7,8,8-Heptachloro-3a,4,7,7a-tetrahydro-4,7-endomethanoindene; 1,4,5,6,7,8,8-Heptachloro-3a,4,7,7a-tetrahydro-4,7-methanol-1H-indene; 1,4,5,6,7,8,8-Eptacloro-3a,4,7,7a-tetraidro-4,7-endo-metano-indene [Italian]; 1,4,5,6,7,8,8-Heptachloor-3a,4,7,7a-tetrahydro-4,7-endo-methano-indeen [Dutch]; 1,4,5,6,7,8,8-Heptachlor-3a,4,7,7,7a-tetrahydro-4,7-endo-methano-inden [German]; DSSTox_RID_75727; DSSTox_GSID_20679; heptaklor; 1,5,7,8,9,10,10-heptachlorotricyclo[5.2.1.0(2,6)]deca-3,8-diene; CAS-76-44-8; Tetrahydro; hepta klor; Spectrum_001951; SpecPlus_000590; Spectrum2_001891; Spectrum3_000865; Spectrum4_000705; Spectrum5_002052; SCHEMBL65124; BSPBio_002509; KBioGR_001229; KBioSS_002505; SPECTRUM330078; MLS002454407; DivK1c_006686; SPBio_001822; CHEMBL194400; DTXSID3020679; KBio1_001630; KBio2_002497; KBio2_005065; KBio2_007633; KBio3_002009; NSC8930; FRCCEHPWNOQAEU-UHFFFAOYSA-N; NSC-8930; Tox21_201911; Tox21_300534; BDBM50410521; CCG-39341; LS-1694; NCGC00091514-01; NCGC00094549-01; NCGC00094549-02; NCGC00094549-03; NCGC00094549-04; NCGC00094549-05; NCGC00254523-01; NCGC00259460-01; SMR001372010; 3,5,6,7,8,8-Heptachlorodicyclopentadiene; C14185; Dicyclopentadiene,4,5,6,7,8,8a-heptachloro-; Q417891; WLN: L C555 A DU IUTJ AG AG BG FG HG IG JG; 4, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro-; 1,5,6,7,8,8-Heptachloro-3a,4,7,7a-tetrahydro-4,7-methanoindene; 3a,5,6,7,8,8-Heptachloro-3a,4,7,7a-tetrahydro-4,7-methanoindene; 1(3a),5,6,7,8,8-Heptachloro-3a(1),4,7,7a-tetrahydro-4,7-methanoindene; 1,4,5,6,7,10,10-hept achloro-4,7,8,9-tetrahydro-4,7-methyleneindene; 1,4,5,6,7,8,8-h eptachloro-3a,4,7,7a-tetrahydro-4,7-endomethanoindene; 1,4,5,6,7,8,8-Heptachloro-3a,4,7,7,7a-tetrahydro-4,7-methylene indene; 1,4,5,6,7,8,8-heptachloro-3a,4,7,7,7a-tetrahydro-4,7-methyleneindene; 1,4,5,6,7,8,8-Heptachloro-3a,4,7,7a-tetrahydro-4,7-endo-methanoindene; 1,4,5,6,7,8,8a-heptachloro-3a,4,7,7a-tetrahydro-4,7-methanoindene; 1,5,6,7,10,10-Heptachloro-4,7,8,9-tetrahydro-4,7-endo-methyleneindene; 1,5,6,7,10,10-Heptachloro-4,7,8,9-tetrahydro-4,7-methyleneindene; 1,5,6,7,8,8-Eptacloro-3a,4,7,7a-tetraidro-4,7-endo-metano-indene; 1,5,6,7,8,8-Heptachloor-3a,4,7,7a-tetrahydro-4,7-endo-methano-indeen; 1,5,6,7,8,8-Heptachlor-3a,4,7,7,7a-tetrahydro-4,7-endo-methano-inden; 1,5,6,7,8,8-Heptachloro-3a,4,7,7,7a-tetrahydro-4,7-methylene indene; 1,5,6,7,8,8-Heptachloro-3a,4,7,7a- tetrahydro-4,7-methanoindene; 1,5,6,7,8,8-Heptachloro-3a,4,7,7a-tetrahydro-4,7-endo-methanoindene; 1H-1,4,5, 6,7,8,8-Heptachloro-3a,4,7,7a-tetrahydro-4,7-methanoindene; 1H-1,4,5,6,7,8,8-Heptachloro-3a,4,7,7a-tetrahydro-4,7-methanoindene; 1H-1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro-4-methanoindene; (4S,7S)-1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro-1H-4,7-methanoindene; 1,4,5,6,7,10,10-Heptachloro-4,7,8,9-tetrahydro-4,7-endo-methyleneindene; Indene, 1,4,5,6,7,8,8-heptachloro-3alpha,4,7,7alpha-tetrahydro-4,7-methano-; 6,7,8,9,10,10-hexachloro-1,5,5a,6,9,9a-hexahydro-3-methyl-4,7-Methano-1H-ind ene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro-6,9-methano-2,4,3-benzodioxathiepin; 6,7,8,9,10,10-hexachloro-1,5,5a,6,9,9a-hexahydro-3-methyl-4,7-Methano-1H-indene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro-6,9-methano-2,4,3-benzodioxathiepin;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C10H5Cl7",
"molecular_weight": "373.3",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "3589",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01968",
"RC02589",
"RC03210"
]
},
{
"compound_ID": "D0957",
"name": "hydroxystilbamidine bis(methanesulfonate)",
"synonyms": "Methanesulfonate; methylsulfonate; Methanesulfonate anion; methanesulphonate; methyl sulfonate; methane sulfonate; methane-sulfonate; Methanesulfonic acid, ion(1-); methyl sulphonate; methane sulphonate; DTXSID7044009; CHEBI:25224; NOCAS_44009; AFVFQIVMOAPDHO-UHFFFAOYSA-M; 16053-58-0; Q27109874;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "CH3O3S-",
"molecular_weight": "95.1",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "85257",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01970",
"RC02591",
"RC03212"
]
},
{
"compound_ID": "D0958",
"name": "idarubicin hydrochloride",
"synonyms": "idarubicin hydrochloride; Idarubicin Hcl; 57852-57-0; Zavedos; Idamycin; Idarubicin (hydrochloride); UNII-5VV3MDU5IE; 5VV3MDU5IE; CPD000466355; Idamycin PFS; MLS001401448; IMI 30; IMI-30; 4-Demethoxydaunorubicin hydrochloride; DSSTox_CID_27775; DSSTox_RID_82550; DSSTox_GSID_47797; SMR000466355; EINECS 260-990-7; CAS-57852-57-0; NSC 256439; NSC-256439; NCGC00093976-03; Idarubicin hydrochloride PFS; SR-01000075934; Daunomycin, 4-demethoxy-, hydrochloride; Idamycin (TN); (1S,3S)-3-Acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside, hydrochloride; DMDR; Idarubicin hydrochlorid; Idarubicin hydrochloride [USAN:USP:INN]; SCHEMBL4838; C26H27NO9.HCl; MLS000759470; CHEMBL1200976; DTXSID0047797; CHEBI:31686; JVHPTYWUBOQMBP-RVFAQHLVSA-N; KUC110342C; (7S-cis)-9-Acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxynaphthacene-5,12-dione hydrochloride; 5,12-Naphthacenedione, 9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxyhydrochloride, (7S-cis)-; EX-A1148; Tox21_111236; MFCD00866457; s1228; Idarubicin hydrochloride (JP17/USP); AKOS025402118; Tox21_111236_1; AC-5255; API0002971; CCG-100886; CS-1061; NC00136; NCGC00093976-08; HY-17381; SAM001246676; SC-25438; KSC-230-185-1; D01747; W-5198; 33820-EP2275420A1; 33820-EP2295055A2; 33820-EP2295416A2; 33820-EP2298748A2; 33820-EP2298764A1; 33820-EP2298765A1; 33820-EP2298768A1; 33820-EP2305642A2; 33820-EP2311453A1; 852I570; Q-101407; SR-01000075934-5; Q27262943; (7S,9S)-9-acetyl-7-((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride; (7S-cis)-9-acetyl-7-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxynaphthacene-5,12-dione hydrochloride; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C26H28ClNO9",
"molecular_weight": "534",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "The drug is eliminated predominately by biliary and to a lesser extent by renal excretion, mostly in the form of idarubicinol.",
"protein_binding": "0.97",
"half_life": "22 hours",
"absorption": "",
"cid": "636362",
"classification": "L",
"indications": "",
"side_effects": "",
"atc_codes": "L01DB06",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01971",
"RC02592",
"RC03213"
]
},
{
"compound_ID": "D0959",
"name": "idazoxan",
"synonyms": "IDAZOXAN; 79944-58-4; Idazoxane; Idazoxano; Idazoxanum; Idazoxane [French]; Idazoxanum [Latin]; 2-(2,3-Dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole; Idazoxano [Spanish]; CHEMBL10316; RX-781094; CHEBI:5862; HPMRFMKYPGXPEP-UHFFFAOYSA-N; NCGC00015560-06; DSSTox_CID_25161; DSSTox_RID_80711; (+-)-2-(1,4-Benzodioxan-2-yl)-2-imidazoline; DSSTox_GSID_45161; 4,5-dihydro-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-1H-imidazole; 1H-Imidazole, 4,5-dihydro-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-; CAS-79944-58-4; Idazoxan [BAN:INN]; Idazoxan [INN:BAN]; idasoxan; 2-(2,3-dihydro-1,4-benzodioxin-3-yl)-4,5-dihydro-1H-imidazole; Prestwick0_000926; Prestwick1_000926; Prestwick2_000926; Prestwick3_000926; Lopac0_000652; US8633208, Idazoxan; BSPBio_000832; SCHEMBL114731; SPBio_003011; BPBio1_000916; DTXSID6045161; HMS2089E14; Tox21 110173; Tox21_110173; BDBM50019848; 2-(1,4-benzodioxan-2-yl)imidazoline; AKOS015915004; Tox21_110173_1; API0007263; CCG-204739; DB12551; NCGC00015560-04; NCGC00015560-05; NCGC00015560-08; NCGC00015560-09; NCGC00015560-10; NCGC00015560-12; NCGC00024794-03; NCGC00024794-04; LS-78447; SBI-0050632.P002; AB00514632; FT-0655996; C10968; AB00489883-09; AB00489883_10; A839791; L000808; Q5987770; BRD-A18696154-003-03-6; BRD-A18696154-003-14-3;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C11H12N2O2",
"molecular_weight": "204.22",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "54459",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01972",
"RC02593",
"RC03214"
]
},
{
"compound_ID": "D0960",
"name": "indole-3-pyruvic acid",
"synonyms": "Indole-3-pyruvic acid; 392-12-1; 3-(1H-Indol-3-yl)-2-oxopropanoic acid; Indole-3-pyruvate; Indolepyruvic acid; 3-Indolylpyruvic acid; indolepyruvate; Indole pyruvic acid; Indolyl-3-pyruvate; 3-Indolepyruvic acid; indol-3-yl pyruvic acid; 3-Indolylpyroracemic acid; beta-Indolepyruvic acid; beta-Indolylpyruvic acid; Indole-3-pyruvic acid monohydrate; Indole-3-pyrubate; UNII-4QM0LT13A8; NSC 88874; 3-(indol-3-yl)pyruvic acid; (Indol-3-yl)pyruvate; 1H-Indole-3-propanoic acid, .alpha.-oxo-; EINECS 206-874-1; (indol-3-yl)pyruvic acid; alpha-Oxo-1H-indole-3-propanoic acid; BRN 0172966; 1H-Indole-3-propanoic acid, alpha-oxo-; 4QM0LT13A8; CHEBI:29750; RSTKLPZEZYGQPY-UHFFFAOYSA-N; 3-indol-3-yl-2-oxopropanoic acid; 3IO; 3-(3-Indolyl)-2-oxopropanoic acid; Indol-3-ylpyruvic acid; 35656-49-6; 3-Indolpyruvic acid; indol-3-pyruvic acid; PubChem7282; 3-indole-pyruvic acid; .beta.-Indolepyruvic acid; .beta.-Indolylpyruvic acid; bmse000646; bmse000685; 1H-Indole-3-pyruvic acid; DSSTox_CID_22053; DSSTox_RID_79908; DSSTox_GSID_42053; 5-22-06-00324 (Beilstein Handbook Reference); MLS000515792; ARONIS24313; SCHEMBL125249; CHEMBL485012; DTXSID3042053; CTK4I1112; HMS2270A21; EBD45217; KS-000018CS; NSC88874; ZINC1532617; 1H-Indole-3-propanoicacid, a-oxo-; Tox21_301365; ANW-46652; CI-014; NSC-88874; SBB003515; STL286879; AKOS005267243; MCULE-1073478615; VI30400; NCGC00247042-01; NCGC00255790-01; AC-10208; AS-63461; CAS-392-12-1; LS-83400; SMR000112266; ST056381; 3-(1H-indol-3-yl)-2-keto-propionic acid; AB1011912; Indole-3-pyruvic acid, >=98.0% (TLC); TC-135397; FT-0627222; ST24028266; KS-00004725; C00331; I-4200; 1H-Indole-3-propanoic acid, alpha-oxo- (9CI); 392I121; 3-(1H-indol-3-yl)-2-oxidanylidene-propanoic acid; AC17FD8D-94BC-4C87-B5E6-D2B60F03B45D; Q23905803; F9995-2651; 3-(3-Indolyl)-2-oxopropanoic acid; 3-Indolylpyruvic acid; 3-Indolylpyruvic acid; 3-(3-Indolyl)-2-oxopropanoic acid; alpha-Oxo-1H-indole-3-propanoic acid;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C11H9NO3",
"molecular_weight": "203.19",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "803",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01973",
"RC02594",
"RC03215"
]
},
{
"compound_ID": "D0961",
"name": "indoxacarb",
"synonyms": "Indoxacarb; Steward; 173584-44-6; Provaunt; Advion; Avatar; Avaunt; Avent; Indoxacarb [ISO]; (S)-Indoxacarb; UNII-52H0D26MWR; (4aS)-indoxacarb; DPX-KN 128; HSDB 7280; DPX-MP 062-381; 52H0D26MWR; CHEBI:38630; 174060-41-4; methyl (4aS)-7-chloro-2-[methoxycarbonyl-[4-(trifluoromethoxy)phenyl]carbamoyl]-3,5-dihydroindeno[1,2-e][1,3,4]oxadiazine-4a-carboxylate; methyl (4aS)-7-chloro-2-{(methoxycarbonyl)[4-(trifluoromethoxy)phenyl]carbamoyl}-2,5-dihydroindeno[1,2-e][1,3,4]oxadiazine-4a(3H)-carboxylate; Methyl (S)-7chloro-2,5-dihydro-2-(((methoxycarbonyl)(4-(trifluoromethoxy)phenyl)amino)carbonylindeno(1,2-e)(1,3,4)oxadiazine-4a(3H)-carboxylate; Indeno(1,2-e)(1,3,4)oxadiazine-4a(3H)-carboxylic acid, 7-chloro-2,5-dihydro-2-(((methoxycarbonyl)(4-(trifluoromethoxy)phenyl)amino)carbonyl)-, methyl ester, (4aS)-; C22H17ClF3N3O7; Indoxacarb (JAN); DSSTox_CID_12690; DSSTox_RID_79034; DSSTox_GSID_32690; SCHEMBL22073; CHEMBL197676; DTXSID1032690; Tox21_300723; ZINC28527855; NCGC00164264-02; NCGC00164264-03; NCGC00254629-01; AS-35129; LS-81841; M576; CAS-173584-44-6; FT-0631195; Indoxacarb, PESTANAL(R), analytical standard; C18569; D06316; 31414-EP2274983A1; 31414-EP2305662A1; 31414-EP2308857A1; 31414-EP2308858A1; 31414-EP2311816A1; 31414-EP2311817A1; Q421469; UNII-PKL1F8Y0FV component VBCVPMMZEGZULK-NRFANRHFSA-N; (S)-methyl 7-chloro-2-(methoxycarbonyl(4-(trifluoromethoxy)phenyl)carbamoyl)-2,3,4a,5-tetrahydroindeno[1,2-e][1,3,4]oxadiazine-4a-carboxylate; Pesticide3_Indoxacarb_C22H17ClF3N3O7_Methyl (4aS)-7-chloro-2-{(methoxycarbonyl)[4-(trifluoromethoxy)phenyl]carbamoyl}-2,5-dihydroindeno[1,2-e][1,3,4]oxadiazine-4a(3H)-carboxylate;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C22H17ClF3N3O7",
"molecular_weight": "527.8",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "107720",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01974",
"RC02595",
"RC03216"
]
},
{
"compound_ID": "D0962",
"name": "iodophthalein",
"synonyms": "Iodophthalein; 386-17-4; Iodophene; 3',3'',5',5''-Tetraiodophenolphthalein; Jodphthaleinum; UNII-R2CC46UA50; EINECS 206-857-9; 3,3-Bis(4-hydroxy-3,5-diiodophenyl)phthalide; BRN 0351654; Iodophthalein sodium free acid; 3,3-bis(4-hydroxy-3,5-diiodo-phenyl)isobenzofuran-1-one; R2CC46UA50; 3,3-bis(4-hydroxy-3,5-diiodophenyl)-2-benzofuran-1(3h)-one; 1(3H)-Isobenzofuranone, 3,3-bis(4-hydroxy-3,5-diiodophenyl)-; 3,3-Bis(4-hydroxy-3,5-diiodophenyl)isobenzofuran-1(3H)-one; Phenolphthalein, 3',3'',5',5''-tetraiodo-; 561-28-4; 3,3-bis(4-hydroxy-3,5-diiodophenyl)-2-benzofuran-1-one; 3,3-Bis(4-hydroxy-3,5-diiodophenyl)-1(3H)-isobenzofuranone; 3,3-bis(4-hydroxy-3,5-diiodophenyl)-3-hydroisobenzofuran-1-one; Tetraiodophthalein; UPCMLD-DP078; 4-18-00-01949 (Beilstein Handbook Reference); MLS004773975; SCHEMBL2833068; CHEMBL1325961; UPCMLD-DP078:001; CTK5A4667; DTXSID10971479; NSC4904; NSC-4904; ZINC8214582; ACM386174; ANW-43515; MFCD00001614; SBB057654; AKOS001044034; MCULE-7693796339; AS-58248; SMR002529480; LS-105082; ST51006759; Q19286247; 3,3-bis(4-hydroxy-3,5-diiodophenyl)-1,3-dihydro-2-benzofuran-1-one;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C20H10I4O4",
"molecular_weight": "821.9",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "67846",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01975",
"RC02596",
"RC03217"
]
},
{
"compound_ID": "D0963",
"name": "iodophthalein sodium",
"synonyms": "Iodophthalein sodium; Iodotetragnost; Tipps; Tetiothalein sodium; Cholepulvis; Iodognostum; Iodorayoral; Iodtetragnost; Photobiline; Radiotetrane; Antinosin; Cholumbrin; Galisol; Iodeikon; Iodognost; Keraphen; Piliophen; Shadocol; Sombrachol; Stipolac; Tetraiode; Videophel; Foriod; Opacin; Oral-Tetragnost; Iodophene sodium; Nosophene sodium; Soluble iodophthalein; Tetraiodophenolphthalein sodium; Tetraiodophthalein sodium; UNII-B4MZ5QGA1M; Iodoftaleina sodica [INN-Spanish]; Iodophtaleine sodique [INN-French]; EINECS 218-715-3; Iodophthaleinum natricum [INN-Latin]; B4MZ5QGA1M; 2217-44-9; Disodium salt of tetraiodophenolphthalein; Jodphthalein sodium; DSSTox_CID_26768; DSSTox_RID_81891; DSSTox_GSID_46768; Phenolphthalein, 3',3'',5',5''-tetraiodo-, disodium salt; Iodoftaleina sodica; CAS-2217-44-9; Iodophtaleine sodique; Iodophthaleinum natricum; NCGC00168349-01; Iodophthalein sodium [INN:NF]; 2-[(3,5-diiodo-4-oxocyclohexa-2,5-dienylidene)(4-hydroxy-3,5-diiodophenyl)meth yl]benzoic acid, sodium salt, sodium salt; IODOPHTHALEIN, SOLUBLE; 3',3'',5',5''-Tetraiodophenolphthalein, disodium; SCHEMBL2138835; CHEMBL3185933; DTXSID1046768; Tox21_112622; SBB057279; AKOS024364984; Tox21_112622_1; ACM2217449; MCULE-3067364044; NCGC00161636-02; LS-105083; ST50997601; 16290-EP2281563A1; 16290-EP2316459A1; Q27274363; 2-[alpha-(3,5-Diiodo-4-oxo-2,5-cyclohexadienylidene)-3,5-diiodo-4-(sodiooxy)benzyl]benzoic acid sodium salt;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C20H8I4Na2O4",
"molecular_weight": "865.9",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "75194",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01976",
"RC02597",
"RC03218"
]
},
{
"compound_ID": "D0964",
"name": "isobutylparaben",
"synonyms": "Isobutyl 4-hydroxybenzoate; Isobutylparaben; 4247-02-3; Isobutyl p-hydroxybenzoate; 2-Methylpropyl 4-hydroxybenzoate; isobutyl paraben; Isobutyl-4-hydroxybenzoate; Isobutyl parahydroxybenzoate; 4-Hydroxybenzoic Acid Isobutyl Ester; Benzoic acid, 4-hydroxy-, 2-methylpropyl ester; p-Oxybenzoesaureisobutylester; UNII-0QQJ25X58G; 0QQJ25X58G; CCRIS 2463; XPJVKCRENWUEJH-UHFFFAOYSA-N; BENZOIC ACID, p-HYDROXY-, ISOBUTYL ESTER; EINECS 224-208-8; p-Hydroxybenzoic acid isobutyl ester; ISOBUTYL PARA HYDROXY BENZOATE; p-Oxybenzoesaureisobutylester [German]; BRN 2642305; 4-Hydroxybenzoic acid, 2-methylpropyl ester; Isobutyl4-hydroxybenzoate; DSSTox_CID_749; ChemDiv2_000057; ACMC-2097ew; Isobutyl-4-hydroxy benzoate; DSSTox_RID_75767; DSSTox_GSID_20749; SCHEMBL34633; Methylpropyl p-hydroxybenzoate; KSC489Q8T; BIDD:ER0110; ARONIS013135; CHEMBL3182006; DTXSID4020749; CTK3I9889; KS-00000VPJ; Isobutyl 4-hydroxybenzoate, 97%; HMS1369C13; ZINC225900; KS-000043VJ; 4-Hydroxybenzoic acid-isobutyl ester; Tox21_200501; ANW-13878; MFCD00020167; SBB080168; STL067196; p-Hydroxybenzoic acid iso-butyl ester; p-Hydroxybenzoic acid sec-butyl ester; AKOS000319531; LS-7460; MCULE-4335589438; RTR-016620; TRA0067808; NCGC00248662-01; NCGC00258055-01; AK114266; AS-15247; O620; CAS-4247-02-3; DB-070303; TR-016620; EU-0033430; FT-0618696; I0816; ST24047425; ST45049845; C20342; 3-10-00-00308 (Beilstein Handbook Reference); SR-01000389342; SR-01000389342-1; W-106272; Q27237117; Benzoic acid, 4-hydroxy-, 2-methylpropyl ester (9CI); 2-Methylpropyl 4-Hydroxybenzoate (Isobutyl Parahydroxybenzoate); 4-Hydroxybenzoic acid-iso-butyl ester 100 microg/mL in Acetonitrile; Butyl parahydroxybenzoate impurity E, European Pharmacopoeia (EP) Reference Standard;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C11H14O3",
"molecular_weight": "194.23",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "20240",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01977",
"RC02598",
"RC03219"
]
},
{
"compound_ID": "D0965",
"name": "isodrin",
"synonyms": "ISODRIN; Isodrine [France]; Isodrin (VAN); Isodrin [BSI]; Compound 711; Isodrin (insecticide); Latka 711 [Czech]; Experimental insecticide 711; HSDB 6049; NSC 8936; EINECS 207-366-2; ENT 19,244; SD 3418; BRN 3214094; AI3-19244; RCRA waste no. P060; (1alpha,4alpha,4abeta,5beta,8beta,8abeta)-1,2,3,4,10,10-Hexachloro-1,4,4a,5,8,8a-hexahydro-1,4:5,8-dimethanonaphthalene; (1alpha,4alpha,4Abeta,5beta,8beta8abeta)-1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-1,4:5,8-dimethanonaphthalene; (1R,4S,5R,8S)-1,2,3,4,10,10-Hexachloro-1,4,4a,5,8,8a-hexahydro-1,4:5,8-dimethanonaphthalene; 1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, (1alpha,4alpha,4abeta,5beta,8 beta,8abeta)-; 1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, (1R,4S,4aS,5R,8S,8aR)-rel-; 465-73-6; CHEBI:82100; 1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, (1alpha,4alpha,4abeta,5beta,8beta,8abeta)-; 1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, endo, endo-; LS-62015; C18961; Q18589682;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C12H8Cl6",
"molecular_weight": "364.9",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "10066",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01978",
"RC02599",
"RC03220"
]
},
{
"compound_ID": "D0966",
"name": "isoxaben",
"synonyms": "Isoxaben; 82558-50-7; Benzamizole; Flexidor; Gallery; X-Pand; Cent 7; Prolan (herbicide); EL 107; Caswell No. 419F; Compound 121607; Isoxaben [BSI:ISO]; 2,6-dimethoxy-N-[3-(3-methylpentan-3-yl)-1,2-oxazol-5-yl]benzamide; UNII-101V41EEA4; NA 8318; HSDB 6691; N-(3-(1-Ethyl-1-methylpropyl)-5-isoxazolyl)-2,6-dimethoxybenzamide; EPA Pesticide Chemical Code 125851; 2,6-Dimethoxy-N-(3-(1-ethyl-1-methylpropyl)-5-isoxazolyl)benzamide; CHEBI:63956; PMHURSZHKKJGBM-UHFFFAOYSA-N; 101V41EEA4; N-(3-(1-Ethyl-methylpropyl)-5-isoxazolyl)-2,6-dimethoxybenzamide; Benzamide, N-[3-(1-ethyl-1-methylpropyl)-5-isoxazolyl]-2,6-dimethoxy-; DSSTox_CID_4159; DSSTox_RID_77309; DSSTox_GSID_24159; N-[3-(1-Ethyl-1-methylpropyl)-5-isoxazolyl]-2,6-dimethoxybenzamide; Benzamide, 2,6-dimethoxy-N-(3-(1-ethyl-1-methylpropyl)-5-isoxazolyl)-; CAS-82558-50-7; Knot out; Benzamide, N-(3-(1-ethyl-1-methylpropyl)-5-isoxazolyl)-2,6-dimethoxy-; N-[3-(1-ethyl-1-methylpropyl)isoxazol-5-yl]-2,6-dimethoxybenzamide; N-[3-(1-ethyl-1-methylpropyl]-5-isoxazolyl]-2,6-dimethoxybenzamide; EC 407-190-8; SCHEMBL54432; CHEMBL2142789; DTXSID8024159; CTK8G0402; PMHURSZHKKJGBM-UHFFFAOYSA-; ZINC2004090; Tox21_201574; Tox21_300696; Isoxaben 100 microg/mL in Methanol; NCGC00164275-01; NCGC00164275-02; NCGC00164275-03; NCGC00164275-04; NCGC00254604-01; NCGC00259123-01; CC-29728; LS-26561; DB-056630; FT-0630906; Isoxaben, PESTANAL(R), analytical standard; C18504; C-20085; Q2677285; N-(3-(1-Ethyl-1-methylpropyl)-1,2-oxazol-5-yl)-2,6-dimethoxybenzamide; InChI=1/C18H24N2O4/c1-6-18(3,7-2)14-11-15(24-20-14)19-17(21)16-12(22-4)9-8-10-13(16)23-5/h8-11H,6-7H2,1-5H3,(H,19,21);",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C18H24N2O4",
"molecular_weight": "332.4",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "73672",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01979",
"RC02600",
"RC03221"
]
},
{
"compound_ID": "D0967",
"name": "isoxicam",
"synonyms": "isoxicam; 34552-84-6; Maxicam; Isoxicamo; Isoxicamum; UNII-8XU734C4NG; Pacyl (antiinflammatory); Isoxicamum [INN-Latin]; Isoxicamo [INN-Spanish]; EINECS 252-084-5; W 8495; BRN 0577221; CHEBI:76163; 8XU734C4NG; C14H13N3O5S; NCGC00016829-05; CAS-34552-84-6; W-8495; 4-Hydroxy-2-methyl-N-(5-methyl-3-isoxazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 4-Hydroxy-2-methyl-N-(5-methyl-3-isoxazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; DSSTox_CID_25462; DSSTox_RID_80893; DSSTox_GSID_45462; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-3-isoxazolyl)-, 1,1-dioxide; 4-hydroxy-2-methyl-N-(5-methyl-1,2-oxazol-3-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H-1,2-benzothiazine 1,1-dioxide; SR-01000003112; Isoxicam [USAN:BAN:INN]; Isoxicam [USAN:INN:BAN]; Prestwick_505; Maxicam (TN); Spectrum_001605; Isoxicam (USAN/INN); Prestwick0_000044; Prestwick1_000044; Prestwick2_000044; Prestwick3_000044; Spectrum2_000862; Spectrum3_001580; Spectrum4_000183; Spectrum5_001253; SCHEMBL25947; BSPBio_000167; BSPBio_003120; Isoxicam, analytical standard; KBioGR_000725; KBioSS_002085; MLS000069554; CHEMBL53292; DivK1c_000661; SPECTRUM1503242; SPBio_000903; SPBio_002088; BPBio1_000185; SCHEMBL1477990; CHEMBL1898455; DTXSID0045462; CTK6C5653; HMS502B03; KBio1_000661; KBio2_002085; KBio2_004653; KBio2_007221; KBio3_002620; NINDS_000661; YYUAYBYLJSNDCX-UHFFFAOYSA-N; HMS1568I09; HMS1922M07; HMS2092P16; HMS2095I09; HMS2232A13; HMS3373J12; HMS3712I09; Pharmakon1600-01503242; HY-B1130; Tox21_110634; 2482AH; BDBM50248151; CCG-40307; MFCD00079374; NSC758436; STK603272; ZINC13130154; ZINC49538599; AKOS005539580; AKOS026749856; Tox21_110634_1; API0007739; CS-4726; DB08942; KS-1364; MCULE-1659746677; NSC-758436; ACM34552846; IDI1_000661; SMP1_000071; NCGC00016829-01; NCGC00016829-02; NCGC00016829-03; NCGC00016829-04; NCGC00016829-06; NCGC00016829-09; NCGC00023881-03; NCGC00023881-04; LS-40540; SMR000058828; SBI-0051800.P002; FT-0725584; ST51015023; SW220080-1; D04639; AB00052335_13; AB00052335_14; J-019644; SR-01000003112-2; SR-01000003112-3; Q22075801; (4-hydroxy-2-methyl-1,1-dioxobenzo[e]1,2-thiazin-3-yl)-N-(5-methylisoxazol-3-y l)carboxamide; 3-{hydroxy[(5-methyl-1,2-oxazol-3-yl)amino]methylidene}-2-methyl-2,3-dihydro-4H-1,2-benzothiazin-4-one 1,1-dioxide; 4-hydroxy-2-methyl-N-(5-methyl-3-isoxazolyl)-2H- 1,2-benzothiazine-3-carboxamide-1,1-dioxide; N-(5-methyl-3-isoxazolyl)-4-hydroxy-2-methyl-2H-1,2-benzthiazine-3-carboxamide 1,1-dioxide;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C14H13N3O5S",
"molecular_weight": "335.34",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "54677972",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01980",
"RC02601",
"RC03222"
]
},
{
"compound_ID": "D0968",
"name": "israpafant",
"synonyms": "Israpafant; 117279-73-9; Y-24180; (+/-)-israpafant; Y 24180; NCGC00183008-01; (+-)-4-(2-chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine; 4-(2-Chlorophenyl)-2-(2-(4-isobutylphenyl)ethyl)-6,9-dimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine; (+-)-4-(o-Chlorophenyl)-2-(p-isobutylphenethyl)-6,9-dimethyl-6H-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine; 4-(2-chlorophenyl)-6,9-dimethyl-2-{2-[4-(2-methylpropyl)phenyl]ethyl}-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine; 6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine, 4-(2-chlorophenyl)-6,9-dimethyl-2-(2-(4-(2-methylpropyl)phenyl)ethyl)-; 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 4-(2-chlorophenyl)-6,9-dimethyl-2-[2-[4-(2-methylpropyl)phenyl]ethyl]-; Israpafant [INN]; Pafnol; DSSTox_CID_312; DSSTox_RID_75507; DSSTox_GSID_20312; SCHEMBL121588; GTPL1857; CHEMBL2107428; DTXSID5020312; RMSWMRJVUJSDGN-UHFFFAOYSA-N; Tox21_113300; LS-185098; CAS-117279-73-9; L000999; Q27881903; 4-(2-chlorophenyl)-2-(4-isobutylphenethyl)-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine; 4-(2-chlorophenyl)-2-[2 -(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine; 7-(2-chlorophenyl)-9,13-dimethyl-4-{2-[4-(2-methylpropyl)phenyl]ethyl}-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaene;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C28H29ClN4S",
"molecular_weight": "489.1",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "119175",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01981",
"RC02602",
"RC03223"
]
},
{
"compound_ID": "D0969",
"name": "kaempferol",
"synonyms": "kaempferol; 520-18-3; Kempferol; Kaempherol; Robigenin; Rhamnolutein; Populnetin; Trifolitin; Pelargidenolon; Rhamnolutin; Swartziol; 3,4',5,7-Tetrahydroxyflavone; Kampherol; Indigo Yellow; Campherol; Kampferol; Kaemferol; Nimbecetin; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7,4'-Trihydroxyflavonol; Pelargidenolon 1497; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; C.I. 75640; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 41; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-; Flavone, 3,4',5,7-tetrahydroxy-; NSC 407289; NSC 656277; UNII-731P2LE49E; EINECS 208-287-6; CHEMBL150; BRN 0304401; AI3-36096; CHEBI:28499; IYRMWMYZSQPJKC-UHFFFAOYSA-N; 731P2LE49E; NSC656277; NSC-407289; NSC-656277; CAS-520-18-3; DSSTox_CID_768; DSSTox_RID_75781; DSSTox_GSID_20768; Q-100584; SMR000112585; Pelargidenon; Kampcetin; 3,5,7,4'-Tetrahydroxyflavone; HSDB 7703; 4det; Kaempferol,(S); Kaempferol, 97%; 3,4′,5,7-Tetrahydroxyflavone; 5,4'-Trihydroxyflavonol; Prestwick0_001098; Prestwick1_001098; Prestwick2_001098; Prestwick3_001098; 3,5,7-Tetrahydroxyflavone; 4',5,7-trihydroxyflavonol; BIDD:PXR0073; Oprea1_650954; SCHEMBL18817; BSPBio_001176; 5-18-05-00251 (Beilstein Handbook Reference); MLS000697730; MLS001055391; MLS001074884; MLS006010737; BIDD:ER0134; SPBio_003058; 3,4,5,7-Tetrahydroxyflavone; Kaempferol, analytical standard; BDBM7462; BPBio1_001294; MEGxp0_001283; DTXSID7020768; Flavone,4',5,7-tetrahydroxy-; ACon1_001867; cid_5280863; CHEBI: 28499; HMS1571K18; HMS2098K18; HMS2267I09; HMS3414C03; HMS3656M03; HMS3678C03; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-1- benzopyran-4-one; Kaempferol, >=97.0% (HPLC); TNP00039; ZINC3869768; Tox21_201165; Tox21_303363; AC-544; CK0011; GP7425; HSCI1_000027; LMPK12110003; LS-176; MFCD00016938; NSC407289; s2314; SBB066091; AKOS015895240; Kaempferol, >=90% (HPLC), powder; CCG-202823; CS-1273; DB01852; GS-3570; MCULE-8965218413; NCGC00016480-01; NCGC00016480-02; NCGC00016480-03; NCGC00016480-04; NCGC00016480-05; NCGC00016480-06; NCGC00016480-07; NCGC00016480-09; NCGC00091036-01; NCGC00091036-02; NCGC00164322-01; NCGC00179275-01; NCGC00179275-02; NCGC00257464-01; NCGC00258717-01; AK168074; CC-29746; HY-14590; SC-17291; ST030560; SY023424; AB0010534; TR-018501; AB00514046; FT-0614420; K0018; N1719; SW197199-2; W1682; 3,4',5,7-tetrahydroxy-Flavone (7CI,8CI); A10495; C05903; J10449; S00111; W-2776; Flavone, 3,4',5,7-tetrahydroxy- (7CI,8CI); 520K183; A828886; C-18018; Q393336; SR-01000765646; Kaempferol, primary pharmaceutical reference standard; SR-01000765646-3; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-chromen-4-one; BRD-K12807006-001-05-2; BRD-K12807006-001-10-2; 2-(4-hydroxyphenyl)-3,5,7-tris(oxidanyl)chromen-4-one; A91A6666-86C8-4B33-B3EF-F74CD3CD7F47; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-1-benzopyran-4-one; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one #; 4H-1-Benzopyran-4-one,5,7-trihydroxy-2-(4-hydroxyphenyl)-; Kaempferol, United States Pharmacopeia (USP) Reference Standard; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)- (9CI);",
"trade_name": "",
"abbrev_name": "",
"description": "a natural flavonol; plant flavonoid",
"molecular_formula": "C15H10O6",
"molecular_weight": "286.24",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5280863",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [
"T019",
"T205"
],
"function": [
"F0108",
"F020103",
"F02110301",
"F02110302",
"F0501"
],
"references": [
"RC01448",
"RC01982",
"RC02603",
"RC03224",
"RC03560",
"RC03561",
"RC03565",
"RC03567"
]
},
{
"compound_ID": "D0970",
"name": "kepone",
"synonyms": "chlordecone; Kepone; 143-50-0; Clordecone; Merex; Decachloroketone; Chlordecone (kepone); Compound 1189; General chemicals 1189; Rcra waste number U142; Decachlorotetracyclodecanone; Chlordecone [ISO]; Caswell No. 275; GC 1189; NCI-C00191; Kepone-2-one, decachlorooctahydro-; CCRIS 128; ENT 16,391; NSC 124074; HSDB 1558; EINECS 205-601-3; RCRA waste no. U142; EPA Pesticide Chemical Code 027701; Decachlorotetrahydro-4,7-methanoindeneone; AI3-16391; Decachloro-1,3,4-metheno-2H-cyclobuta(cd)pentalen-2-one; CHEBI:16548; Decachlorooctahydro-1,3,4-metheno-2H-cyclobuta(cd)pentalen-2-one; 1,1a,3,3a,4,5,5,5a,5b,6-Decachlorooctahydro-1,3,4-metheno-2H-cyclobuta(cd)pentalen-2-one; 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-2H-1,3,4-(methanetriyl)cyclobuta[cd]pentalen-2-one; 1,3,4-Metheno-2H-cyclobuta(cd)pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-; 1,3,4-Metheno-2H-cyclobuta[cd]pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-; Decachlorooctahydro-1,3,4-methano-2H-cyclobuta(cd)pentalen-2-one; DSSTox_CID_770; Perchloropentacyclo(5.3.0.0(2,6).0(3,9).0(4,8))decan-5-one; Decachloropentacyclo(5.2.1.0(2,6).0(3,9).0(5),(8))decan-4-one; Decachloropentacyclo(5.2.1.0(sup 2,6).0(sup 3,9).0(sup 5,8))decan-4-one; Decachloropentacyclo(5.3.0.0(sup 2,6).0(sup 4,10).0(sup 5,9))decan-3-one; 1,2,3,4,5,5,6,7,8,9,10,10-Dodecachlorooctahydro-1,3,4-metheno-2-cyclobuta(c,d)pentalone; 2,3,3a,4,5,6,7,7a,8,8a-Decachloro-3a,4,7,7a-tetrahydro-4,7-methanoinden-1-one; DSSTox_RID_75782; Chlorodecone; DSSTox_GSID_20770; 1,2,3,5,6,7,8,9,10,10-Decachloro(5.2.1.0(sup 2,6).0(sup 3,9).0(sup 5,8))decano-4-one; Decachloropentacyclo[5.2.1.0(2,6).0(3,9).0(5,8)]decan-4-one; ENT-16391; CAS-143-50-0; SMR001261798; perchloropentacyclo[5.3.0.0(2,6).0(3,9).0(4,8)]decan-5-one; Kepone, analytical standard; MLS002177806; MLS002454392; SCHEMBL119101; decachlorooctahydrokepone-2-one; CHEMBL462576; DTXSID1020770; CTK8F0287; LHHGDZSESBACKH-UHFFFAOYSA-N; S00336a; Tox21_201592; Tox21_300098; LS-849; AKOS015950798; NCGC00091008-01; NCGC00091008-02; NCGC00091008-03; NCGC00091008-04; NCGC00091008-05; NCGC00091008-06; NCGC00091008-07; NCGC00091008-08; NCGC00091008-09; NCGC00254136-01; NCGC00259141-01; CC-29755; AB1004846; DB-042689; TR-030542; C01792; Chlordecone, PESTANAL(R), analytical standard; C-22862; Q423892; Chlordecone, 99%, vial of 1 g, (Kepone equiv.); J-007824; decachlorooctahydro-1,3,4- metheno-2H-cyclobuta(cd)pentalen-2-one; Decachlorooctahydro-1,3,4-metheno-2H-cyclobuta[cd]pentalin-2-one; Kepone; Perchloropentacyclo[5.3.0.02,6.03,9.04,8]decan-5-one; Decachloropentacyclo(5.3.0.0(2,6).0(4,10).0(5,9))decan-3-one; decachlorpentacyclo (5.2.1.0(2,6).0(3,9).0(5,8)) decan-4-one; 1,1a,3,3a,4,5,5a,6-decachlorooctahydro-1,3,4-metheno-2H-cyclobuta(cd)pentalen-2-one; 1,2,3,5,6,7,8,9,10,10-Decachloro(5.2.1.0(2,6).0(3,9) .0(5,8))decan-4-one; CHLORDECONE (KEPONE) (SEE ALSO: CHLORDECONE ALCOHOL (CAS 1034-41-9)); (1R,3aS,5bS,6S)-1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-2H-1,3,4-(methanetriyl)cyclobuta[cd]pentalen-2-one; 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-1,3,4-Metheno-2H-cyclobuta[c,d]pentalen-2-one; 1,2,3,4,6,7,8,9,10,10-decachloropentacyclo[5.3.0.0(2,6).0(3,9).0(4,8)]decan-5-one; 1,2,3,5,6,7,8,9,10,10-de cachloropentacyclo[5.2.1.0(2,6).0(3,9).0(5,8)]decano-4-one; 1,2,3,5,6,7,8,9,10,10-decachloropentacyclo[5.2.1.0(2,6).0(3,9).0(5,8)]decano-4-one; 1,3,4-Metheno-2H-cyclobuta(cd)pentalen-2-one, 1,1a,3,3a,4,5,5,5a,5b,6-decachloroctahydro-;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C10Cl10O",
"molecular_weight": "490.6",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "299",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01983",
"RC02604",
"RC03225"
]
},
{
"compound_ID": "D0971",
"name": "lambda-cyhalothrin",
"synonyms": "gamma-cyhalothrin; lambda-Cyhalothrin; 76703-62-3; 91465-08-6; UNII-GOI9BD654Y; GOI9BD654Y; CHEBI:39323; DSSTox_CID_12559; (S)-cyano(3-phenoxyphenyl)methyl (1R,3R)-3-[(1Z)-2-chloro-3,3,3-trifluoroprop-1-en-1-yl]-2,2-dimethylcyclopropanecarboxylate; [(S)-cyano-(3-phenoxyphenyl)methyl] (1R,3R)-3-[(Z)-2-chloro-3,3,3-trifluoroprop-1-enyl]-2,2-dimethylcyclopropane-1-carboxylate; Nexide; Cyhalothrin lambda; I>>-Cyhalothrin; (1R,3R)-((S)-cyano(3-phenoxyphenyl)methyl) 3-((Z)-2-chloro-3,3,3-trifluoroprop-1-enyl)-2,2-dimethylcyclopropanecarboxylate; DSSTox_RID_78987; DSSTox_GSID_32559; DSSTox_GSID_34501; SCHEMBL41362; Cyclopropanecarboxylic acid, 3-(2-chloro-3,3,3-trifluoro-1-propenyl)-2,2-dimethyl-, (S)-cyano(3-phenoxyphenyl)methyl ester, (1R,3R)-; CHEMBL1905223; DTXSID1034501; DTXSID7032559; ZXQYGBMAQZUVMI-GCMPRSNUSA-N; ZX-AP011924; Tox21_303423; Tox21_303815; P0L413; PC5399; ZINC13827939; AKOS015994769; KS-5076; lambda-Cyhalothrin, analytical standard; NCGC00163947-01; NCGC00257330-01; NCGC00356990-01; Cyclopropanecarboxylic acid, 3-(2-chloro-3,3,3-trifluoro-1-propenyl)-2,2-dimethyl-, cyano(3-phenoxyphenyl)methyl ester, (1R-(1alpha(S*),3alpha(Z)))-; CAS-76703-62-3; CAS-91465-08-6; LS-182832; 536-EP2274983A1; gamma-Cyhalothrin 10 microg/mL in Cyclohexane; gamma-Cyhalothrin 100 microg/mL in Cyclohexane; A838803; lambda-Cyhalothrin, PESTANAL(R), analytical standard; Q27119814; UNII-V0V73PEB8M component ZXQYGBMAQZUVMI-GCMPRSNUSA-N; UNII-Z44TGV333K component ZXQYGBMAQZUVMI-GCMPRSNUSA-N; lambda-Cyhalothrin, certified reference material, TraceCERT(R); (1R,3R)-3-[(Z)-2-chloro-3,3,3-trifluoroprop-1-enyl]-2,2-dimethyl-1-cyclopropanecarboxylic acid [(S)-cyano-(3-phenoxyphenyl)methyl] ester; [(S)-cyano-(3-phenoxyphenyl)methyl] (1R,3R)-3-[(Z)-2-chloranyl-3,3,3-tris(fluoranyl)prop-1-enyl]-2,2-dimethyl-cyclopropane-1-carboxylate; [cyano-[3-(phenoxy)phenyl]methyl] (1R,3R)-3-[(Z)-2-chloro-3,3,3-trifluoroprop-1-enyl]-2,2-dimethylcyclopropane-1-carboxylate;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C23H19ClF3NO3",
"molecular_weight": "449.8",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "6440554",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01985",
"RC02606",
"RC03227"
]
},
{
"compound_ID": "D0972",
"name": "lanatoside a",
"synonyms": "Lanatoside A; UNII-H4BU39831E; Adigal; 17575-20-1; Digilanide A; Digilanid A; Lanatosid A; H4BU39831E; Lanatosid A [German]; NSC 7532; EINECS 241-544-0; BRN 0078336; Digitoxigenin + 2 digitoxose + acetyl-digilanidobose [German]; 3-((O-beta-D-Glucopyranosyl-(1-4)-O-3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide (3beta,5beta)-; Digitoxigenin + 2 digitoxose + acetyl-digilanidobose; CHEMBL3391717; ZINC252695326; C-23589; Q27279629; Card-20(22)-enolide, 3-((O-beta-D-glucopyranosyl-(1-4)-O-3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)- (9CI);",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C49H76O19",
"molecular_weight": "969.1",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "10819737",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01986",
"RC02607",
"RC03228"
]
},
{
"compound_ID": "D0973",
"name": "lanatoside b",
"synonyms": "Lanatoside B; Digilanide B; Digilanid B; Lanatosid B [German]; UNII-3822U6I4Z0; NSC 7535; EINECS 241-545-6; 17575-21-2; BRN 0078394; Lanatosid B; 3822U6I4Z0; 3-((O-beta-D-Glucopyranosyl-(1-4)-O-3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14,16-dihydroxycard-20(22)-enolide (3beta,5beta,16beta)-; STL565780; AKOS032437831; ZINC252695290; MCULE-8147689136; LS-87551; C-23592; Q27256727; (3beta,5beta,16beta)-3-{[beta-D-glucopyranosyl-(1->4)-3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-14; Card-20(22)-enolide, 3-((O-beta-D-glucopyranosyl-(1-4)-O-3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14,16-dihydroxy-, (3beta,5beta,16beta)-; Card-20(22)-enolide, 3-((O-beta-D-glucopyranosyl-(1-4)-O-3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14,16-dihydroxy-, (3beta,5beta,16beta)- (9CI);",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C49H76O20",
"molecular_weight": "985.1",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "72604",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01987",
"RC02608",
"RC03229"
]
},
{
"compound_ID": "D0974",
"name": "lanatoside c",
"synonyms": "lanatoside C; 17575-22-3; Isolanid; UNII-5RR3JFZ771; Cedilanid; Ceglunate; Celanidum; 5RR3JFZ771; Digilanid C; Lanatosid C [German]; Lanatosidum C [INN-Latin]; Lanatosido C [INN-Spanish]; EINECS 241-546-1; Lanatosidum C; Lanatosido C; NSC 119991; NCGC00094932-01; Digilanogen C (TN); LANATOSIDE-C; Lanatoside C [INN:BAN:DCF:JAN:NF]; DSSTox_CID_3198; Lanatoside C, >=95%; Lanatoside C (JAN/INN); DSSTox_RID_76921; Glycoside obtained from the leaves of Digitalis lanata Ehrh; DSSTox_GSID_23198; SCHEMBL44110; CHEMBL506569; DTXSID7023198; JAYAGJDXJIDEKI-PTGWOZRBSA-N; HMS3714C13; Lanatoside C (Digoxin Impurity H); 3-((O beta-D-Glucopyranosyl-(1-4)-O-3beta-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12beta,14-dihydroxy-5beta-card-20(22)-enolide; HY-B1030; Tox21_111361; MFCD00869432; s5554; ZINC253387889; CCG-220656; CS-4548; DB13467; AS-35298; D01972; C-23591; J-011131; Q6482953; (3beta,5beta,12beta)-3-{[beta-D-glucopyranosyl-(1->4)-3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; Card-20(22)-enolide, 3-((O-beta-D-glucopyranosyl-(1-4)-O-3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)- (9CI);",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C49H76O20",
"molecular_weight": "985.1",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "656630",
"classification": "C",
"indications": "",
"side_effects": "",
"atc_codes": "C01AA06",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01988",
"RC02609",
"RC03230"
]
},
{
"compound_ID": "D0975",
"name": "lapachol",
"synonyms": "lapachol; 84-79-7; Tecomin; Bethabarra wood; Greenhartin; Lapachol wood; Taiguic acid; Taigu wood; IPE-tobacco wood; C.I. Natural Yellow 16; Greenharten; Lapachic acid; Surinam greenheart wood; Zlut prirodni 16; Tecomin (VAN); NSC 11905; NSC-11905; C.I. 75490; 2-Hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone; Zlut prirodni 16 [Czech]; CCRIS 745; NSC 629756; UNII-B221938VB6; NSC11905; EINECS 201-563-7; NSC629756; BRN 2051889; 2-Hydroxy-3-(3-methylbut-2-enyl)-1,4-naphthoquinone; 2-Hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthalenedione; 4-hydroxy-3-(3-methylbut-2-enyl)naphthalene-1,2-dione; 1,4-Naphthoquinone, 2-hydroxy-3-(3-methyl-2-butenyl)-; CHEBI:6377; 1,4-Naphthalenedione, 2-hydroxy-3-(3-methyl-2-butenyl)-; CIEYTVIYYGTCCI-UHFFFAOYSA-N; B221938VB6; Lapachol, 98%; Natural Yellow-?16; Spectrum2_001451; Spectrum3_000768; Spectrum5_001873; bmse000989; NCIMech_000076; DSSTox_CID_29390; DSSTox_RID_83505; DSSTox_GSID_49430; Oprea1_717083; BSPBio_002416; 4-08-00-02487 (Beilstein Handbook Reference); CHEMBL15193; DivK1c_000594; SCHEMBL157255; SCHEMBL157256; SPECTRUM1501204; SPBio_001341; 2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphtho-quinone; DTXSID6049430; CTK5F3159; HMS501N16; KBio1_000594; KBio3_001636; NINDS_000594; 1,4-Naphthalenedione,2-hydroxy-3-(3-methyl-2-buten-1-yl)-; HMS1921B06; BCP24022; ZINC3873071; Tox21_202948; CCG-35464; s5684; ZINC78934733; AKOS015951424; AKOS032948320; AC-8971; ACN-036176; CI75490; MCULE-9211486718; NSC-629756; SDCCGMLS-0066666.P001; CAS-84-79-7; IDI1_000594; NCGC00094931-01; NCGC00094931-02; NCGC00094931-03; NCGC00094931-04; NCGC00260494-01; WLN: L66 BV EVJ CQ D2UY1&1; 4CN-0974; AK168089; AS-35308; LS-95648; NCI60_000457; NCI60_000587; SC-91848; 1, 2-hydroxy-3-(3-methyl-2-butenyl)-; AB1010137; FT-0649649; W2146; C10366; Cancer Chemother Rep (part 2) 4: 11 (1974); Q739601; SR-05000002489; 2-Hydroxy-3-(3-methyl-2-butenyl)naphthoquinone #; SR-05000002489-1; NSC-11905; NSC 11905; NSC11905; 2-hydroxy-3-(3-methylbut-2-enyl)naphthalene-1,4-dione; 3-(3-Methyl-2-butenyl)-4-hydroxy-1,2-naphthoquinone; 1,4-Naphthalenedione, 2-hydroxy-3-(3-methyl-2-butenyl)- (9CI);",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C15H14O3",
"molecular_weight": "242.27",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "3884",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01989",
"RC02610",
"RC03231"
]
},
{
"compound_ID": "D0976",
"name": "lasalocid sodium",
"synonyms": "Lasalocid sodium; Lasalocid A sodium salt; Lasalocid (sodium); Lasalocid A Sodium; Bovatec; Avatec; 25999-20-6; UNII-W2S5C71Y3G; Lasalocid sodium salt; Ro 2-2985; Lascaloid; MLS001304052; Sodium lasalocid; W2S5C71Y3G; Lasalocid A monosodium salt; Sodium lasalocid A; SMR000538906; Lasalocid A Na salt; EINECS 247-400-3; MT2007; NSC 243046; MT 2007; Bovate 20; Bovatec 150FP; NSC243046; NCGC00095029-01; 6-(7-(5-Ethyl-5-(5-ethyltetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl)tetrahydro-3-methyl-2-furanyl)-4-hydroxy-3,5-dimethyl-6-oxononyl)-2-hydroxy-3-methylbenzoic acid monosodium salt, (2R-(2alpha(2S*(3R*,4S*,5S*,7R*),3S*,5S*),5alpha,6beta))-; sodium;6-[(3R,4S,5S,7R)-7-[(2S,3S,5S)-5-ethyl-5-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyloxan-2-yl]-3-methyloxolan-2-yl]-4-hydroxy-3,5-dimethyl-6-oxononyl]-2-hydroxy-3-methylbenzoate; CAS-25999-20-6; DSSTox_CID_25895; DSSTox_RID_81207; DSSTox_GSID_45895; MLS001173429; MLS001334026; MLS001334027; MLS006011597; CHEMBL1489769; DTXSID9045895; BDBM79589; cid_6426773; HY-B1071A; HMS2097F17; HMS2235P08; NP167; 2,3-Cresotic acid, 6-(7-(5-ethyl-5-(5-ethyltetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl)tetrahydro-3-methyl-2-furyl)-4-hydroxy-3,5-dimethyl-6-oxononyl)-, monosodium salt. (-)-; Benzoic acid, 6-((3R,4S,5S,7R)-7-((2S,3S,5S)-5-ethyl-5-((2R,5R,6S)-5-ethyltetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl)tetrahydro-3-furanyl)-4-hydroxy-3,5-dimethyl-6-oxononyl)-2-hydroxy-3-methyl-, monosodium salt; Benzoic acid, 6-(7-(5-ethyl-5-(5-ethyltetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl)tetrahydro-3-methyl-2-furanyl)-4-hydroxy-3,5-dimethyl-6-oxononyl)-2-hydroxy-3-methyl-, monosodium salt, (2R-(2alpha(2S*(3R*,4S*,5S*,7R*),3S*,5S*),5alpha,6beta))-; Tox21_111396; AKOS025311506; CS-5930; MCULE-6219687714; R987; Lasalocid A sodium 100 microg/mL in Acetonitrile; J-016217; Q27292230; Lasalocid A Sodium Salt (Solution in acetonitrile 0.2mg/2ml); Lasalocid A sodium salt solution, ~100 microg/ml in acetonitrile; Benzoic acid,6-[(3R,4S,5S,7R)-7-[(2S,3S,5S)-5-ethyl-5-[(2R,5R,6S)-5-ethyltetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl]tetrahydro-3-methyl-2-furanyl]-4-hydroxy-3,5-dimethyl-6-oxononyl]-2-hydroxy-3-methy; Lasalocid A sodium salt solution, 100 mug/mL in acetonitrile, VETRANAL(TM), analytical standard;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C34H53NaO8",
"molecular_weight": "612.8",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "6426773",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01990",
"RC02611",
"RC03232"
]
},
{
"compound_ID": "D0977",
"name": "lercanidipine hydrochloride",
"synonyms": "Lercanidipine hydrochloride; 132866-11-6; Lercanidipine HCl; Cardiovasc; Corifeo; Carmen; Lerzam; Lercadip; Lercan; Lercanidipine (hydrochloride); Rec-15/2375; Lercanidipine hydrochloride hemihydrate; Zanidip (hydrochloride); 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester hydrochloride; Masnidipine (hydrochloride); 3-(1-((3,3-diphenylpropyl)(methyl)amino)-2-methylpropan-2-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride; Lercapin; Lercaton; Lerkamen; Renovia; Vasodip; Zanicor; Zandip; DSSTox_CID_26665; DSSTox_RID_81807; DSSTox_GSID_46665; 5-O-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;hydrochloride; CAS-132866-11-6; NCGC00167492-01; R 75; Zanedip; Zanidip; Lerdip; Cardiovasc (TN); LCP-Lerc; Lercanidipine hydrochloride [USAN]; Zanidip hydrochloride; Masnidipine hydrochloride; G00009-Watson-Int; 100427-27-8; lercanidipine-hydrochloride; C36H42ClN3O6; SCHEMBL217099; CHEMBL2106419; DTXSID3046665; CHEBI:31771; HY-B0612A; TJN-324; WMFYOYKPJLRMJI-UHFFFAOYSA-N; Lercanidipine hydrochloride (1:x); BCP11375; EBD51404; KS-000002DP; Tox21_112493; Tox21_500144; s4597; AKOS015846519; Tox21_112493_1; AC-1420; CCG-221448; CS-2831; LP00144; MCULE-2712241399; Lercanidipine hydrochloride (JAN/USAN); NCGC00167492-03; NCGC00260829-01; AK550821; AS-13358; H990; DB-042142; FT-0627794; FT-0631144; L0282; Lercanidipine hydrochloride, >=98% (HPLC); D01849; 866L116; A806509; J-006235; J-006236; J-521641; Q27285537; 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid O5-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] ester O3-methyl ester hydrochloride; 2-((3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl methyl (4RS)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate monohydrochloride; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-((3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl methyl ester, monohydrochloride; 3,5-Pyridinedicarboxylic acid, 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl methyl ester, monohydrochloride; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-[2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl] 5-methyl ester, hydrochloride (1:1); 3-(1-((3,3-Diphenylpropyl);(methyl);amino);-2-methylpropan-2-yl); 5-methyl 2,6-dimethyl-4-(3-nitrophenyl);-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride; O5-[1-[3,3-diphenylpropyl(methyl)amino]-2-methyl-propan-2-yl] O3-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C36H42ClN3O6",
"molecular_weight": "648.2",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "157917",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01991",
"RC02612",
"RC03233"
]
},
{
"compound_ID": "D0978",
"name": "lestaurtinib",
"synonyms": "Lestaurtinib; 111358-88-4; CEP-701; KT-5555; SP924; UNII-DO989GC5D1; SPM-924; C26H21N3O4; CHEMBL603469; DO989GC5D1; NCGC00168772-01; CEP 701; KT5555; SP 924; KT 5555; 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-; Lestaurtinib (USAN/INN); Lestaurtinib [USAN:INN]; 4otg; 9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-; A 1544750; SP-924; A-1544750; DSSTox_CID_26778; DSSTox_RID_81897; DSSTox_GSID_46778; cc-713; GTPL5672; SCHEMBL1649693; DTXSID5046778; CHEBI:91471; CTK8F0849; BIL2000; UIARLYUEJFELEN-LROUJFHJSA-N; BCP06977; ZINC3781738; Tox21_112633; BDBM50308060; KT-555; MFCD12828858; AKOS024457603; AC-5243; AM81228; DB06469; NCGC00168772-02; NCGC00168772-03; NCGC00168772-04; HY-50867; RT-013568; CAS-111358-88-4; CS-0004336; FT-0670762; V0246; D04696; A-154475; J-002567; Q6531771; BRD-K23192422-001-01-1; A-154475.0; (15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8,10,12,20,22,24-nonaen-3-one; (5R,7S,8S)-7-hydroxy-7-(hydroxymethyl)-8-methyl-5,6,7,8,13,14-hexahydro-15H-16-oxa-4b,8a,14-triaza-5,8-methanodibenzo[b,h]cycloocta[jkl]cyclopenta[e]-as-indacen-15-one; (9S,10S,12R)-10-Hydroxy-10-(hydroxymethyl)-9-methyl-2,3,9,10,11,12-hexahydro-9,12-epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one; (9S,10S,12R)-2,3,9,10,11,12-Hexahyd ro-10-hydroxy-10-(hydroxymethyl)-9-methyl-9,12-epo xy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1, 6]benzodiazocin-1-one; (9S,10S,12R)-2,3,9,10,11,12-Hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one; 16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8(13),9,11,20(25),21,23-nonaen-3-one; 9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S-(9alpha,10beta,12alpha))-; CEP-701|||KT-5555|||(5S,6S,8R)-6-Hydroxy-6-(hydroxymethyl)-5-methyl-7,8,14,15-tetrahydro-5H-16-oxa-4b,8a,14-triaza-5,8-methanodibenzo[b,h]cycloocta[jkl]cyclopenta[e]-as-indacen-13(6H)-one;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C26H21N3O4",
"molecular_weight": "439.5",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "126565",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01992",
"RC02613",
"RC03234"
]
},
{
"compound_ID": "D0979",
"name": "lopinavir",
"synonyms": "Lopinavir; ABT-378; 192725-17-0; Aluviran; ABT 378; A 157378.0; A-157378.0; RS-346; UNII-2494G1JF75; CHEBI:31781; Lopinavir (ABT-378); (alphaS)-Tetrahydro-N-((alphaS)-alpha-((2S,3S)-2-hydroxy-4-phenyl-3-(2-(2,6-xylyloxy)acetamido)butyl)phenethyl)-alpha-isopropyl-2-oxo-1(2H)-pyrimidineacetamide; LPV; Koletra; A 157378; A-157378-0; 2494G1JF75; (2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide; N-{1-BENZYL-4-[2-(2,6-DIMETHYL-PHENOXY)-ACETYLAMINO]-3-HYDROXY-5-PHENYL-PENTYL}-3-METHYL-2-(2-OXO-TETRAHYDRO-PYRIMIDIN-1-YL)-BUTYRAMIDE; NCGC00164576-02; DSSTox_CID_26456; DSSTox_RID_81630; DSSTox_GSID_46456; (1S-(1R*(R*),3R*,4R*))-N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide; (2S)-N-[(1S,3S,4S)-1-benzyl-4-[[2-(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-pentyl]-3-methyl-2-(2-oxohexahydropyrimidin-1-yl)butanamide; (alphaS)-N-[(1S,3S,4S)-4-[[2-(2,6-Dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide; (S)-N-((2S,4S,5S)-5-(2-(2,6-dimethylphenoxy)acetamido)-4-hydroxy-1,6-diphenylhexan-2-yl)-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide; 1(2H)-Pyrimidineacetamide, N-((1S,3S,4S)-4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahyrdo-alpha-1-methylethyl)-2-oxo-, (alphaS)-; SMR002529581; Lopinavir [USAN:INN:BAN]; CAS-192725-17-0; Lopinavir (JAN/USAN/INN); HSDB 8138; 1mui; 2qhc; 2rkf; 2rkg; 3ogq; Lopinavir [USAN:USP:INN:BAN]; AIDS032937; (2S)-N-((1S,3S,4S)-1-benzyl-4-{[(2,6-dimethylphenoxy)acetyl]amino}-3-hydroxy-5-phenylpentyl)-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide; (2S)-N-[(1S,3S,4S)-1-benzyl-4-{[(2,6-dimethylphenoxy)acetyl]amino}-3-hydroxy-5-phenylpentyl]-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide; Lopinavir & PLGA; ABT 157378; 2o4s; 2q5k; 4l1a; Lopinavir, ABT 378; CHEMBL729; LPV & AAG; SCHEMBL21775; MLS003915624; MLS004774152; MLS006011206; N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide; DTXSID8046456; CTK8E9936; AOB1042; KJHKTHWMRKYKJE-SUGCFTRWSA-N; BCPP000184; KS-000000TF; ZINC3951740; Tox21_112204; BDBM50180655; Lopinavir & alpha1-acid glycoprotein; s1380; AKOS025243115; Lopinavir & Poly-lactide-co-glycolide; Tox21_112204_1; BCP9000857; CS-2077; DB01601; KS-1436; RTR-008945; NCGC00164576-01; NCGC00164576-03; NCGC00164576-04; HY-14588; AB0071033; LS-173766; TR-008945; SW219767-1; C12871; D01425; 24233-EP2298761A1; 24233-EP2298783A1; 24233-EP2314590A1; AB01274785-01; AB01274785_02; 111995-EP2272516A2; 111995-EP2298761A1; 111995-EP2298783A1; Q422585; SR-01000931910; J-521653; SR-01000931910-2; BRD-K99451608-001-02-4; (2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide; (2S)-N-[(2S,4S,5S)-5-{[(2,6-dimethylphenoxy)acetyl]amino}-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide; 1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-.alpha.-(1-methylethyl)-2-oxo-, (aS)-; 1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)- (9CI); 1(2H)-pyrimidineacetamide, N-[(1S,3S,4S)-4-[[2-(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)-; 1(2H)-Pyrimidineacetamide, N-[4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, [1S-[1R*(R*),3R*,4R*]]-; 1(2H)-pyrimidineacetamide,N-((1S,3S,4S)-4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-1-methylethyl)-2-oxo-,(alphaS)-;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C37H48N4O5",
"molecular_weight": "628.8",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "92727",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01993",
"RC02614",
"RC03235"
]
},
{
"compound_ID": "D0980",
"name": "lornoxicam",
"synonyms": "Lornoxicam; 70374-39-9; Chlortenoxicam; Xefocam; Xefo; Lornoxicamum; Lorcam; Lornoxicamum [INN-Latin]; Taigalor; Safem; Telos; Ro 13-9297; Lorcam (TN); CLTX; Lornoxicam (Xefo); Lornoxicam [USAN:INN:BAN]; UNII-ER09126G7A; CCRIS 8589; BRN 1039965; C13H10ClN3O4S2; CHEBI:31783; ER09126G7A; Ro-13-9297; 2H-Thieno(2,3-e)-1,2-thiazine-3-carboxamide, 6-chloro-4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 6-chloro-4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide; 6-Chloro-4-hydroxy-2-methyl-N-2-pyridyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide; 6-chloro-4-hydroxy-2-methyl-N-pyridin-2-yl-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide; SMR000550483; lornoxicam-xefo; 2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXAMIDE, 6-CHLORO-4-HYDROXY-2-METHYL-N-2-PYRIDINYL-, 1,1-DIOXIDE; SCHEMBL35101; SCHEMBL35102; MLS001165721; MLS001304721; MLS006010084; Lornoxicam (JAN/USAN/INN); SCHEMBL1650239; CHEMBL1569487; CHEMBL3188235; Lornoxicam, >=98% (HPLC); BDBM92331; CTK8B3366; WLHQHAUOOXYABV-UHFFFAOYSA-N; HMS2231B07; HMS3264I20; HMS3655N13; Pharmakon1600-01502302; TS110; ALBB-014101; BCP04666; HY-B0367; KS-00000GI1; ZINC5318420; ANW-42384; MFCD00866163; NSC759620; s2047; SBB056363; STL504715; TS 110; TS-110; ZINC49089868; AKOS000281810; AKOS026750113; ZINC100015491; AB07518; AC-4675; BCP9000860; CCG-213023; CS-2424; DB06725; KS-1080; NSC-759620; Ro-139297; 6-chloro-4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide; NCGC00246566-01; NCGC00346667-01; 6-chloro-4-hydroxy-2-methyl-3-(2-pyridylcarbamoyl)-2H-thieno[2,3-e]-1,2-thiazine-1,1-dioxide; 6-Chloro-4-hydroxy-2-methyl-N-2-pyridinyl-2H-thieno[2,3-e]-1,2-thiazine-3-carboxamide 1,1-Dioxide; AK468625; HN-10000; BCP0726000036; AB0012428; AB2000451; LS-152550; FT-0630797; L0239; SW220125-1; D01866; S-7774; AB00876293_04; AB00876293_06; 374L399; A836864; SR-01000799148; Q-101309; Q2734874; SR-01000799148-3; (3E)-6-chloro-3-[hydroxy(pyridin-2-ylamino)methylene]- 2-methyl-2,3-dihydro-4H-thieno[2,3-e][1,2] thiazin- 4 - one 1,1-dioxide; (3e)-6-chloro-3-[hydroxyl(pyridin-2-ylamino)methylene]-2-methyl-2,3-dihydro-4h-thieno[2,3-e][1,2]thiazin-4-one 1,1-dioxide; (3Z)-6-chloranyl-2-methyl-1,1-bis(oxidanylidene)-3-[oxidanyl-(pyridin-2-ylamino)methylidene]thieno[2,3-e][1,2]thiazin-4-one; (3Z)-6-chloro-3-[hydroxy-(2-pyridinylamino)methylidene]-2-methyl-1,1-dioxo-4-thieno[2,3-e]thiazinone; (6-chloro-4-hydroxy-2-methyl-1,1-dioxothiopheno[2,3-e]1,2-thiazin-3-yl)-N-(2-p yridyl)carboxamide; 2H-Thieno(2,3-e)-1,2-thiazine-3-carboxamide, 6-chloro-4-hydroxy-2-methyl-N-2-pyridinyl-,1,1-dioxide; 2H-Thieno(3,2-e)-1,2-thiazine-3-carboxamide, 6-chloro-4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 6-chloro-4-hydroxy-2-methyl-1,1-dioxo-N-(pyridin-2-yl)-2H-1|E?-thieno[2,3-e][1,2]thiazine-3-carboxamide; 6-Chloro-4-hydroxy-2-methyl-N-(2-pyridyl)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-Dioxide; 6-Chloro-4-hydroxy-2-methyl-N-pyridin-2-yl-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide (Lornoxicam);",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C13H10ClN3O4S2",
"molecular_weight": "371.8",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "Lornoxicam is 99% bound to plasma proteins (almost exlusively to serum albumin).",
"half_life": "3-5 hours",
"absorption": "Lornoxicam is absorbed rapidly and almost completely from the GI tract (90-100%).",
"cid": "54690031",
"classification": "M",
"indications": "",
"side_effects": "",
"atc_codes": "M01AC05",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01994",
"RC02615",
"RC03236"
]
},
{
"compound_ID": "D0981",
"name": "lufenuron",
"synonyms": "Lufenuron; 103055-07-8; Fluphenacur; N-((2,5-Dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl)carbamoyl)-2,6-difluorobenzamide; PWPJGUXAGUPAHP-UHFFFAOYSA-N; 1-(2,5-Dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl)-3-(2,6-difluorobenzoyl)urea; UNII-9CR45YMS74; N-{[2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]carbamoyl}-2,6-difluorobenzamide; 9CR45YMS74; CHEBI:39384; UNII-4629851K7Q; N-[[2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]carbamoyl]-2,6-difluorobenzamide; NCGC00095978-02; 4629851K7Q; DSSTox_CID_14357; DSSTox_RID_79146; DSSTox_GSID_34357; Benzamide, N-[[[2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]amino]carbonyl]-2,6-difluoro-; N-({[2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]amino}carbonyl)-2,6-difluorobenzamide; Lufenurone; Lufenuronum; Cigna; Match (pesticide); Program flavor tabs; CAS-103055-07-8; Lufenuron [INN:BAN]; Lufenurone [INN-French]; Lufenuronum [INN-Latin]; C17H8Cl2F8N2O3; Lufenuron (INN); CGA 184699; Lufenuron, (+)-; Lufenuron, (-)-; EC 410-690-9; Program [veterinary] (TN); SCHEMBL27105; BSPBio_002424; MLS004712069; SPECTRUM1505355; CHEMBL1364906; DTXSID5034357; HMS3264N09; Pharmakon1600-01505355; BCP15961; Tox21_111542; Tox21_300907; NSC759097; AKOS022185021; Tox21_111542_1; CCG-213976; DB11424; NSC-759097; VA11207; N-[[2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]carbamoyl]-2,6-difluoro-benzamide; NCGC00095978-01; NCGC00095978-03; NCGC00095978-04; NCGC00095978-06; NCGC00254811-01; AK117729; AS-13363; CC-30083; H999; N-(2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)-phenyl-aminocarbonyl)-2,6-difluorobenzamide; SC-14159; SMR001563631; SBI-0207025.P001; AB2000759; DB-040412; FT-0631021; ST24048228; Lufenuron, PESTANAL(R), analytical standard; C18434; D08150; AB01563233_01; 055L078; C-23005; Q412933; SR-01000872762; J-521659; SR-01000872762-1; BRD-A71774530-001-01-8; BRD-A71774530-001-02-6; Lufenuron, European Pharmacopoeia (EP) Reference Standard; Lufenuron, United States Pharmacopeia (USP) Reference Standard; Lufenuron for peak identification, European Pharmacopoeia (EP) Reference Standard; N-(2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenylcarbamoyl)-2,6-difluorobenzamide; 130841-22-4; 130841-26-8; Benzamide, N-(((2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl)amino)carbonyl)-2,6-difluoro-, (+)-; Benzamide, N-(((2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl)amino)carbonyl)-2,6-difluoro-, (-)-; Benzamide,N-[[[2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]amino]carbonyl]-2,6-difluoro-;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C17H8Cl2F8N2O3",
"molecular_weight": "511.1",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "71777",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01995",
"RC02616",
"RC03237"
]
},
{
"compound_ID": "D0982",
"name": "lynestrenol",
"synonyms": "LYNESTRENOL; 52-76-6; Linestrenol; Ethinylestrenol; Ethynylestrenol; Lynoestrenol; Orgametril; Orgametrol; Exluton; Endometril; Exlution; Exlutona; Orgametil; 3-Desoxynorlutin; Ethynloestrenol; Exluten; Lynenol; Lynstranol; Ethinyloestranol; Ethinyl oestrenol; NSC-37725; Org 485-50; IND 1006; Linestrenolo [DCIT]; 17alpha-Ethynylestrenol; 17-alpha-Ethynylestrenol; 17-alpha-Ethynyloestrenol; UNII-N2Z8ALG4U5; Linestrenol [INN-Spanish]; Lynestrenolum [INN-Latin]; CCRIS 9093; EINECS 200-151-4; Lynoestrenol [Progestins]; NSC 37725; 17.alpha.-Ethynylestrenol; 19-Norpregn-4-en-20-yn-17-ol, (17alpha)-; Estr-4-en-17beta-ol, 17-ethynyl-; N2Z8ALG4U5; 17-alpha-Ethynylestr-4-en-17-beta-ol; delta4-17alpha-Ethinylestren-17beta-ol; 17-alpha-Ethynyloestr-4-en-17-beta-ol; 17-alpha-Ethinyl-17-beta-hydroxyestr-4-ene; 19-Nor-17alpha-pregn-4-en-20-yn-17-ol; 17-alpha-Ethinyl-17-beta-hydroxyoestr-4-ene; CHEBI:31790; 17-alpha-Ethynil-delta-4-estrene-17-beta-ol; (17-alpha)-19-Norpregn-4-en-20-yn-17-ol; delta(sup 4)-17-alpha-Ethinylestren-17-beta-ol; delta(sup 4)-17-alpha-Ethinyloestren-17-beta-ol; NSC37725; 19-Norpregn-4-en-20-yn-17-ol, (17.alpha.)-; (8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol; 19-norpregn-4-en-20-yn-17alpha-ol; Estr-4-en-17.beta.-ol, 17-ethynyl-; 19-Nor-17-alpha-pregn-4-en-20-yn-17-ol; 19-Nor-17.alpha.-pregn-4-en-20-yn-17-ol; .DELTA.4-17.alpha.-Ethinylestren-17.beta.-ol; 19 Norpregn-4-en-20-yn-17-ol, (17alpha)-; Linesterol; Linestrenolo; Lynestrenolum; Lynestrenol [USAN:INN:JAN]; HSDB 7899; (17alpha)-17-ethynylestr-4-en-17-ol; Lynestrenol [USAN:INN:BAN:JAN]; Prestwick_533; Prestwick0_000095; Prestwick1_000095; Prestwick2_000095; Prestwick3_000095; Lynestrenol (JAN/USAN); SCHEMBL37816; BSPBio_000050; SPBio_001989; 17-Ethynylestr-4-en-17-ol; BPBio1_000056; CHEMBL2107431; YNVGQYHLRCDXFQ-XGXHKTLJSA-N; HMS1568C12; HMS2095C12; HMS3712C12; BCP04136; NSC73879; ZINC3875355; LMST02030127; NSC-73879; s4883; AKOS024462708; 19-Nor-4-pregnen-20-yn-17beta-ol; CCG-220095; DB12474; LS-7125; NCGC00179676-01; AK161684; SC-47263; L0246; ST24047514; 19-Norpregn-4-en-20-yn-17-ol, (17a)-; C13037; D01580; 052L766; 19-Nor-17alpha-pregn-4-en-20-yn-17-ol (8CI); Q2071071;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C20H28O",
"molecular_weight": "284.4",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5857",
"classification": "G",
"indications": "",
"side_effects": "",
"atc_codes": "G03AC02; G03DC03; G03AA03; G03AB02; G03FA07; G03FB02",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01996",
"RC02617",
"RC03238"
]
},
{
"compound_ID": "D0983",
"name": "lysergide",
"synonyms": "Lysergide; LYSERGIC ACID DIETHYLAMIDE; D-Lysergic acid diethylamide; Delysid; N,N-Diethyllysergamide; D-Lsd; 50-37-3; LSD; Lysergamid; Lysergsaeurediaethylamid; N,N-Diethyl-D-lysergamide; Cubes; Pearly gates; Heavenly Blue; Lysergaure diethylamid; Royal blue; LSD (alkaloid); LSD 25; Lysergsauerediaethylamid; Lysergic acid diethylamide-25; LSD-25; Lysergidum [INN-Latin]; (+)-LSD; Lisergide [DCIT]; Lysergamide, N,N-diethyl-; N,N-Diethyl-(+)-Lysergamide; HSDB 3920; Lisergido [INN-Spanish]; UNII-8NA5SWF92O; Lysergide [INN:BAN:DCF]; Diethylamid kyseliny lysergove [Czech]; (+)-Lysergic acid diethylamide; Lysergsaeurediethylamid; EINECS 200-033-2; BRN 0094179; 8NA5SWF92O; [3H]-LSD; CHEBI:6605; CHEMBL263881; DEA No. 7315; VAYOSLLFUXYJDT-RDTXWAMCSA-N; Ergoline-8-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl-, (8beta)-; Acid [Street Name]; Cubes [Street Name]; NCGC00168265-01; NCGC00168265-02; Wedding bells; 9,10-Didehydro-N,N-diethyl-6-methyl-ergoline-8-beta-carboxamide; Ergoline-8beta-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl-; DSSTox_CID_3231; Royal Blue [Street Name]; Pearly gates [Street Name]; DSSTox_RID_76934; DSSTox_GSID_23231; Wedding bells [Street Name]; Diethylamid kyseliny lysergove; Heavenly Blue [Street Name]; Clearlight; Lysergidum; Ubergluben; Barrels; Bartman; Cupcakes; Greenies; Lisergide; Lisergido; Microdots; Spoonies; Sunshine; Trippers; Yellows; Beast; CHEMBL463207; Chief; Domes; Fifty; Flats; Frogs; Owsley; Scapes; Wedges; (8R)-9,10-didehydro-N,N-diethyl-6-methylergoline-8-carboxamide; Chocolate Chips; Orange Mushroom; Orange Sunshine; Purple Microdot; Gelatin Chips; Mellow Yellow; Orange Wedges; Bart Simpson; Blotter Acid; Contact Lens; (8alpha)-N,N-Diethyl-6-Methyl-9,10-Didehydroergoline-8-Carboxamide; (8beta)-N,N-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide; Ergoline-8-beta-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl-; Purple Haze; White Light; Window Pane; Blue Cheer; Brown Dots; Cherry Top; Mean Green; Paper Acid; Sugar Lump; Blue Acid; Blue Mist; Blue Star; Strawberry Fields; The Hawk; CAS-50-37-3; California Sunshine; (4R,7R)-N,N-diethyl-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide; Big F; Hawk; Haze; Lucy in the Sky with Diamonds; Instant Zen; Wedding Bells Acid; (6aR,9R)-N,N-diethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide; [N-methyl-3H]LSD; LSD,l-; GTPL17; Indolo[4,3-fg]quinoline, ergoline-8-carboxamide deriv.; 4-25-00-00939 (Beilstein Handbook Reference); SCHEMBL113755; DTXSID1023231; NIOSH/KE4200000; BDBM21342; LSD,(+); 9,10-Didehydro-N,N-diethyl-6-methylergoline-8b-carboxamide; Lysergic acid diethylamide, l-isomer; Tox21_112872; Tox21_113508; BDBM50241702; Ergoline-8-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl-, (8b)-; PDSP1_001431; PDSP1_001540; PDSP2_001415; PDSP2_001524; ZINC96903803; Lysergic acid diethylamide tartrate ci; DB04829; LS-64351; LSD (Lysergic Acid Diethylamide;Lysergide); 752-EP2269986A1; 752-EP2270004A1; 752-EP2270006A1; 752-EP2270014A1; 752-EP2270016A1; 752-EP2272537A2; 752-EP2272822A1; 752-EP2272834A1; 752-EP2272842A1; 752-EP2272972A1; 752-EP2272973A1; 752-EP2275403A1; 752-EP2275411A2; 752-EP2275417A2; 752-EP2277866A1; 752-EP2277872A1; 752-EP2281812A1; 752-EP2282982A1; 752-EP2284162A2; 752-EP2284163A2; 752-EP2284178A2; 752-EP2284179A2; 752-EP2286811A1; 752-EP2287153A1; 752-EP2287155A1; 752-EP2289868A1; 752-EP2289885A1; 752-EP2292228A1; 752-EP2292589A1; 752-EP2292613A1; 752-EP2292619A1; 752-EP2292624A1; 752-EP2295402A2; 752-EP2295406A1; 752-EP2295407A1; 752-EP2295410A1; 752-EP2295411A1; 752-EP2298731A1; 752-EP2298735A1; 752-EP2298736A1; 752-EP2298745A1; 752-EP2298761A1; 752-EP2298763A1; 752-EP2298767A1; 752-EP2298770A1; 752-EP2298772A1; 752-EP2298777A2; 752-EP2298783A1; 752-EP2301627A1; 752-EP2301918A1; 752-EP2301928A1; 752-EP2301929A1; 752-EP2301935A1; 752-EP2301937A1; 752-EP2305033A1; 752-EP2305640A2; 752-EP2305648A1; 752-EP2305650A1; 752-EP2305652A2; 752-EP2305663A1; 752-EP2305666A1; 752-EP2305673A1; 752-EP2305674A1; 752-EP2305685A1; 752-EP2305686A1; 752-EP2308838A1; 752-EP2308839A1; 752-EP2308847A1; 752-EP2308848A1; 752-EP2308849A1; 752-EP2308850A1; 752-EP2308861A1; 752-EP2308867A2; 752-EP2308870A2; 752-EP2308871A1; 752-EP2308873A1; 752-EP2311808A1; 752-EP2311825A1; 752-EP2311829A1; 752-EP2311834A1; 752-EP2311842A2; 752-EP2311850A1; 752-EP2314571A2; 752-EP2314581A1; 752-EP2314587A1; 752-EP2316470A2; 752-EP2316831A1; 752-EP2316832A1; 752-EP2316833A1; 752-EP2371797A1; 752-EP2371798A1; 752-EP2371800A1; 752-EP2371804A1; 752-EP2374786A1; 752-EP2374787A1; 752-EP2377849A2; FT-0670891; KE42000000; 6482-EP1441224A2; 6482-EP2311494A1; 6482-EP2311801A1; 6482-EP2311802A1; 6482-EP2311803A1; 6482-EP2371814A1; C07542; Q23118; LSD (Lysergic Acid Diethylamide) 0.025 mg/ml in Acetonitrile; LSD (Lysergic Acid Diethylamide) 1.0 mg/ml in Acetonitrile; Ergoline-8-beta-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl-, (-)-; Ergoline-8b-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl- (8CI); LSD solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material; LSD solution, 25 mug/mL in acetonitrile, ampule of 1 mL, certified reference material; (6aR,9R)-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide; 7LD;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C20H25N3O",
"molecular_weight": "323.4",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5761",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01997",
"RC02618",
"RC03239"
]
},
{
"compound_ID": "D0984",
"name": "malachite green oxalate",
"synonyms": "Malachite Green Oxalate; 2437-29-8; Basic Green 4; UNII-GY1H9O33VU; GY1H9O33VU; Malachite Green oxalate salt; Malachite Green, Oxalate; EINECS 219-441-7; DSSTox_CID_5513; Malachite Green oxalate salt (C.I. 42000); 13425-25-7; DSSTox_RID_77817; DSSTox_GSID_25513; Malachite Green oxalate, pure, certified; CAS-2437-29-8; N,N,N',N'-Tetramethyl-4,4'-diaminotriphenylcarbenium oxalate; C.I. 4200; Bis[[4-[4-(dimethylamino)benzhydrylidene]cyclohexa-2,5-dien-1-ylidene]dimethylammonium] oxalate, dioxalate; Methanaminium, N-(4-((4-(dimethylamino)phenyl)phenylmethylene)-2,5-cyclohexadien-1-ylidene)-N-methyl-, ethanedioate, ethanedioate (2:2:1); Malachite Green oxalate, pure, high purity biological stain; [4-[[4-(dimethylamino)phenyl]-phenylmethylidene]cyclohexa-2,5-dien-1-ylidene]-dimethylazanium;2-hydroxy-2-oxoacetate;oxalic acid; Bis (N-{4-[[4-(dimethylamino)phenyl](phenyl)methylene]cyclohexa-2,5-dien-1-ylidene}-N-methylmethanaminium) trioxalate; MFCD00011766; NCGC00091944-01; Ammonium, (4-(p-(dimethylamino)-alpha-phenylbenzylidene)-2,5-cyclohexadien-1-ylidene)-dimethyl-, oxalate (2:1), oxalate (1:1); Bis((4-(4-(dimethylamino)benzhydrylidene)cyclohexa-2,5-dien-1-ylidene)dimethylammonium) oxalate, dioxalate; oic acid, ethanedioic acid; CHEMBL1545634; DTXSID6025513; Tox21_110008; Tox21_202521; MFCD00151209; SBB058166; AKOS015910564; Tox21_110008_1; MCULE-5320008974; NCGC00013058-01; NCGC00013058-02; NCGC00091944-02; NCGC00091944-03; NCGC00260070-01; FT-0628110; M0497; ST51015062; Malachite green oxalate 100 microg/mL in Methanol; Malachite Green oxalate, SAJ first grade, >=80.0%; Q27279349; (4-{[4-(dimethylamino)phenyl]phenylmethylene}cyclohexa-2,5-dienylidene)dimethy lamine, (4-{[4-(dimethylamino)phenyl]phenylmethylene}cyclohexa-2,5-dienylidene )dimethylamine, ethanedioic acid, ethanedi; (4-{[4-(dimethylamino)phenyl]phenylmethylene}cyclohexa-2,5-dienylidene)dimethy lamine, (4-{[4-(dimethylamino)phenyl]phenylmethylene}cyclohexa-2,5-dienylidene )dimethylamine, ethanedioic acid, ethanedioic acid, ethanedioic acid; Methanaminium, N-(4-((4-(dimethylamino)phenyl)phenylmethylene)-2,5-cyclohexadien-1-ylidene)-N-methyl-, ethanedioate (2:2:1);",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C52H54N4O12",
"molecular_weight": "927",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "2724411",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01998",
"RC02619",
"RC03240"
]
},
{
"compound_ID": "D0985",
"name": "malotilate",
"synonyms": "malotilate; 59937-28-9; Kantec; Malotilatum; NKK 105; NKK-105; Diisopropyl 1,3-dithiol-2-ylidenemalonate; Malotilatum [INN-Latin]; Malotilato [INN-Spanish]; dipropan-2-yl 2-(1,3-dithiol-2-ylidene)propanedioate; UNII-RV59PND975; Malotilate [USAN:INN:JAN]; EINECS 261-987-3; CL-1500; Diisopropyl-1,3-dithiol-2-ylidenemalonate; RV59PND975; Diisopropyl 2-(1,3-dithiol-2-ylidene)malonate; YPIQVCUJEKAZCP-UHFFFAOYSA-N; Diisopropyl 1,3-dithiole-delta(sup 2,alpha)-malonate; NCGC00164588-01; 1,3-Dithiol-2-ylidenepropanedioic acid, bis(1-methylethyl) ester; Propanedioic acid, 1,3-dithiol-2-ylidene-, bis(1-methylethyl) ester; DSSTox_CID_26463; DSSTox_RID_81637; DSSTox_GSID_46463; Malotilato; MALONIC ACID, (1,3-DITHIOL-2-YLIDENE)-, DIISOPROPYL ESTER; CAS-59937-28-9; Tractal; Malotilate/; C12H16O4S2; Kantec (TN); MLS006010037; Malotilate (JAN/USAN/INN); SCHEMBL635496; NKK105; CHEMBL1697754; DTXSID7046463; CHEBI:31798; CTK8E7254; KS-00000XLR; HMS3654I08; BCP01805; HY-A0060; ZINC1542902; Tox21 112214; Tox21_112214; ABP000477; KM0356; s1137; AKOS025119303; Tox21_112214_1; BCP9000892; CS-1594; DA-3857; VA11228; NCGC00164588-02; NCGC00164588-03; AK327287; AS-11770; CC-30142; LS-88812; SC-13551; SMR002530051; AB0007968; TC-030563; Diisopropyl (1,3-Dithiol-2-ylidene)malonate; FT-0082404; FT-0601567; M2674; SW219173-1; D01770; AB01566806_01; 937M289; C-18144; Q6744548; Bis(1-methylethyl) 1,3-dithiol-2-ylidenepropanedioate; BRD-K97884852-001-02-1; (1,3-Dithiol-2-ylidene)malonic Acid Diisopropyl Ester;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C12H16O4S2",
"molecular_weight": "288.4",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "4006",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC01999",
"RC02620",
"RC03241"
]
},
{
"compound_ID": "D0986",
"name": "manidipine",
"synonyms": "manidipine; 89226-50-6; Franidipine; 120092-68-4; Manidipine 6300; Artedil; Iperten; 3-(2-(4-Benzhydrylpiperazin-1-yl)ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Manidipine HCl; Manidipine [INN]; Manidipine (Manyper); C35H38N4O6; CV 4093; CHEMBL312176; Manidipine (INN); 2-(4-Diphenylmethyl-1-piperazinyl)ethyl methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate; 89226-75-5; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(4-(diphenylmethyl)-1-piperazinyl)ethyl methyl ester; 3,5-Pyridinedicarboxylicacid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,3-[2-[4-(diphenylmethyl)-1-piperazinyl]ethyl] 5-methyl ester, hydrochloride(1:2); 3-{2-[4-(diphenylmethyl)piperazin-1-yl]ethyl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; SMR003500793; NCGC00167493-01; NCGC00167493-04; Manidipine 6300 [INN]; Manidipine(Manyper); Artedil (TN); ACMC-20conv; 3-(2-(4-Benzhydrylpiperazin-1-yl)ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-; SCHEMBL49368; 2-[4-(diphenylmethyl)piperazin-1-yl]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; MLS004774156; MLS006011791; DTXSID2043745; CTK5G2647; KS-00000GIQ; ANEBWFXPVPTEET-UHFFFAOYSA-N; CHEBI:135849; HMS2089K12; HMS3264H11; HMS3656C06; BCP21717; HY-B0419; BDBM50227969; s2481; STK635322; AKOS003589070; AKOS016842350; BCP9000893; BCP9000919; CCG-213069; CS-2523; DB09238; DS-1275; MCULE-7098869865; VA11233; VP13803; NCGC00167493-02; NCGC00167493-03; 5-O-[2-(4-benzhydrylpiperazin-1-yl)ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; AK-72917; BR-72917; SC-25949; AB0012678; AB2000589; DB-041526; LS-130875; TR-038262; 4CH-007438; FT-0631098; FT-0670936; ST24028270; SW219347-1; Z5288; D08155; S-6064; AB01274741-01; AB01274741-02; AB01274741-03; AB01274741_04; AB01274741_05; 092M684; A804429; C-23346; Q921133; SR-05000002134; SR-05000002134-1; BRD-A90695733-001-01-7; CV 4093;CV-4093;CV4093;Franidipine;89226-50-6; 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid O5-[2-[4-(diphenylmethyl)-1-piperazinyl]ethyl] ester O3-methyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-[2-[4-(diphenylmethyl)-1-piperazinyl]ethyl] 5-methyl ester; Manidipine pound>>CV-4093 pound>>Franidipine pound>>( inverted exclamation markA)-Manidipine; O5-[2-[4-(diphenylmethyl)piperazin-1-yl]ethyl] O3-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C35H38N4O6",
"molecular_weight": "610.7",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "Manidipine is eliminated through extensive metabolism. 63% is eliminated in the feces and 31% in the urine as metabolites [A7845].",
"protein_binding": "Manidipine is 99% bound to human plasma proteins [A7845].",
"half_life": "The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.",
"absorption": "The median Tmax is 1.5 h [A7845]. Administration with food produces an 1.3-1.6-fold increase in Cmax but no change in Tmax. Manidipine does not accumulate significantly with multiple doses.",
"cid": "4008",
"classification": "C",
"indications": "",
"side_effects": "",
"atc_codes": "C08CA11; C09BB12",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02000",
"RC02621",
"RC03242"
]
},
{
"compound_ID": "D0987",
"name": "mepartricin",
"synonyms": "",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C60H88N2O19",
"molecular_weight": "1141.3",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "9941647",
"classification": "G; A; D",
"indications": "",
"side_effects": "",
"atc_codes": "G04CX03; G01AA09; A01AB16; D01AA06",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02003",
"RC02624",
"RC03245"
]
},
{
"compound_ID": "D0988",
"name": "mepronil",
"synonyms": "MEPRONIL; 55814-41-0; Basitac; 3'-Isopropoxy-2-methylbenzanilide; Mepronil [ISO]; 3'-Isopropoxy-o-toluanilide; Mepronil (pesticide); UNII-QJK1MXY8DW; 2-Methyl-3'-isopropoxybenzanilide; KCO-1; 2-Methyl-N-(3-(1-methylethoxy)phenyl)benzamide; Benzamide, 2-methyl-N-(3-(1-methylethoxy)phenyl)-; QJK1MXY8DW; 2-methyl-N-(3-propan-2-yloxyphenyl)benzamide; B1-2459; BRN 2381749; CHEBI:81823; BCTQJXQXJVLSIG-UHFFFAOYSA-N; 2-Methyl-N-[3-(1-Methylethoxy)phenyl]benzamide; Benzamide, 2-methyl-N-[3-(1-methylethoxy)phenyl]-; MRN; Maybridge1_007427; DSSTox_CID_17565; DSSTox_RID_79337; 3'-isopropoxy-2-toluanilide; DSSTox_GSID_37565; Oprea1_007450; SCHEMBL18447; CHEMBL1615095; DTXSID1037565; BCTQJXQXJVLSIG-UHFFFAOYSA-; CTK8E4473; HMS562J13; ZINC105794; 3'-iso-propoxy-2-methylbenzanilide; Tox21_302431; Mepronil 10 microg/mL in Cyclohexane; AKOS003488106; 3'-ISOPROPOXY-ORTHO-TOLUANILIDE; KS-5375; MCULE-4214400541; NCGC00163916-01; NCGC00255513-01; LS-27202; N-(3-Isopropoxyphenyl)-2-methylbenzamide; O670; 3'-isopropoxy-2-methylbenzoic acid anilide; CAS-55814-41-0; DB-052804; TR-019676; 2-Methyl-N-(3-isopropoxy-phenyl)-benzamide; FT-0640339; Mepronil, PESTANAL(R), analytical standard; N-(3-Isopropoxyphenyl)-2-methylbenzamide #; C18548; 2-methyl-N-[3-(propan-2-yloxy)phenyl]benzamide; 814M410; Q19296228; InChI=1/C17H19NO2/c1-12(2)20-15-9-6-8-14(11-15)18-17(19)16-10-5-4-7-13(16)3/h4-12H,1-3H3,(H,18,19);",
"trade_name": "Miltown, Equanil, Meprospan, Amepromat, Quivet, Zirponand,",
"abbrev_name": "",
"description": "carbamate derivative; anxiolytic drug; minor tranquilizer",
"molecular_formula": "C17H19NO2",
"molecular_weight": "269.34",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "41632",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108",
"F020403"
],
"references": [
"RC02004",
"RC02625",
"RC03246",
"RC04937"
]
},
{
"compound_ID": "D0989",
"name": "mesotrione",
"synonyms": "Mesotrione; 104206-82-8; 2-(4-(Methylsulfonyl)-2-nitrobenzoyl)cyclohexane-1,3-dione; UNII-48TR68G21T; 1,3-Cyclohexanedione, 2-[4-(methylsulfonyl)-2-nitrobenzoyl]-; CHEBI:38321; 2-(4-Mesyl-2-nitrobenzoyl)-1,3-cyclohexanedione; KPUREKXXPHOJQT-UHFFFAOYSA-N; 48TR68G21T; (2-nitro-4-(methylsullfonyl))benzoylcyclohexane-1,3-dione; 2-(4-methylsulfonyl-2-nitrobenzoyl)cyclohexane-1,3-dione; NCGC00163843-03; 2-[4-(methanesulfonyl)-2-nitrobenzoyl]cyclohexane-1,3-dione; 2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione; 2-(4-methylsulphonyl-2-nitrobenzoyl)-1,3-cyclohexanedione; 2-(2'-nitro-4'-methylsulfonylbenzoyl)cyclohexane-1,3-dione; 1,3-Cyclohexanedione, 2-(4-(methylsulfonyl)-2-nitrobenzoyl)-; Mesotrione [ISO]; Tenacity; 2-[4-(methylsulfonyl)-2-nitrobenzoyl]cyclohexane-1,3-dione; C14H13NO7S; HSDB 7250; ZA 1296; EINECS Annex I Index 609-064-00-X; DSSTox_CID_12424; DSSTox_RID_78945; DSSTox_GSID_32424; SCHEMBL22116; CHEMBL1873440; DTXSID7032424; BCP31203; KS-00000Q3K; Tox21_400050; BDBM50264337; AKOS015895775; ZINC100004047; NCGC00163843-01; NCGC00163843-02; NCGC00163843-04; AK321877; CC-30237; DS-11960; AB1008404; CAS-104206-82-8; FT-0631031; Z1948; Mesotrione, PESTANAL(R), analytical standard; 206M828; A800923; C-20293; Q409390; J-001131; 2-(2-nitro-4-methanesulphonyl benzoyl)cyclohexan-1,3-dione; 1,3-Cyclohexanedione, 2-4-(methylsulfonyl)-2-nitrobenzoyl-; 2-(2'-nitro-4'-methylsulphonylbenzoyl)-1,3-cyclohexanedione; 2-(4-methylsulfonyl-2-nitro-phenyl)carbonylcyclohexane-1,3-dione; 2-[(4-methylsulfonyl-2-nitrophenyl)-oxomethyl]cyclohexane-1,3-dione;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C14H13NO7S",
"molecular_weight": "339.32",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "175967",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02005",
"RC02626",
"RC03247"
]
},
{
"compound_ID": "D0990",
"name": "metanixin",
"synonyms": "Metanixin; Acide nixylique; Acido nixilico; Acidum nixylicum; Metanixin [INN]; Metanixine [French]; Metanixinum [Latin]; Metanixino [Spanish]; OWY6DMB1YX; UNII-OWY6DMB1YX; Metanixine [INN-French]; Metanixinum [INN-Latin]; 4394-04-1; Metanixino [INN-Spanish]; 2-(2,6-Xylidino)nicotinsaeure; 2-(2,6-Xylidino)nicotinic acid; UP 74; BRN 0482454; NICOTINIC ACID, 2-(2,3-XYLIDINO)-; Metanixino; Metanixinum; DSSTox_CID_25693; DSSTox_RID_81065; DSSTox_GSID_45693; SCHEMBL2107737; ZINC1694; CHEMBL2104706; DTXSID3045693; 2-[(2,6-dimethylphenyl)amino]pyridine-3-carboxylic Acid; Tox21_110969; AKOS009173650; LS-96642; CAS-4394-04-1; Q27285895; Z2677432404; 3-Pyridinecarboxylic acid, 2-((2,6-dimethylphenyl)amino)-; 3-Pyridinecarboxylic acid, 2-((2,6-dimethylphenyl)amino)- (9CI);",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C14H14N2O2",
"molecular_weight": "242.27",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "10466908",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02006",
"RC02627",
"RC03248"
]
},
{
"compound_ID": "D0991",
"name": "methfuroxam",
"synonyms": "Methfuroxam; 2,4,5-Trimethyl-3-furanilide; 28730-17-8; Fenfuroxam; Furavax; Furoxam; Trivax; Methfuroxam [ANSI]; Caswell No. 549BB; UNII-4K9VG91RQZ; 3-Furancarboxamide, 2,4,5-trimethyl-N-phenyl-; UBI-H 719; 2,4,5-Trimethyl-N-phenyl-3-furancarboxamide; 2,4,5-trimethyl-N-phenylfuran-3-carboxamide; UBI-2238; EINECS 249-194-0; EPA Pesticide Chemical Code 116301; UBI-H 719-1220; UBI-H 719-1222; 4K9VG91RQZ; H 719; ZWJNEYVWPYIKMB-UHFFFAOYSA-N; 3-FURANILIDE, 2,4,5-TRIMETHYL-; 2,4,5-TRIMETHYL-N-PHENYL-3-FURAMIDE; N-phenyl(2,4,5-trimethyl(3-furyl))carboxamide; Methfuroxam [ANSI:ISO]; methfuroxame; 3-Furanilide, 2,4,5-trimethyl- (8CI); DSSTox_CID_22137; DSSTox_RID_79933; DSSTox_GSID_42137; SCHEMBL21663; CHEMBL1395509; DTXSID8042137; CTK4G1987; CHEBI:142825; ZINC155059; Tox21_301332; SBB057104; AKOS009046001; MCULE-7824115062; NCGC00166155-01; NCGC00255828-01; LS-70232; CAS-28730-17-8; ST50412107; 3-Furancarboxamide,2,4,5-trimethyl-N-phenyl-; Methfuroxam, PESTANAL(R), analytical standard; J-017223; Q22808392;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C14H15NO2",
"molecular_weight": "229.27",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "34313",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02007",
"RC02628",
"RC03249"
]
},
{
"compound_ID": "D0992",
"name": "methisazone",
"synonyms": "Methisazone; Metisazone; Marboran; Kemoviran; Metisazon; Metisazonum; Viruzona; 1910-68-5; Compound 33T57; 1-Methylisatin 3-thiosemicarbazone; N-Methylisatin thiosemicarbazone; N-Methylisatin 3-(thiosemicarbazone); NSC 69811; NSC-69811; 33T57; Methsazone; BW 33-T-57; Metisazonum [INN-Latin]; N-Methylisatin-3-thiosemicarbazone; B. W. 33-T-57; Metisazona [INN-Spanish]; N-Methylindole-2,3-dione thiosemicarbazone; UNII-K3QML4J07E; NSC 70969; MIBT; Methisazone [USAN]; Isatin, 1-methyl-, 3-(thiosemicarbazone); beta-Thiosemicarbazone-N-methylisatin; EINECS 217-616-2; N-Methylisatin beta-thiosemicarbazide; N-Methylisatin-beta-thiosemicarbazone; 1-Methylisatin beta-thiosemicarbazone; K3QML4J07E; Hydrazinecarbothioamide, 2-(1,2-dihydro-1-methyl-2-oxo-3H-indol-3-ylidene)-; AI3-62297; 1-Methylisatin 3-semicarbazone; C10H10N4OS; 1-Methylindole-2,3-Dione 3-thiosemicarbazone; INDOLE-2,3-DIONE, 1-METHYL-, 3-(THIOSEMICARBAZONE); 1-Methylindole-2,3-dione 3-(thiosemicarbazone); 1-methylisatin, 3-thiosemicarbazide; Metisazone (INN); Metisazone [INN]; NSC69811; NSC70969; Methisazone (USAN); .beta.-Thiosemicarbazone-N-methylisatin; 26153-15-1; N-Methylisatin .beta.-thiosemicarbazone; 1-Methylisatin .beta.-thiosemicarbazone; NCGC00164522-01; Isatin, 3-(thiosemicarbazone); Metisazona; WLN: T56 BNVYJ B1 DUNMYZUS; N-Methylisatin .beta.-thiosemicarbazide; N-Methylisatin-.beta.-thiosemicarbazone; Indole-2, 1-methyl-, 3-(thiosemicarbazone); Methisazone [USAN:BAN]; Methisazon; Marborane; 3-{[(aminothioxomethyl)amino]azamethylene}-1-methylbenzo[d]azolin-2-one; Hydrazinecarbothioamide,2-dihydro-1-methyl-2-oxo-3H-indol-3-ylidene)-; M-IBT; DSSTox_CID_26413; DSSTox_RID_81592; NCIOpen2_003221; NCIOpen2_003444; DSSTox_GSID_46413; ARONIS24450; SCHEMBL145868; [(Z)-(1-methyl-2-oxoindol-3-ylidene)amino]thiourea; CHEMBL362994; CHEMBL1512080; CHEMBL2354555; DTXSID7046413; CTK8H4221; CHEBI:134952; DLGSOJOOYHWROO-WQLSENKSSA-N; BW-33T57; KS-000028NE; Tox21_112155; BW 33-T57; NSC-70969; SBB062505; STK387544; AKOS002376731; AKOS003232549; AKOS030253422; ZINC100011971; ZINC100054648; ZINC254565689; ACM1910685; BW-33-T-57; DB13641; MCULE-5335782926; MS-6486; NCGC00164522-02; LS-83039; ST074458; CAS-1910-68-5; 1-Methyl-3-thiosemicarbazonoindoline-2-one; DB-044754; FT-0633906; D02496; C-49877; SR-01000945054; Q4562049; SR-01000945054-1; 1-Methyl-1H-indole-2,3-dione 3-thiosemicarbazone #; (3E)-1-methyl-1H-indole-2,3-dione 3-thiosemicarbazone; [(Z)-(1-methyl-2-oxo-indolin-3-ylidene)amino]thiourea; (E)-2-(1-methyl-2-oxoindolin-3-ylidene)hydrazinecarbothioamide; [(1-methyl-2-oxo-2,3-dihydro-1H-indol-3-ylidene)amino]thiourea; {[(3Z)-1-methyl-2-oxo-2,3-dihydro-1H-indol-3-ylidene]amino}thiourea; (2E)-2-(1-methyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene)hydrazinecarbothioamide; Hydrazinecarbothioamide, 2-(1,2-dihydro-1-methyl-2-oxo-3H-indole-3-ylidene)-;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C10H10N4OS",
"molecular_weight": "234.28",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "667492",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02008",
"RC02629",
"RC03250"
]
},
{
"compound_ID": "D0993",
"name": "methyl 2,4-dihydroxy-3,6-dimethylbenzoate",
"synonyms": "Methyl 2,4-dihydroxy-3,6-dimethylbenzoate; 4707-47-5; Atraric acid; methyl2,4-dihydroxy-3,6-dimethylbenzoate; UNII-12YH9T04QE; Benzoic acid, 2,4-dihydroxy-3,6-dimethyl-, methyl ester; Methyl 3,6-dimethylresorcylate; 12YH9T04QE; .beta.-Resorcylic acid, 3,6-dimethyl-, methyl ester; METHYL-2,4-DIHYDROXY-3,6-DIMETHYLBENZOATE; W-109992; 91061-32-4; Methyl beta-orcinolcarboxylate; Methyl 3-methylorsellinate; Evernyl; Veramoss; Methyl atratate; Methyl beta-resorcinolcarboxylate; EINECS 225-193-0; PubChem15390; methyl 2,4-dihydroxy-3,6-dimethyl-benzoate; atraratic acid methyl ester; Methyl atratate, >=98%; DSSTox_CID_21653; DSSTox_RID_79803; DSSTox_GSID_41653; CBDivE_016254; beta-Resorcylic acid, 3,6-dimethyl-, methyl ester; MLS000517295; SCHEMBL113732; beta-Resorcyclic acid, 3,6-dimethyl-, methyl ester; methyl-beta-orcinol carboxylate; CHEMBL508287; DTXSID9041653; Methyl .beta.-orcinolcarboxylate; CTK4I9719; CHEBI:144127; UUQHKWMIDYRWHH-UHFFFAOYSA-N; HMS1579G21; HMS2267P05; ZINC239015; BB_NC-01285; Tox21_301667; ANW-45830; BBL028296; MFCD00157202; SBB064865; STK021597; AKOS005379221; FCH1113164; LS10120; MCULE-5480918412; Methyl 2,4-diOH-3,6-dimethylbenzoate; Methyl 3,6-dimethyl-.beta.-resorcylate; NCGC00247061-01; NCGC00255527-01; 4CN-1213; AK-86919; SMR000127412; VS-08714; CAS-4707-47-5; AX8138082; DB-070774; RT-004872; FT-0628828; ST24030876; ST50408246; 707M475; C-55798; 2,4-Dihydroxy-3,6-dimethylbenzoic acid, methyl ester; Q15634313; Benzoic acid,2,4-dihydroxy-3,6-dimethyl-, methyl ester; 2,4-DIHYDROXY-3,6-DIMETHYL-BENZOIC ACID METHYL ESTER;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C10H12O4",
"molecular_weight": "196.2",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "78435",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02010",
"RC02631",
"RC03252"
]
},
{
"compound_ID": "D0994",
"name": "methyl triclosan",
"synonyms": "Methyl triclosan; 2,4-dichloro-1-(4-chloro-2-methoxyphenoxy)benzene; 4640-01-1; Triclosan Methyl Ether; UNII-5174UR1DP5; 5174UR1DP5; Benzene, 4-chloro-1-(2,4-dichlorophenoxy)-2-methoxy-; Methyltriclosan; Triclosan-methyl; Triclosan methyl; Triclosan-methyl ether; DSSTox_CID_27850; DSSTox_RID_82603; DSSTox_GSID_47874; SCHEMBL676629; CHEMBL2325395; DTXSID0047874; CTK8G3591; KS-00000TVS; NLYDHBBTVWMLFD-UHFFFAOYSA-N; ZINC2526438; Tox21_200199; Triclosan-methyl, analytical standard; NCGC00248561-01; NCGC00257753-01; AK549015; DS-19481; CAS-4640-01-1; 2,4,4'-Trichloro-4'-methoxydiphenyl ether; FT-0675460; Q1925612; 4-Chloro-1-(2,4-dichlorophenoxy)-2-methoxybenzene #; BRD-K62328564-001-01-1;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C13H9Cl3O2",
"molecular_weight": "303.6",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "627458",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02011",
"RC02632",
"RC03253"
]
},
{
"compound_ID": "D0995",
"name": "methyl violet",
"synonyms": "Gentian Violet B; 603-47-4; Methyl Violet 2BN200; Pentamethyl pararosaniline chloride; UNII-V3Z44MJ9SB; EINECS 210-042-3; NSC 47731; V3Z44MJ9SB; 4-[[4-(dimethylamino)phenyl][4-(methylimino)cyclohexa-2,5-dien-1-ylidene]methyl]-N,N-dimethylaniline monohydrochloride; Benzenamine, 4-((4-(dimethylamino)phenyl)(4-(methylimino)-2,5-cyclohexadien-1-ylidene)methyl)-N,N-dimethyl-, monohydrochloride; 4-((4-(Dimethylamino)phenyl)(4-(methylimino)cyclohexa-2,5-dien-1-ylidene)methyl)-N,N-dimethylaniline monohydrochloride; Benzenamine, N,N-dimethyl-4-((4-(dimethylamino)phenyl)(4-(methylimino)-2,5-cyclohexadien-1-ylidene)methyl)-, monohydrochloride; MFCD00012568; Methyl Violet dye salt; Methyl Violet (Crystal Violet); Pyoktanin Blue, SAJ first grade; DTXSID90943876; Pyoktanin Blue, SAJ special grade; Methyl Violet (C.I. 42535); NSC47731; GT4491; GT7577; NSC-47731; Methyl Violet 2B (C.I. 42535); PENTAMETHYLPARAROSANILINE CHLORIDE; LS-28294; T318; UNII-H2G44K8M7S component JFTBTTPUYRGXDG-UHFFFAOYSA-N; Methyl violet 2B, certified by the Biological Stain Commission; Aniline,5-cyclohexadien-1-ylidene]methyl]-N,N-dimethyl-, monohydrochloride; Benzenamine,5-cyclohexadien-1-ylidene]methyl]-N,N-dimethyl-, monohydrochloride; 21325-96-2; 4,4'-{[4-(Methylimino)cyclohexa-2,5-dien-1-ylidene]methylene}bis(N,N-dimethylaniline)--hydrogen chloride (1/1); 4-[[4-(dimethylamino)phenyl]-(4-methyliminocyclohexa-2,5-dien-1-ylidene)methyl]-N,N-dimethylaniline;hydrochloride; Aniline, p-((p-(dimethylamino)phenyl)(4-(methylimino)-2,5-cyclohexadien-1-ylidene)methyl)-N,N-dimethyl-, monohydrochloride; Aniline, p-((p-(dimethylamino)phenyl)(4-(methylimino)-2,5-cyclohexadien-1-ylidene)methyl)-N,N-dimethyl-, monohydrochloride (8CI); Methyl violet, for microscopy (Bact., Bot., Hist.), indicator (pH 0.1-2.0), mixture of polymethylated pararosaniline hydrochlorides;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C24H27N3",
"molecular_weight": "357.5",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "164877",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02012",
"RC02633",
"RC03254"
]
},
{
"compound_ID": "D0996",
"name": "methyldigoxin",
"synonyms": "metildigoxin; Methyldigoxin; MEDIGOXIN; beta-Methyldigoxin; 30685-43-9; Lanitop; UNII-I7GG1YUC5V; 4'''-O-Methyldigoxin; I7GG1YUC5V; 4'''-Methyldigoxin; Betamethyl digoxin; Medigossina [DCIT]; Medigoxina [Spanish]; Metildigoxine [INN-French]; Metildigoxinum [INN-Latin]; beta-Metildigoxina [Spanish]; Metildigoxina [INN-Spanish]; Digoxin, 4'''-O-methyl-; Medigossina; Medigoxina; Metildigoxina; Metildigoxine; Metildigoxinum; beta-Methyl Digoxin; EINECS 250-292-0; beta-Metildigoxina; BRN 1339127; Metildigoxin [INN:BAN:JAN]; Medigoxin (BAN); NCGC00168746-01; Metildigoxin (INN); DSSTox_CID_3294; DSSTox_RID_76961; DSSTox_GSID_23294; SCHEMBL43349; CHEMBL1697843; DTXSID0023294; CTK8G3982; CHEBI:135885; IYJMSDVSVHDVGT-PEQKVOOWSA-N; Card-20(22)-enolide, 3-((O-2,6-dideoxy-4-O-methyl-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3-beta,5-beta,12-beta)-; Tox21_112625; AKOS030242278; ZINC254011770; DB13401; CAS-30685-43-9; FT-0628872; D09847; Q550017; (3beta,5beta,12beta)-3-{[2,6-dideoxy-4-O-methyl-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C42H66O14",
"molecular_weight": "795",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "443946",
"classification": "C",
"indications": "",
"side_effects": "",
"atc_codes": "C01AA08",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02013",
"RC02634",
"RC03255"
]
},
{
"compound_ID": "D0997",
"name": "methylene blue trihydrate",
"synonyms": "Methylene Blue trihydrate; 7220-79-3; Methylthionine chloride; C.I. Basic Blue 9 trihydrate; Phenothiazin-5-ium, 3,7-bis(dimethylamino)-, chloride, trihydrate; UNII-T42P99266K; C.I. 52015; 3,7-Bis(dimethylamino)phenothiazin-5-ium chloride trihydrate; T42P99266K; Methylene blue (USP); Methylene blue [USP]; Methylthionine HCl; Methylene Blue trihydrate (C.I. 52015); C16H18ClN3S; Methylene Blue trihydrate, 95%, pure; MFCD00012111; NSC-215213; NSC-617593; Methylene Blue [USAN]; Basic Blue 9 trihydrate; CI 52015; CCRIS 9312; C.I. Basic Blue 9, trihydrate; MFCD00150008; DSSTox_CID_5600; Trx0014; 61-73-4 (anhydrous); DSSTox_RID_77848; DSSTox_GSID_25600; CHEMBL550495; DTXSID0025600; C16H18N3S.Cl.3H2O; C16H20N3S.3H2O.Cl; KS-00000YCE; Tox21_202525; 6337AF; GT0735; AKOS015915395; AC-8349; LS-1619; C.I. Basic Blue 9, trihydrate (8CI); Methylthioninium chloride proveblue (TN); NCGC00091924-01; NCGC00260074-01; CAS-7220-79-3; FT-0628873; ST50406156; D02312; [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium chloride; [7-(dimethylamino)benzo[e]benzo[3,4-b]1,4-thiazin-3-yl]dimethylamine, hydrate, hydrate, hydrate, chloride;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C16H24ClN3O3S",
"molecular_weight": "373.9",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "104827",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02015",
"RC02636",
"RC03257"
]
},
{
"compound_ID": "D0998",
"name": "methylsilanetriyl triacetate",
"synonyms": "Methyltriacetoxysilane; 4253-34-3; Triacetoxy(methyl)silane; Methylsilanetriyl triacetate; Triacetoxymethylsilane; Silanetriol, methyl-, triacetate; Silane, methyltriacetoxy-; Methylsilanetriol triacetate; Methyltrihydroxysilane triacetate; APK 1 (silane derivative); K 10S; EINECS 224-221-9; NSC 139845; BRN 1788668; Silanetriol, 1-methyl-, 1,1,1-triacetate; TVJPBVNWVPUZBM-UHFFFAOYSA-N; methyltriacetoxysilan; triacetoxy(methylsilane); CH3Si(OCOCH3)3; DSSTox_CID_7565; EC 224-221-9; DSSTox_RID_78506; DSSTox_GSID_27565; SCHEMBL63651; 4-04-00-04208 (Beilstein Handbook Reference); KSC491G6P; CHEMBL3184776; DTXSID0027565; CTK3J1367; bis(acetyloxy)(methyl)silyl acetate; KS-00000VV3; Tox21_200663; ANW-29829; CM8980; MFCD00008694; NSC139845; AKOS008901251; ZINC169746434; MCULE-3227275066; NSC-139845; RTR-016640; TRA0067854; s11725; NCGC00248787-01; NCGC00258217-01; CC-30921; CAS-4253-34-3; LS-145223; TR-016640; FT-0689240; A19554; Triacetoxy(methyl)silane, technical grade, 90%; C-34701; J-522700; Methylsilanetriyl triacetate; Triacetoxy(methyl)silane;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C7H12O6Si",
"molecular_weight": "220.25",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "77929",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02016",
"RC02637",
"RC03258"
]
},
{
"compound_ID": "D0999",
"name": "methyltrioctylammonium trifluoromethanesulfonate",
"synonyms": "METHYLTRIOCTYLAMMONIUM TRIFLUOROMETHANESULFONATE; 121107-18-4; Methyltricaprylylammonium triflate; UNII-0LD8B8W58Y; 0LD8B8W58Y; ACMC-1C8RH; DSSTox_CID_27880; DSSTox_RID_82633; DSSTox_GSID_47904; methyltrioctylammonium triflate; SCHEMBL597290; CHEMBL3185210; DTXSID5047904; CTK0H0349; Tox21_200581; AKOS005145512; NCGC00248745-01; NCGC00258135-01; TX-010202; CAS-121107-18-4; Methyl(trioctyl)ammonium trifluoromethanesulfonate; Methyltri-N-octylammonium trifluoromethanesulfonate; Q27236939; 1-Octanaminium, N-methyl-N,N-dioctyl-, trifluoromethanesulfonate (1:1); 1-Octanaminium, N-methyl-N,N-dioctyl-, salt with trifluoromethanesulfonic acid (1:1); Methanesulfonic acid, trifluoro-, ION(1-), N-methyl-N,N-dioctyl-1-octanaminium;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C26H54F3NO3S",
"molecular_weight": "517.8",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "22678982",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02017",
"RC02638",
"RC03259"
]
},
{
"compound_ID": "D1000",
"name": "metochalcone",
"synonyms": "Metochalcone; Lesidrin; Megalip; Solvocolo; Spechol; Trimecolo; Trimepaton; Vesidril; Vesidryl; Gebyl; Metochalcon; UNII-1754ZE4075; Chemicol; CHEMBL36584; 18493-30-6; Metochalcone [INN:DCF]; 1754ZE4075; (2E)-1-(2,4-Dimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one; Metocalcona [INN-Spanish]; Metochalconum [INN-Latin]; 2',4,4'-Trimethoxychalcone; Metocalcona; Metochalconum; Chalcone, 2',4,4'-trimethoxy-; EINECS 242-377-6; NSC 97905; 1314 CB; 1314-CB; Trimethoxy 4-2'-4' chalcone [French]; Trimethoxy 4-2'-4' chalcone; NCGC00160442-01; 2',4'-Trimethoxychalcone; 1-(2,4-Dimethoxyphenyl)-3-(4-methoxyphenyl)-2-propen-1-one; MLS001049137; SCHEMBL309111; 2',4,4'-trimeth-oxychalcone; HMS2270C09; NSC97905; ZINC3979084; (E)-1-(2,4-dimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one; 2',4,4'-Trimethoxy-trans-chalcone; BDBM50107308; NSC-97905; STL513032; AKOS001024014; ACM18493306; SMR000386963; AB00053250-08; AB00053250-10; SR-01000025297; SR-01000025297-1; Q27251868; 1-(2,4-Dimethoxy-phenyl)-3-(4-methoxy-phenyl)-propenone; 2-Propen-1-one,4-dimethoxyphenyl)-3-(4-methoxyphenyl)-; (E)-1-(2,4-Dimethoxy-phenyl)-3-(4-methoxy-phenyl)-propenone; 2-Propen-1-one, 1-(2,4-dimethoxyphenyl)-3-(4-methoxyphenyl)- (9CI); 2-Propen-1-one, 1-(2,4-dimethoxyphenyl)-3-(4-methoxyphenyl)-, (2E)-; (E)-1-(2'',4''-Dimethoxyphenyl)-3-(4''''-methoxyphenyl)prop-2-en-1-one; 30925-62-3;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C18H18O4",
"molecular_weight": "298.3",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "6063342",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02018",
"RC02639",
"RC03260"
]
},
{
"compound_ID": "D1001",
"name": "mgk-264",
"synonyms": "Pyrodone; MGK 264; N-(2-Ethylhexyl)-5-norbornene-2,3-dicarboximide; MGK-264; Pyrdone (obsolete); Sinepyrin 222; Synergist 264; Octacide 264; MGK repellent 264; Van Dyk 264; 113-48-4; Synepirin 222; N-2-Ethylhexylbicycloheptenedicarboximide; ENT 8,184; N-Octyl bicycloheptene dicarboximide; NSC 36678; N-2-Ethylhexylimide endomethylenetetrahydrophthalic acid; Octylbicycloheptenedicarboximide; endo Methylenetetrahydrophthalic acid, N-2-ethylhexyl imide; CHEBI:81966; 5-Norbornene-2,3-dicarboximide, N-(2-ethylhexyl)-; 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-(2-ethylhexyl)-3a,4,7,7a-tetrahydro-; Caswell No. 613; Bicyclo(2.2.1)heptene-2-dicarboxylic acid, 2-ethylhexylimide; N-(2-Ethylhexyl)bicyclo-(2,2,1)-hept-5-ene-2,3-dicarboximide; 2-(2-ethylhexyl)-3a,4,7,7a-tetrahydro-1H-4,7-methanoisoindole-1,3(2H)-dione; 2-(2-Ethylhexyl)-3a,4,7,7a-tetrahydro-4,7-methano-1H-isoindole-1,3(2H)-dione; Dicarboximide; Octyl bicycloheptenedicarboximide; HSDB 1745; EINECS 204-029-1; 5-Norbornene-2, N-(2-ethylhexyl)-; EPA Pesticide Chemical Code 057001; BRN 0025024; N-2-Ethylhexyl bicycloheptenedicarboximide; AI3-08184; WLN: T C555 A DVNV IUTJ E1Y4 & 2; N-Octylbicyclo-(2.2.1)-5-heptene-2,3-dicarboximide; N-Octylbicyclo[2.2.1]-5-heptene-2,3-dicarboximide; Endomethylenetetrahydrophthalic acid, N-2-ethylhexylimide; Endomethylenetetrahydrophthalic acid, N-2-ethylhexyl imide; N-(2-Ethylhexyl)bicyclo[2,1]hept-5-ene-2,3-dicarboximide; Carboximide; N-Octyl bicycloheptenedicarboximide; 4,3(2H)-dione, 2-(2-ethylhexyl)-3a,4,7,7a-tetrahydro-; Bicyclo[2.2.1]heptene-2-dicarboxylic acid, 2-ethylhexylimide; N-(2-Ethylhexyl)bicyclo(2.2.1)-5-heptene-2,3-dicarboximide; N-(2-Ethylhexyl)-8,9,10-trinorborn-5-ene-2,3-dicarboximide; N-2-Ethylhexylimid kyseliny bicyklo-(2,2,1)-5-hepten-2,3-dikarboxylove; 2-(2-Ethylhexyl)-3a,7,7a-tetrahydro-4,7-methano-1H-isoindole-1,3(2H)-dione; N-2-Ethylhexylimid kyseliny bicyklo-(2,2,1)-5-hepten-2,3-dikarboxylove [Czech]; AMTGC147; DSSTox_CID_12562; DSSTox_RID_78988; DSSTox_GSID_32562; SCHEMBL159735; CHEMBL1874490; DTXSID6032562; WLLGXSLBOPFWQV-UHFFFAOYSA-N; KS-000002AI; NSC36678; Tox21_300786; NSC-36678; NSC406879; AKOS015901672; AS-3197; NSC-406879; NCGC00168324-01; NCGC00168324-02; NCGC00254690-01; CAS-113-48-4; LS-97203; C18795; J-002969; Q6951386; N-(2-Ethylhexyl)bicyclo-(2.2.1)-5-heptene-2,3-dicarboximide; 4-(2-Ethylhexyl)-4-azatricyclo-[5.2.1.0?,6]dec-8-ene-3,5-dione; 4-(2-ethylhexyl)-4-azatricyclo[5.2.1.0^{2,6}]dec-8-ene-3,5-dione; 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-(2-ethylhexyl)-3a,4,7,7a-tetra hydro-;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C17H25NO2",
"molecular_weight": "275.4",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "8227",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02019",
"RC02640",
"RC03261"
]
},
{
"compound_ID": "D1002",
"name": "mifepristone",
"synonyms": "mifepristone; 84371-65-3; Mifegyne; Mifeprex; RU-486; Corlux; Korlym; RU486; Mifepriston; RU 486; Mifepristonum [Latin]; Mifepristona [Spanish]; RU 38486; RU-38486; UNII-320T6RNW1F; Mifepristone [USAN:INN:BAN]; HSDB 6841; R 38486; BRN 5779404; RU 486-6; MLS000069785; 320T6RNW1F; VGX-410C; CHEBI:50692; VGX-410; Mifepristone, 98%; (8S,11R,13S,14S,17S)-11-(4-(dimethylamino)phenyl)-17-hydroxy-13-methyl-17-(prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; NCGC00025179-05; SMR000058481; DSSTox_CID_3322; C-1073; 11beta-(4-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-on; 17-beta-Hydroxy-11-beta-(4-dimethylaminophenyl-1)-17-alpha-(prop-1-ynyl)oestra-4,9-dien-3-one; DSSTox_RID_76976; DSSTox_GSID_23322; (8S,11R,13S,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; (8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE; 11beta-(4-(Dimethylamino)phenyl)-17-hydroxy-21-methyl-19-nor-17alpha-pregna-4,9-dien-20-m-3-on; 11beta-(4-(N,N-Dimethylamino)phenyl)-17alpha-(prop-1-ynyl)-delta4,9-estradiene-17beta-ol-3-one; Mifepristona; Mifepristonum; 11beta-(p-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one; ZK-98296; (11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one; (11beta,17beta)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-prop-1-yn-1-ylestra-4,9-dien-3-one; Estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-, (11-beta,17-beta)-; RU486 (tetramethyl-rhodamine conjugated); Mifepristone(Mifeprex); SR-01000076011; C29H35NO2; Pictovir; CCRIS 9332; 1nhz; Mifeprex (TN); Pictovir (TM); CPD000058481; Prestwick_570; CAS-84371-65-3; Korlym (TN); ZK98296; 2w8y; Mifepristone (Mifeprex); Mifepristone(Mifeprex)/; Opera_ID_562; Mifepristone, >=98%; Prestwick0_000299; Prestwick1_000299; Prestwick2_000299; Prestwick3_000299; Spectrum5_002045; R38486; BIDD:PXR0123; Lopac0_000801; R-38486; SCHEMBL16087; BSPBio_000238; MLS001074115; MLS001424271; (non-labelled)Mifepristone-d3; ARONIS27015; SPBio_002457; BPBio1_000262; CHEMBL438575; GTPL2805; Mifepristone (JAN/USAN/INN); CHEMBL1276308; DTXSID5023322; BDBM18627; CTK8B2959; AOB6893; VKHAHZOOUSRJNA-GCNJZUOMSA-N; HMS1568L20; HMS2052L05; HMS2090L22; HMS2095L20; HMS2230P21; HMS3262B03; HMS3412D17; HMS3649J08; HMS3676D17; HMS3712L20; ACT02598; BCP02145; ZINC3831128; Tox21_110952; Tox21_301841; Tox21_500801; ABP000437; ANW-41472; BDBM50072024; HSCI1_000369; MFCD00867226; s2606; VX-410; AKOS015895416; Tox21_110952_1; API0003390; CCG-101164; CI-1073; CS-1435; DB00834; LP00801; NC00414; Mifepristone 1.0 mg/ml in Acetonitrile; NCGC00025179-06; NCGC00025179-07; NCGC00025179-08; NCGC00025179-09; NCGC00025179-12; NCGC00025179-13; NCGC00179632-01; NCGC00255152-01; NCGC00261486-01; (11beta,17beta)-11-(4-(Dimethylamino)-phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one; (11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one; AS-13938; Estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-, (11beta,17beta)-; HY-13683; LS-64723; RU486;C-1073; SC-16222; AB2000695; TR-026092; EU-0100801; FT-0082666; FT-0602519; C07652; D00585; M 8046; RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex; W-5163; 29523-EP2272827A1; 29523-EP2275420A1; 29523-EP2295055A2; 29523-EP2295416A2; 29523-EP2298748A2; 29523-EP2298764A1; 29523-EP2298765A1; 29523-EP2305642A2; 29523-EP2308880A1; 29523-EP2311453A1; 29523-EP2311808A1; 29523-EP2311829A1; 29523-EP2311842A2; 75603-EP2269977A2; 75603-EP2308880A1; 371M653; A840767; Q411240; SR-01000721888; Q-201405; SR-01000076011-1; SR-01000076011-3; SR-01000076011-5; SR-01000076011-9; SR-01000721888-4; BRD-K37270826-001-04-5; BRD-K37270826-001-31-8; Mifepristone, United States Pharmacopeia (USP) Reference Standard; (11?,17?)-11-[4-(Dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one; 11.beta.-[4-(Dimethylamino)phenyl]-17.beta.-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one; 11beta-(4-Dimethyl-amino)-phenyl-17beta-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one; 11ss-[p-(Dimethylamino)fenyl]-17ss-hydroxy- 17-(1-propynyl)estra-4,9-dien-3-on; (10S,11S,14S,15S,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-1,6-dien-5-one; (10S,11S,14S,15S,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1,6-dien-5-one; (11R,13S,14S,17S)-11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one; (8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-13-methyl-17-oxidanyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; (8S,11R,13S,14S,17S)-11-[4-(Dimethylamino)phenyl]-17-hydroxy-13-methyl-17-(prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one (non-preferred name); 83203-42-3; Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-, (11b,17b)-;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C29H35NO2",
"molecular_weight": "429.6",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "55245",
"classification": "G",
"indications": "",
"side_effects": "",
"atc_codes": "G03XB01",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02020",
"RC02641",
"RC03262"
]
},
{
"compound_ID": "D1003",
"name": "miripirium chloride",
"synonyms": "Miripirium chloride; 2748-88-1; Quatresin; 4-methyl-1-tetradecylpyridin-1-ium chloride; Myristyl-gamma-picolinium chloride; Wet-Tone B; Pyridinium, 4-methyl-1-tetradecyl-, chloride; 4-Methyl-1-tetradecylpyridinium chloride; Miripirium chloride [INN]; UNII-3D6CWI0P23; MYRISTYL-G-PICOLINIUM CHLORIDE; Tetradecyl-4-methylpyridinium chloride; 1-Myristylpicolinium; Miripirii chloridum [INN-Latin]; Cloruro de miripirio [INN-Spanish]; EINECS 220-387-1; Chlorure de miripirium [INN-French]; NSC 36338; 4-Picolinium, 1-tetradecyl-, chloride; 3D6CWI0P23; 1-TETRADECYL-4-PICOLINIUM CHLORIDE; Miripirium chloride (INN); Pyridinium, 4-methyl-1-tetradecyl-, chloride (1:1); Miripirii chloridum; Cloruro de miripirio; Chlorure de miripirium; NCGC00181085-01; 4-Picolinium, chloride; DSSTox_CID_26834; DSSTox_RID_81946; DSSTox_GSID_46834; myristyl--picolinium chloride; SCHEMBL58027; 1-Myristylpicolinium Chloride; CHEMBL2107233; DTXSID2046834; BCP16386; NSC36338; WLN: T6KJ A14 D1 &G; Myristyl-.gamma.-picolinium chloride; Tox21_112704; NSC-36338; AKOS015891973; ACM2748881; AM84867; SC-19251; CAS-2748-88-1; AX8140608; DB-047232; LS-109733; FT-0603618; WLN: T6KJ A14 D &G &3/13; D10217; 140480-EP2277565A2; 140480-EP2277566A2; 140480-EP2277567A1; 140480-EP2277568A2; 140480-EP2277569A2; 140480-EP2277570A2; 140480-EP2292280A1; C-19856; Q27257063;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C20H36ClN",
"molecular_weight": "326",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "17671",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02021",
"RC02642",
"RC03263"
]
},
{
"compound_ID": "D1004",
"name": "mk-2206",
"synonyms": "MK-2206; 1032349-93-1; UNII-51HZG6MP1K; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; NCGC00186465-01; DSSTox_CID_28874; DSSTox_RID_83143; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 8-(4-(1-Aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthy ridin-3(2H)-one; CAS-1032350-13-2; MK-2206 free base; 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; SCHEMBL530721; GTPL7945; DTXSID3048948; ULDXWLCXEDXJGE-UHFFFAOYSA-N; BCP20200; Tox21_113368; BDBM50313650; ZINC36382821; AKOS032945686; Tox21_113368_1; API0006847; BCP9000938; MK 2206;MK2206; SB16805; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; NCGC00186465-02; NCGC00186465-03; NCGC00186465-04; NCGC00186465-08; DB-058959; FT-0738942; MK2206;MK 2206;MK-2206 dihydrochloride; Z-3283; cas:1032350-13-2;MK 2206; BRD-K68065987-300-02-6; Q25100065; 1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-ol; 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridin-3(2H)-one;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C25H21N5O",
"molecular_weight": "407.5",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "24964624",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02022",
"RC02643",
"RC03264"
]
},
{
"compound_ID": "D1005",
"name": "mometasone furoate",
"synonyms": "mometasone furoate; 83919-23-7; Nasonex; Asmanex; Elocon; mometasone 17-furoate; Mometasone fuorate; MOMETASONE FUROATE MONOHYDRATE; Danitin; Ecural; Sch32088; UNII-04201GDN4R; Sch-32088; Asmanex Twisthaler; CHEMBL1161; Elocone; Flumeta; Nosorex; Rimelon; CHEBI:47564; 04201GDN4R; Sch 32088; [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate; Elomet; DSSTox_CID_3333; DSSTox_RID_76981; DSSTox_GSID_23333; (9beta,10alpha,11alpha,14beta,16alpha,17alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate; 9,21-dichloro-11beta-hydroxy-16alpha-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate; C27H30Cl2O6; Monovo; Ovixan; Asmanex HFA; BRN 4340538; (11beta,16alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate; (11beta,16alpha)-9,21-Dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione; (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate; MOF; Sinuva; mometasone-furoate; 9,21-Dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 17-(2-furoate); NCGC00016950-01; Prestwick_924; Asmanex (TN); Mometasone furoate [USAN:USP:JAN]; CAS-83919-23-7; Elocon (TN); LAS 41002; Prestwick0_000572; Prestwick1_000572; Prestwick2_000572; Prestwick3_000572; mometasone furancarboxylate; Mometasone furoate anhydrous; SCHEMBL4568; BSPBio_000384; Mometasone 17-(2-furoate); MLS002153879; Mometasone Furoate Impurity G; SPBio_002603; Mometasone furoate (JAN/USP); BPBio1_000424; DTXSID4023333; KS-00000SPL; WOFMFGQZHJDGCX-ZULDAHANSA-N; HMS1569D06; HMS2096D06; HMS2235I14; HMS3713D06; Pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-, (11beta,16alpha)-; ZINC3938677; Tox21_110705; AC-941; BDBM50148733; NSC746171; s1987; Mometasone furoate, >=98% (HPLC); AKOS015994732; Tox21_110705_1; CCG-220572; CS-2389; DB14512; KS-1275; NSC-746171; NCGC00179578-01; NCGC00179578-03; NCGC00179578-04; HY-13693; SMR001233233; AB2000407; M2354; ST24048112; C07817; D00690; 919M237; A840685; SR-01000841209; Q-101380; Q1044248; SR-01000841209-2; BRD-K60640630-001-03-7; BRD-K60640630-001-11-0; Mometasone furoate, European Pharmacopoeia (EP) Reference Standard; Mometasone furoate, United States Pharmacopeia (USP) Reference Standard; 11?,16?)-9,21-Dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate; Mometasone Furoate, Pharmaceutical Secondary Standard; Certified Reference Material; [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloranyl-17-(2-chloranylethanoyl)-10,13,16-trimethyl-11-oxidanyl-3-oxidanylidene-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate; 2-furancarboxylic acid [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloro-1-oxoethyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] ester; Pregna-1,20-dione, 9,21-dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)-;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C27H30Cl2O6",
"molecular_weight": "521.4",
"state": "solid",
"clearance": "The clearance rate of mometasone furoate is not readily available[A176900], though it may be close to 90L/h[A176906].",
"volume_of_distribution": "Steady state volume of distribution of 152L[FDA Label].",
"route_of_elimination": "For an inhaled dose, approximately 74% is excreted in the feces and 8% is excreted in the urine[FDA Label][F4292].",
"protein_binding": "98% to 99% (in vitro concentration of 5 to 500ng/mL)[FDA Label][F4292].",
"half_life": "The terminal half life of an inhaled dose is approximately 5 hours[FDA Label] though it has been reported as 5.8 hours by other sources[F4292,A176906].",
"absorption": "The mean time to peak concentration is 1.0 to 2.5 hours[FDA Label]. Bioavailability has been reported as <1%[FDA Label] but studies of repeat doses of inhaled corticosteroids suggest a bioavailability of 11%[A176918]. The 0.1% ointment may have a bioavailability of 0.7%[F4295].",
"cid": "441336",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02023",
"RC02644",
"RC03265"
]
},
{
"compound_ID": "D1006",
"name": "montelukast sodium",
"synonyms": "MONTELUKAST SODIUM; 151767-02-1; Singulair; Montair; Montelukast (sodium); UNII-U1O3J18SFL; Montelukast sodium [USAN]; MONTELUKAST Na; MK 476; MK-476; MK-0476; U1O3J18SFL; CHEBI:6993; Singular; CPD000469188; MK 0476; DSSTox_CID_26450; DSSTox_RID_81624; DSSTox_GSID_46450; Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, sodium salt (1:1); Sodium 1-((((R)-m-((E)-2-(7-chloro-2-quinolyl)vinyl)-alpha-(o-(1-hydroxy-1-methylethyl)phenethyl)benzyl)thio)methyl)cyclopropaneacetate; Kokast; MLS001304727; Cyclopropaneacetic acid, 1-((((1R)-1-(3-((1E)-2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-, monosodium salt; Cyclopropaneacetic acid, 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-, sodium salt, (R-(E))-; sodium {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetate; CAS-151767-02-1; Montelukast sodium salt; SMR000469188; Kipres; Lukasm; montelukast-sodium; Singulair (TN); sodium;2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetate; Montelukast sodium, 98%; NCGC00164568-01; C35H35ClNO3S.Na; Montelukast monosodium salt; SCHEMBL9414; SCHEMBL9415; MLS001424198; CYC099; CHEMBL1200681; DTXSID8046450; AOB6098; DTXSID60931503; LBFBRXGCXUHRJY-HKHDRNBDSA-M; Montelukast sodium (JP17/USAN); HMS2051F18; HMS2235H19; 142522-81-4; ACT06295; AMX10104; Tox21_112197; CM0155; s4211; AKOS015833416; AKOS032949734; Tox21_112197_1; ACN-052465; AM62787; BCP9000959; CCG-101049; CS-0548; KS-1087; NC00299; NCGC00164568-04; HY-13315; SAM001246657; LS-173407; FT-0082752; M2340; SW197679-2; 2-[1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]thio]methyl]cyclopropyl]acetate; sodium; D00529; 176636-EP2287154A1; J-008841; J-522711; L-706631; Q27107384; 1-((((1R)-1-(3-((1E)-2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid monosodium salt; 1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid sodium salt; 1-[[[(R)-1-[3-[2-(7-Chloro-2-quinolyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-1-cyclopropaneacetic acid sodium salt; Cyclopropaneacetic acid,1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-,sodium salt; Sodium (1-{[(1-{3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl)sulfanyl]methyl}cyclopropyl)acetate; sodium (R,E)-2-(1-((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl)cyclopropyl)acetate; Sodium 1-((((R)-m -((E)-2-(7-chloro-2-quinolyl)vinyl)-alpha-(o-(1-hydroxy-1-methylethyl)phenethyl)benzyl)thio)methyl)cyclopropaneacetate; sodium 1-[[[(1R)-1-[3-[(1E)-2-(7-chloroquinoline-2-yl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetate; sodium 2-(1-((((R)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)sulfanyl)methyl)cyclopropyl)acetate;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C35H35ClNNaO3S",
"molecular_weight": "608.2",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "23663996",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02024",
"RC02645",
"RC03266"
]
},
{
"compound_ID": "D1007",
"name": "n,n-diethylbenzene-1,4-diamine",
"synonyms": "93-05-0; N,N-DIETHYL-P-PHENYLENEDIAMINE; 4-Amino-N,N-diethylaniline; N,N-Diethyl-1,4-phenylenediamine; N1,N1-Diethylbenzene-1,4-diamine; p-Aminodiethylaniline; 4-(Diethylamino)aniline; p-Amino-N,N-diethylaniline; Diethylaminoaniline; p-(Diethylamino)aniline; Diethyl-p-phenylenediamine; N,N-diethylbenzene-1,4-diamine; N,N-Diethyl-1,4-benzenediamine; N,N-Diethyl-4-aminoaniline; p-Phenylenediamine, N,N-diethyl-; Diethyl-para-phenylenediamine; 1,4-Benzenediamine, N,N-diethyl-; para-Aminodiethylaniline; N,N-Diethyl 4-phenylenediamine; UNII-0QQA4DFV2J; NSC 147488; CCRIS 4620; HSDB 5281; N,N-Diethyl-para-phenylenediamine; EINECS 202-214-1; 0QQA4DFV2J; 1,4-Benzenediamine, N1,N1-diethyl-; MLS002454419; QNGVNLMMEQUVQK-UHFFFAOYSA-N; 4-Amino-N,N-diethylaniline, dist.; SMR001372013; (4-aminophenyl)diethylamine; N,N-Diethyl-p-phenylenediamine, 98%; N4,N4-diethylbenzene-1,4-diamine; p-Diethylaminoaniline; 4-diethylaminoaniline; 4-N,4-N-diethylbenzene-1,4-diamine; ACMC-209rju; DSSTox_CID_5058; EC 202-214-1; cid_7120; DSSTox_RID_77645; DSSTox_GSID_25058; SCHEMBL33781; 4-(N,N-diethylamino)aniline; N,N-diethyl-p-phenylendiamine; p-Phenylenediamine,N-diethyl-; WLN: ZR DN2&2; (4-aminophenyl)-diethyl-amine; 4-(N,N-diethylamino)-aniline; 4-(N,N-diethyl-amino)-aniline; CHEMBL1452158; DTXSID2025058; BDBM89017; CTK3J4604; QNGVNLMMEQUVQK-UHFFFAOYSA-; N,N-diethyl-1,4-diamino-benzene; N,N-Diethyl-benzene-1,4-diamine; ZINC388427; Tox21_200888; ANW-39976; BBL004015; NSC147488; SBB040493; STK122955; AKOS000101559; N,N-Diethyl-p-phenylenediamine, 97%; CS-W010827; FS-4085; LS-1942; MCULE-5614671566; NSC-147488; RTC-060022; TRA0075559; CAS-93-05-0; NCGC00091343-01; NCGC00091343-02; NCGC00091343-03; NCGC00258442-01; M713; N,N-Diethyl-1,4-phenylenediamine; >98%; DB-057362; TC-060022; BB 0259338; D0518; FT-0629487; ST24033292; ST50213823; T8295; KS-00001281; Q3032706; W-100259; F0001-2236; N,N-Diethyl-1,4-phenylenediamine;N,N-Diethyl-p-phenylenediamine; InChI=1/C10H16N2/c1-3-12(4-2)10-7-5-9(11)6-8-10/h5-8H,3-4,11H2,1-2H3;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C10H16N2",
"molecular_weight": "164.25",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "7120",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02025",
"RC02646",
"RC03267"
]
},
{
"compound_ID": "D1008",
"name": "n,n-dimethyl-p-phenylenediamine",
"synonyms": "99-98-9; N,N-Dimethyl-p-phenylenediamine; N,N-Dimethyl-1,4-phenylenediamine; N1,N1-Dimethylbenzene-1,4-diamine; p-Aminodimethylaniline; DMPD; 4-Amino-N,N-dimethylaniline; p-Amino-N,N-dimethylaniline; 4-(Dimethylamino)aniline; Dimethyl-p-phenylenediamine; 1,4-Benzenediamine, N,N-dimethyl-; p-(Dimethylamino)aniline; Dimethyl-4-phenylenediamine; N,N-DIMETHYL-P-BENZENEDIAMINE; p-Dimethylaminophenylamine; N,N-Dimethyl-1,4-benzenediamine; N,N-dimethylbenzene-1,4-diamine; p-Phenylenediamine, N,N-dimethyl-; 4-(Dimethylamino)benzenamine; 4-dimethylaminoaniline; 4-Aminodimethylaniline; UNII-7GZH2FMK7X; NSC 1493; C.I. 76075; 4-(Dimethylamino)phenylamine; Dimethyl-para-phenylenediamine; N,N-Dimethyl-p-fenylendiamin; CCRIS 6024; HSDB 5330; Dimethyl-p-phenylenediamine (VAN); EINECS 202-807-5; 7GZH2FMK7X; N,N-Dimethyl-p-fenylendiamin [Czech]; 1,4-Benzenediamine, N1,N1-dimethyl-; p-(Dimethylamino)phenylamine; CI 76075; AI3-52360; CHEBI:15783; BZORFPDSXLZWJF-UHFFFAOYSA-N; N,N-dimethyl-benzene-1,4-diamine; 1-N,1-N-dimethylbenzene-1,4-diamine; N,N-Dimethyl-p-phenylenediamine, 97%; (4-aminophenyl)dimethylamine; p-dimethylaminoaniline; 4-Amino-N; 4-N,4-N-dimethylbenzene-1,4-diamine; 4-dimethylamino aniline; 4-dimethylamino-aniline; ACMC-209seo; DSSTox_CID_5149; Dimethyl-paraphenylenediamine; DSSTox_RID_77688; DSSTox_GSID_25149; SCHEMBL15246; KSC496G1T; CHEMBL36296; 4-(N,N-dimethylamino)aniline; n,n-dimethyl-p-phenylendiamine; (4-aminophenyl)-dimethyl-amine; DTXSID6025149; WLN: ZR DN1 & 1; BZORFPDSXLZWJF-UHFFFAOYSA-; CTK3J6319; KS-00000VAK; N,N-dimethyl paraphenylenediamine; n,n-dimethyl-p-phenylene-diamine; ZINC56911; NSC1493; N,N-dimethyl-1,4-diamino-benzene; NSC-1493; N',N'-dimethyl-p-phenylene diamine; Tox21_200191; ANW-41086; LS-287; MFCD00007860; N, N-dimethyl-para-phenylene diamine; SBB058715; STL255600; N',N'-dimethyl-benzene-1,4-diamine; AKOS000101558; MCULE-4782652197; NE10522; RTR-033076; TRA0054903; CAS-99-98-9; NCGC00091245-01; NCGC00091245-02; NCGC00257745-01; AS-47649; SC-65295; AB1003350; TR-033076; 4CH-011916; D0779; ST24025677; ST51037495; C04203; Q409957; Q-201433; F2190-0446; N,N-Dimethyl-p-phenylenediamine, technical, >=95.0% (GC); InChI=1/C8H12N2/c1-10(2)8-5-3-7(9)4-6-8/h3-6H,9H2,1-2H3; N,N-Dimethyl-p-phenylenediamine, for spectrophotometric det. of SO42-, S2-, >=97.0%; 4-(Dimethylamino)aniline; 4-Amino-N,N-dimethylaniline; N,N-Dimethyl-1,4-phenylenediamine; DMPPDA;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C8H12N2",
"molecular_weight": "136.19",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "7472",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02026",
"RC02647",
"RC03268"
]
},
{
"compound_ID": "D1009",
"name": "n,nφ-diethylcarbanilide",
"synonyms": "1,3-Diethyl-1,3-diphenylurea; 85-98-3; N,N'-Diethylcarbanilide; Centralite; Ethyl centralite; Centralite I; N,N'-Diethyl-N,N'-diphenylurea; Carbamite; 1,3-Diethyldiphenylurea; s-Diethyldiphenylurea; Centralite-1; sym-Diethyldiphenylurea; N,N-Diethylcarbanilide; Urea, N,N'-diethyl-N,N'-diphenyl-; Bis(N-ethyl-N-phenyl)urea; USAF EK-1047; Centralite 1; UNII-4169Z9SDJG; Urea, 1,3-diethyl-1,3-diphenyl-; NSC 44038; Carbanilide, N,N'-diethyl-; Bis-(N-ethyl-N-fenyl)mocovina; CCRIS 4618; 1,3-Diethyl-1,3-difenylmocovina; EINECS 201-645-2; Bis-(N-ethyl-N-fenyl)mocovina [Czech]; BRN 2751977; 1,3-Diethyl-1,3-difenylmocovina [Czech]; AI3-01942; Centralite1; 4169Z9SDJG; Carbanilide,N'-diethyl-; WLN: 2NR&VN2&R; W-104072; Urea,3-diethyl-1,3-diphenyl-; Urea,N'-diethyl-N,N'-diphenyl-; 1,3-diethyl-1,3-diphenyl-urea; 1,3-Diethylcarbanilide; N,N'-Diethyldiphenylurea; DSSTox_CID_5040; EC 201-645-2; DSSTox_RID_77635; DSSTox_GSID_25040; MLS002415749; SCHEMBL263716; CHEMBL1566472; DTXSID8025040; CTK5F6126; PZIMIYVOZBTARW-UHFFFAOYSA-; N,N'-Diphenyl-N,N'-diethylurea; PZIMIYVOZBTARW-UHFFFAOYSA-N; HMS3039F11; 1,3-diethyl-1,3-di(phenyl)urea; NSC28779; NSC44038; ZINC3875598; Tox21_200369; Urea,N,N'-diethyl-N,N'-diphenyl-; 6400AF; GL5447; MFCD00035794; NSC-28779; NSC-44038; N-ethyl(ethylphenylamino)-N-benzamide; AKOS015913312; LS-1850; MCULE-6917831209; 1,3-Diethyl-1,3-diphenylurea, 99%; CAS-85-98-3; NCGC00091392-01; NCGC00091392-02; NCGC00257923-01; AS-59399; SMR001370912; DB-056891; D0485; FT-0623546; ST51038243; C-51905; Q5062193; InChI=1/C17H20N2O/c1-3-18(15-11-7-5-8-12-15)17(20)19(4-2)16-13-9-6-10-14-16/h5-14H,3-4H2,1-2H3;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C17H20N2O",
"molecular_weight": "268.35",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "6828",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02027",
"RC02648",
"RC03269"
]
},
{
"compound_ID": "D1010",
"name": "natamycin",
"synonyms": "NATAMYCIN; pimaricin; 7681-93-8; Natamycin(Pimaricin); Tennecetin; UNII-8O0C852CPO; Delvocid; Mycophyt; Myprozine; Synogil; Antibiotic A-5283; 8O0C852CPO; Pimarizin [German]; Antibiotic A 5283; Natamycine [INN-French]; Natamycinum [INN-Latin]; Natamicina [INN-Spanish]; CL 12625; Natamicina; Natamycine; Natamycinum; Pimarizin; EINECS 231-683-5; CL 12,625; Pimaracin; Natamycin [USAN:USP:INN:BAN]; NCGC00016686-01; 16-(3-Amino-3,6-didesoxy-beta-D-mannopyranosyloxy)-5,6-epoxy-8,12,14-trihydroxy-26-methyl-2,10-dioxo-1-oxacyclohexacosa-3,17,19,21,23-pentaen-13-carbonsaeure; E235; Stereoisomer of 22-((3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo(22.3.1.0(sup 5,7))octacosa-8,14,16,18,20-pentaene-25-carboxylic acid; CAS-7681-93-8; ene-25-carboxylic acid; DSSTox_CID_1163; DSSTox_RID_75985; DSSTox_GSID_21163; SCHEMBL18140; INS NO.235; CHEMBL1200656; INS-235; (1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0~5,7~]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid; EX-A1989; HY-B0133; ZINC8220909; Tox21_110561; BDBM50370755; MFCD00135085; AKOS030485970; CS-1909; DB00826; NICOTINAMIDE_ADENINE_DINUCLEOTIDE; CL-12625; E 235; E-235; Natamycin, VETRANAL(TM), analytical standard; NCGC00373238-02_C33H47NO13_Delvocid; 681N938; Pimaricin preparation, ~2.5%, aqueous suspension; Q248466; Natamycin, United States Pharmacopeia (USP) Reference Standard; Pimaricin, from Streptomyces chattanoogensis, >=95% (HPLC); Natamycin, Pharmaceutical Secondary Standard; Certified Reference Material; rioxatricyclo[22.3.1.05,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid; (1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-(((2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-t; (1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-[(3-Amino-3,6-dideoxy-?-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.05,7]octacosa-8,14,16,18,20-penta; (5R,7R,24S)-22R-[(3S-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1R,3S,26S-trihydroxy-12R-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.05,7]octacosa-8E,14E,16E,18E,20E-pentaene-25R-carboxylic acid;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C33H47NO13",
"molecular_weight": "665.7",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "Systemic absorption should not be expected following topical administration, and as with other polyene antibiotics, absorption from the gastrointestinal tract is very poor.",
"cid": "5284447",
"classification": "S; G; A; D",
"indications": "",
"side_effects": "",
"atc_codes": "S01AA10; G01AA02; D01AA02; A07AA03; A01AB10",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02028",
"RC02649",
"RC03270"
]
},
{
"compound_ID": "D1011",
"name": "n-benzyl-6-ethoxy-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxamide",
"synonyms": "CP-457920; UNII-13BME2F602; 13BME2F602; 220860-50-4; DGFVZQGXKQCQGK-UHFFFAOYSA-N; DSSTox_CID_27254; DSSTox_RID_82213; DSSTox_GSID_47254; SCHEMBL6386679; CHEMBL3184675; DTXSID4047254; Tox21_300208; NCGC00247930-01; NCGC00253969-01; CAS-220860-50-4; CP-457,920; Q27251503; N-benzyl-6-ethoxy4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxamide; N-benzyl-6-ethoxy-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxamide; 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-4-oxo-N-(phenylmethyl)-;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C18H17N3O3",
"molecular_weight": "323.3",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "9831581",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02029",
"RC02650",
"RC03271"
]
},
{
"compound_ID": "D1012",
"name": "n-cyclohexyl-4-methyl benzenesulfonamide",
"synonyms": "80-30-8; N-Cyclohexyl-p-toluenesulfonamide; N-CYCLOHEXYL-4-METHYLBENZENESULFONAMIDE; Santicizer 1H; p-Toluenesulfonamide, N-cyclohexyl-; Benzenesulfonamide, N-cyclohexyl-4-methyl-; (Tosylamino)cyclohexane; N-cyclohexyl-4-methyl-benzenesulfonamide; CCRIS 6008; UNII-0QPV1AE9EM; N-Cyclohexyltoluene-4-sulphonamide; AI3-15119; EINECS 201-268-3; NSC 14856; 0QPV1AE9EM; BRN 2698317; N-Cyclohexyl-4-methyl benzenesulfonamide; N-cyclohexyl-4-methylbenzene-1-sulfonamide; MLS002152910; SMR001224514; cyclohexyl[(4-methylphenyl)sulfonyl]amine; NSC14856; N-Tosylcyclohexylamine; ACMC-20aj0v; DSSTox_CID_4885; cid_6633; DSSTox_RID_77566; DSSTox_GSID_24885; Oprea1_175608; Oprea1_267555; SCHEMBL128274; CHEMBL1371652; DTXSID1024885; n-cyclohexyl p-toluenesulfonamide; BDBM74248; CTK5E7678; ZINC75462; N-Cyclohexyl-4-toluenesulfonamide; DKYVVNLWACXMDW-UHFFFAOYSA-N; N-Cyclohexyl-p-toluenesulphonamide; HMS3039A07; NSC48143; 4-Toluenesulfonamide, N-cyclohexyl-; Tox21_200091; ANW-75581; NSC-14856; NSC-48143; SBB006339; STL137409; N-Cyclo Hexyl P-Toluene Sulphonamide; AKOS000384083; LS-1793; MCULE-4608424356; VZ36534; CAS-80-30-8; NCGC00091891-01; NCGC00091891-02; NCGC00257645-01; AS-64100; Benzenesulfonamide,N-cyclohexyl-4-methyl-; M750; N-CYCLOHEXYL P-TOLUENESULFONYLAMINE; N-Cyclohexyl-p-toluenesulfonamide, 98+%; ST024178; DB-056428; TR-025430; A9949; FT-0631357; 10.14272/DKYVVNLWACXMDW-UHFFFAOYSA-N; Benzenesulfonamide, N-cyclohexyl-4-methyl- (9CI); doi:10.14272/DKYVVNLWACXMDW-UHFFFAOYSA-N; W-104240; p-Toluenesulfonamide, N-cyclohexyl- (6CI,7CI,8CI); Q27237113; Z45509354;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C13H19NO2S",
"molecular_weight": "253.36",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "6633",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02030",
"RC02651",
"RC03272"
]
},
{
"compound_ID": "D1013",
"name": "nelfinavir mesylate",
"synonyms": "Nelfinavir mesylate; 159989-65-8; Viracept; Nelfinavir mesilate; Nelfinavir Mesylate [USAN]; UNII-98D603VP8V; HSDB 7159; Nelfinavir mesylate hydrate; C32H45N3O4S.CH4O3S; AG1343; Nelfinavir Methanesulfonate; AG-1343; Nelfinavir (Mesylate); CHEBI:7497; 98D603VP8V; AG 1343; Viracept (TN); NFV; DSSTox_CID_10777; DSSTox_RID_79093; DSSTox_GSID_33736; Nelfin; CHEMBL1205; (3S,4aS,8aS)-N-tert-Butyl-2-((2R,3R)-3-(3,2-cresotamido)-2-hydroxy-4-(phenylthio)butyl)decahydro-3-isoquinolinecarboxamide monomethanesulfonate (salt); 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-((2R,3R)-2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S,4aS,8aS)-, monomethanesulfonate (salt); 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S-(2(2,S*,3S*),3-alpha,4a-beta,8a-beta))-, monomethanesulfonate (salt); SMR000469186; CAS-159989-65-8; NSC722664; NCGC00090782-03; Nelfinavir methanesulfonate hydrate; nelfinavir-mesylate; AG 1343 Mesylate; Nelfinavir mesilate (JAN); AZT/3TC/NLFR combination; SCHEMBL40942; MLS001055355; MLS001401378; MLS006010141; ARV-SR0121; DTXSID2033736; CTK8E9065; Nelfinavir mesylate (USAN/INN); SYN3022; C33H49N3O7S2; NQHXCOAXSHGTIA-SKXNDZRYSA-N; HMS2051N05; HMS2090L17; HMS2233M20; HMS3261P12; HMS3715B04; Tox21_111021; Tox21_200921; Tox21_500635; MFCD00931436; s4282; AKOS015963185; Tox21_111021_1; AG 1341; AG-1346; CCG-100925; KS-1089; NC00175; NSC-722664; NCGC00090782-01; NCGC00090782-06; NCGC00258475-01; NCGC00261320-01; 3S,4aS,8aS)-N-(1,1-Dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-3-isoquinolinecarboxamide methanesulfonate; AC-20033; CPD000469186; LS-85416; SAM001246655; SC-79735; LY-312857; RT-014683; N0986; Nelfinavir mesylate hydrate, >=98% (HPLC); SW197555-2; C08091; D00899; W-5226; 989N658; J-009662; Q27107510; (3S, 4aS, 8aS)-2-[(2R, 3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzoylamino)-4-phenylthiobutyl]decahydroiso-quinoline-3-carboxylic acid t-butylamide methanesulfonate; (3S, 4aS, 8aS)-2-[(2R, 3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzoylamino)-4-phenylthiobutyl]decahydroisoquinoline-3-carboxylic acid t-butylamide methanesulfonate; (3S,4aS,8aS)-2-[(2R,3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzoylamino)-4-phenylthiobutyl]decahydroisoquinoline-3-carboxylic acid t-butylamide methanesulfonate; (3S,4aS,8aS)-3-(tert-butylcarbamoyl)-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylsulfanyl)butyl]decahydroisoquinolinium methanesulfonate; (3S,4aS,8aS)-N-(1,1-Dimethylethyl)decahydro-2-[(2R,3R)-2- hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-3-isoquinolinecarboxamide methanesulfonate; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylsulfanyl)butyl]decahydroisoquinoline-3-carboxamide methanesulfonate; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]decahydroisoquinoline-3-carboxamide methanesulfonate (salt); 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-, methanesulfonate (1:1); 3-Isoquinolinecarboxamide,1-dimethylethyl)decahydro-2- [(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, methanesulfonate (3S,4aS,8aS)-;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C33H49N3O7S2",
"molecular_weight": "663.9",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "64142",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02031",
"RC02652",
"RC03273"
]
},
{
"compound_ID": "D1014",
"name": "niflumic acid",
"synonyms": "niflumic acid; 4394-00-7; Nifluril; Forenol; Landruma; Actol; Nifluminic acid; Acido niflumico; Acide niflumique; Acide niflumique [INN-French]; Acido niflumico [INN-Spanish]; Acidum niflumicum [INN-Latin]; 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid; Acide niflumique [French]; Acido niflumico [Italian]; UP 83; 2-(3-(Trifluoromethyl)-phenyl)aminonicotinic acid; 2-(3-(Trifluoromethyl)anilino)nicotinic acid; 2-[3-(Trifluoromethyl)anilino]nicotinic acid; Lopac-N-0630; 2-(3-Trifluoromethylanilino)nicotinic Acid; UNII-4U5MP5IUD8; 3-Pyridinecarboxylic acid, 2-[[3-(trifluoromethyl)phenyl]amino]-; 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid; 2-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}NICOTINIC ACID; SC 1332; CCRIS 5740; 2-(alpha,alpha,alpha-Trifluoro-m-toluidino)nicotinic acid; EINECS 224-516-2; 2-[(3-TRIFLUOROMETHYL)PHENYL]AMINO-3-PYRIDINE-CARBOXYLIC ACID; BRN 0489360; 4U5MP5IUD8; MLS000069713; NFL; CHEBI:34888; 3-Pyridinecarboxylic acid, 2-((3-(trifluoromethyl)phenyl)amino)-; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino [French]; JZFPYUNJRRFVQU-UHFFFAOYSA-N; 2-((3-(Trifluoromethyl)phenyl)amino)nicotinic acid; NCGC00015724-10; Donalgin; Niflumate; SMR000058199; CAS-4394-00-7; DSSTox_CID_3368; 2-(3-[Trifluoromethyl]anilino)nicotinic acid; Acidum niflumicum; DSSTox_RID_76996; 2-(3-(Trifluoromethyl)phenylamino)nicotinic acid; DSSTox_GSID_23368; Nicotinic acid, 2-(alpha,alpha,alpha-trifluoro-m-toluidino)-; Niflamol; Niflumic acid [INN:DCF]; Niflugel (TN); Niflumic acid (INN); SR-01000000231; 2-(3-Trifluoromethyl-phenylamino)-nicotinic acid; 2-[[3-(trifluoromethyl)phenyl]amino]pyridine-3-carboxylic acid; niflumic-acid; NiflumicAcid; ni-flumic acid; Niflumic acid [INN:BAN:DCF]; Actol, analgesic; Prestwick_890; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino; PubChem21796; Spectrum_001353; 1td7; ACMC-209jvx; Opera_ID_1746; Prestwick0_000255; Prestwick1_000255; Prestwick2_000255; Prestwick3_000255; Spectrum2_000794; Spectrum3_001485; Spectrum4_000043; Spectrum5_001216; Niflumic acid (Hit 16); N 0630; 2-[(3-Trifluoromethylphenyl)amino]nicotinic Acid; CBiol_001828; Lopac0_000845; SCHEMBL24706; BSPBio_000070; BSPBio_001393; BSPBio_003069; KBioGR_000113; KBioGR_000505; KBioSS_000113; KBioSS_001833; 5-22-13-00598 (Beilstein Handbook Reference); KSC587Q8N; MLS001076327; CHEMBL63323; DivK1c_000277; SPECTRUM1502015; SPBio_000928; SPBio_002289; BPBio1_000078; GTPL2439; DTXSID1023368; BDBM85507; CTK4I7886; HMS500N19; KBio1_000277; KBio2_000113; KBio2_001833; KBio2_002681; KBio2_004401; KBio2_005249; KBio2_006969; KBio3_000225; KBio3_000226; KBio3_002569; NINDS_000277; 2-[(3-Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic Acid; Bio1_000114; Bio1_000603; Bio1_001092; Bio2_000113; Bio2_000593; HMS1361F15; HMS1568D12; HMS1791F15; HMS1921D12; HMS1989F15; HMS2090D19; HMS2095D12; HMS2234F11; HMS3262J11; HMS3374H01; HMS3402F15; HMS3649A08; HMS3656P14; HMS3712D12; Pharmakon1600-01502015; UP-83; ZINC125031; HY-B0493; KS-00000CB5; NSC_4488; Tox21_110206; Tox21_500845; ANW-30043; BBL003619; CCG-40157; DL-457; MFCD00010569; Nicotinic acid, 2-(.alpha.,.alpha.,.alpha.-trifluoro-m-toluidino)-; NSC758196; s3018; SBB001146; STK803109; AKOS000519590; Tox21_110206_1; AC-2652; CS-2614; DB04552; GS-3202; LP00845; MCULE-3027710274; NSC-758196; RTR-017015; IDI1_000277; IDI1_033863; 2-(3-trifluoromethylphenoxy)nicotinamide; NCGC00015724-01; NCGC00015724-02; NCGC00015724-03; NCGC00015724-04; NCGC00015724-05; NCGC00015724-06; NCGC00015724-07; NCGC00015724-08; NCGC00015724-09; NCGC00015724-11; NCGC00015724-12; NCGC00015724-13; NCGC00015724-14; NCGC00015724-17; NCGC00023636-03; NCGC00023636-04; NCGC00023636-05; NCGC00023636-06; NCGC00023636-07; NCGC00023636-08; NCGC00023636-09; NCGC00261530-01; AK-72979; BR-72979; LS-96639; ST013871; CAS_4394-00-7; SBI-0050821.P003; 2(3'-trifluormethylanilino)-nicotinic acid; AB0012229; AB1004097; AB00052255; AM20070143; EU-0100845; FT-0603659; ST24027408; SW197011-3; T7852; C13698; D08275; S00109; AB00052255-17; AB00052255_18; AB00052255_19; 394N007; Q304285; SR-01000000231-2; SR-01000000231-5; SR-01000000231-6; W-106215; BRD-K98763141-001-04-3; BRD-K98763141-001-06-8; BRD-K98763141-001-17-5; SR-01000000231-11; 2-[3-(Trifluoromethyl)anilino]-3-pyridinecarboxylic acid; Niflumic acid, European Pharmacopoeia (EP) Reference Standard; 2-[3-(Trifluoromethyl)anilino]nicotinic acid; 2-(|A,|A,|A-Trifluoro-m-toluidino)nicotinic acid;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C13H9F3N2O2",
"molecular_weight": "282.22",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "90% bound to plasma proteins.",
"half_life": "2.5 hours",
"absorption": "Well absorbed following oral administration.",
"cid": "4488",
"classification": "M",
"indications": "",
"side_effects": "",
"atc_codes": "M01AX02; M02AA17",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02033",
"RC02654",
"RC03275"
]
},
{
"compound_ID": "D1015",
"name": "nifuroxazide",
"synonyms": "Nifuroxazide; 965-52-6; Nifuroxazid; Dicoferin; Diarlidan; Ercefuryl; Ercefurol; UNII-PM5LI0P38J; Nifuroxazidum [INN-Latin]; Nifuroxazida [INN-Spanish]; Nifuroxazide-d4; CCRIS 5490; RC 27109; p-Hydroxybenzoic acid (5-nitrofurfurylidene)hydrazide; R.C. 27-109; EINECS 213-522-0; BRN 1352180; PM5LI0P38J; MLS000069620; C12H9N3O5; 4-Hydroxy-N'-(5-nitrofurfuryliden)benzhydrazid; Nifuroxazida; Nifuroxazidum; 4-hydroxy-N-[(E)-(5-nitro-2-furyl)methyleneamino]benzamide; RC-27109; SMR000058185; (Nitro-5' furfurylidene-2') hydroxy-4 benzhydrazide [French]; 4-hydroxy-N-[(E)-(5-nitrofuran-2-yl)methylideneamino]benzamide; BENZOIC ACID, p-HYDROXY-, (5-NITROFURFURYLIDENE)HYDRAZIDE; p-Hydroxybenzoic acid 5-nitrofurfurylidene hydrazide; Benzoic acid, 4-hydroxy-, 2-[(5-nitro-2-furanyl)methylene]hydrazide; Benzoic acid, 4-hydroxy-, ((5-nitro-2-furanyl)methylene)hydrazide; Nifuroxazide [INN:DCF]; Diaryl; Nifuroxazide [INN:BAN:DCF]; Prestwick_874; (Nitro-5' furfurylidene-2') hydroxy-4 benzhydrazide; Nifuroxazide (INN); Opera_ID_40; Prestwick2_000555; Prestwick3_000555; BSPBio_000629; SCHEMBL542542; SCHEMBL543480; ARONIS016368; BPBio1_000693; CHEMBL244888; SCHEMBL14608895; CHEBI:94556; CHEBI:135136; YCWSUKQGVSGXJO-NTUHNPAUSA-N; HMS1569P11; HMS2096P11; HMS3713P11; Pharmakon1600-01505788; HY-B1436; ZINC7997719; BDBM50396177; NSC759261; s4182; STK091243; STL454990; AKOS000483758; AC-8713; CCG-213989; CS-4918; DB13855; NSC-759261; AS-13310; H868; LS-37645; SC-16466; BIM-0014420.P001; SBI-0014420.P002; TX-017860; AB00513861; SJ000287313; D07111; AB00513861_02; AB00513861_03; Nifuroxazide, VETRANAL(TM), analytical standard; 965N526; A845610; W-100139; BRD-K68188368-001-03-7; 4-Dydroxy-N-[(E)-(5-nitro-2-furyl)methyleneamino]benzamide; 4-hydroxy-N'-[(1E)-(5-nitro-2-furyl)methylene]benzohydrazide; Nifuroxazide, European Pharmacopoeia (EP) Reference Standard; 4-hydroxy-N'-[(E)-(5-nitrofuran-2-yl)methylidene]benzohydrazide; 4-hydroxy-N-[(E)-(5-nitro-2-furanyl)methylideneamino]benzamide; N-[(E)-(5-nitrofuran-2-yl)methylideneamino]-4-oxidanyl-benzamide; 4-hydroxy-N-[(E)-(5-nitrofuran-2-yl)methylidene]benzenecarbohydrazonic acid; Benzoic acid, 4-hydroxy-, [(1E)-(5-nitro-2-furanyl)methylene]hydrazide;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C12H9N3O5",
"molecular_weight": "275.22",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "5337997",
"classification": "A",
"indications": "",
"side_effects": "",
"atc_codes": "A07AX03",
"group": "Drug",
"drug_type": "",
"target": [
"T001",
"T002",
"T408"
],
"function": [
"F0108",
"F0201",
"F0303"
],
"references": [
"RC02034",
"RC02655",
"RC03276",
"RC04098",
"RC04222",
"RC04346",
"RC04470",
"RC04594"
]
},
{
"compound_ID": "D1016",
"name": "ninhydrin",
"synonyms": "NINHYDRIN; 485-47-2; Ninhydrine; 1,2,3-Indantrione monohydrate; Ninhydrin hydrate; 2,2-Dihydroxy-1H-indene-1,3(2H)-dione; 1H-Indene-1,3(2H)-dione, 2,2-dihydroxy-; 2,2-Dihydroxy-1,3-indandione; Triketohydrindene hydrate; 1,2,3-Indantrione, 2-hydrate; 2,2-Dihydroxy-1,3-indanedione; 2,2-Dihydroxyindane-1,3-dione; Ninhydrin Spray; Trioxohydrindene monohydrate; UNII-HCL6S9K23A; CCRIS 4849; Ninhydrin, ACS reagent; 1,3-Indandione, 2,2-dihydroxy-; EINECS 207-618-1; MFCD00003791; 2,2-dihydroxy-2,3-dihydro-1H-indene-1,3-dione; BRN 1910963; HCL6S9K23A; AI3-04464; CHEMBL1221925; CHEBI:86374; FEMOMIGRRWSMCU-UHFFFAOYSA-N; Ninhydrin, spectrophotometric grade; 2,2-dihydroxy-2-hydrocyclopenta[1,2-a]benzene-1,3-dione; Ningidrin; nin-hydrin; Ninhydrin ACS grade; zlchem 153; DSSTox_CID_5716; DSSTox_RID_77890; DSSTox_GSID_25716; Ninhydrin, AR, >=99%; SCHEMBL17986; 4-07-00-02786 (Beilstein Handbook Reference); MLS002454421; DTXSID7025716; CTK7H1849; ZLB0142; Ninhydrin, >=95.0% (UV); ZINC388306; ACT05788; Tox21_200705; 1,2,3-Triketohydrindene Monohydrate; BBL012206; BDBM50324901; LS-132; Ninhydrin, puriss. p.a., >=99%; SBB009147; STL163548; AKOS004906785; 1H-Indene-1,2,3, trione Monohydrate; 1H-Indene-1,2,3-trione, 2-hydrate; MCULE-8190517984; NE10279; NCGC00091114-01; NCGC00091114-02; NCGC00091114-03; NCGC00258259-01; AC-11764; AS-14832; BP-11883; CAS-485-47-2; M765; Ninhydrin, p.a., ACS reagent, 99.0%; SMR001372015; ST094931; Ninhydrin spray reagent, 0.2% in ethanol; Ninhydrin, SAJ special grade, >=98.0%; DB-051560; Ninhydrin, ACS reagent, >=98.0% (UV); ST2415506; FT-0632202; I0015; N0094; N0719; Ninhydrin, suitable for amino acid detection; 27828-EP2292592A1; 27828-EP2292628A2; 27828-EP2298767A1; 27828-EP2305671A1; 27828-EP2305808A1; 27828-EP2311842A2; 27828-EP2314587A1; AQ-911/40896973; Q421098; J-610068; Q-201472; Ninhydrin, ozone friendly ready to use spray for TLC; F0001-2517; Ninhydrin, >=98.0%, suitable for amino acid analysis; InChI=1/C9H6O4/c10-7-5-3-1-2-4-6(5)8(11)9(7,12)13/h1-4,12-13;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C9H6O4",
"molecular_weight": "178.14",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "10236",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02036",
"RC02657",
"RC03278"
]
},
{
"compound_ID": "D1017",
"name": "nitromide",
"synonyms": "3,5-Dinitrobenzamide; nitromide; 121-81-3; Tristat; Unistat; Benzamide, 3,5-dinitro-; component of Unistat-3; Nitromide [USAN]; component of Tristat; Nitroamide; UNII-9DUJ3CMK8S; C7H5N3O5; EINECS 204-499-8; NSC 60719; 9DUJ3CMK8S; BRN 1981935; UUKWKUSGGZNXGA-UHFFFAOYSA-N; NSC60719; Nitromide (USAN); NCGC00094736-01; DSSTox_CID_25836; DSSTox_RID_81163; DSSTox_GSID_45836; CAS-121-81-3; SR-05000002028; Spectrum_001065; 3, 5-Dinitrobenzamide; ACMC-20anc0; Spectrum2_001044; Spectrum3_000519; Spectrum4_000077; Spectrum5_001200; BSPBio_002077; KBioGR_000633; KBioSS_001545; 4-09-00-01351 (Beilstein Handbook Reference); MLS002207159; 3,5-Dinitrobenzamide, 97%; DivK1c_000813; SCHEMBL193674; SPECTRUM1500435; SPBio_000968; 3,5-DINITRO BENZAMIDE; CHEMBL1437065; DTXSID0045836; CTK0H4630; HMS502I15; KBio1_000813; KBio2_001545; KBio2_004113; KBio2_006681; KBio3_001577; UUKWKUSGGZNXGA-UHFFFAOYSA-; NINDS_000813; HMS1920B06; HMS2091J06; Pharmakon1600-01500435; ACT07882; HY-B0945; ZINC1690424; Tox21_111321; 5264AH; CCG-39929; MFCD00007985; NSC-60719; NSC757245; SBB057213; AKOS001434379; Tox21_111321_1; MCULE-9213012419; NSC-757245; TRA0037962; VZ25861; IDI1_000813; UPCMLD0ENAT5895628:001; NCGC00094736-02; NCGC00094736-03; NCGC00094736-05; AS-57407; LS-26754; NCI60_004694; SC-47147; SMR001306736; SBI-0051459.P003; AB0004874; DB-022109; TC-169911; FT-0614715; ST50308244; Nitromide, VETRANAL(TM), analytical standard; A-8855; D05191; AB00052054_04; A804791; J-004683; SR-05000002028-1; SR-05000002028-3; BRD-K76381435-001-02-9; BRD-K76381435-001-04-5; Q27272407; InChI=1/C7H5N3O5/c8-7(11)4-1-5(9(12)13)3-6(2-4)10(14)15/h1-3H,(H2,8,11);",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C7H5N3O5",
"molecular_weight": "211.13",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "4511",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02039",
"RC02660",
"RC03281"
]
},
{
"compound_ID": "D1018",
"name": "nitrovin",
"synonyms": "NITROVIN; Difurazone; 804-36-4; Nitrovin [BAN]; 2-(1,5-Bis(5-nitrofuran-2-yl)penta-1,4-dien-3-ylidene)hydrazinecarboximidamide; CHEBI:82516; Nitrovin (BAN); Panazon; W-104235; EINECS 212-358-7; BRN 4827520; ((3-(5-Nitro-2-furyl)-1-(2-(5-nitro-2-furyl)vinyl)allylidene)amino)guanidine; Bis(5-nitrofurfurylidene)acetone guanylhydrazone; sym-Bis(5-nitro-2-furfurylidene) acetone guanylhydrazone; 1,5-Bis(5-nitro-2-furyl)-3-pentadienone amidinonhydrazone; 1,5-Bis(5-nitro-2-furyl)-3-pentadienone guanylhydrazone; Difurazon; 1,5-Bis(5-nitro-2-furanyl)-1,4-pentadien-3-one, (aminoiminomethyl)hydrazone; 1-(3-(5-Nitro-2-furyl)-1-(2-(5-nitro-2-furyl)vinyl)allylideneamino)guanidine hydrochloride; 2-[[(1E,4E)-1,5-bis(5-nitrofuran-2-yl)penta-1,4-dien-3-ylidene]amino]guanidine; C14H12N6O6; NCGC00181330-01; Nitrovin (TN); Hydrazinecarboximidamide, 2-(3-(5-nitro-2-furanyl)-1-(2-(5-nitro-2-furanyl)ethenyl)-2-propenylidene)-; Bis(2-(5-nitro-2-furyl)vinyl)methylenehydrazinoformamidine; SCHEMBL440144; CHEMBL1395447; SCHEMBL17975315; Guanidine, ((3-(5-nitro-2-furyl)-1-(2-(5-nitro-2-furyl)vinyl)allylidene)amino)-; ZINC8767800; AKOS015895949; AS-56265; LS-73832; AX8144918; C19487; D02534; 804N364; A839910; Q6043358; 1,5-bis(5-Nitro-2-furyl)-3-pentadienoneamidinonhydrazone; 2-[[(1E,4E)-1,5-bis(5-nitro-2-furanyl)penta-1,4-dien-3-ylidene]amino]guanidine; {(3E)-2-[(1E)-2-(5-Nitro(2-furyl))vinyl]-1-aza-4-(5-nitro(2-furyl))buta-1,3-dienyl}aminocarboxamidine; 1-[[(E)-3-(5-nitro-2-furyl)-1-[(E)-2-(5-nitro-2-furyl)vinyl]prop-2-enylidene]amino]guanidine;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C14H12N6O6",
"molecular_weight": "360.28",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "6252910",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02040",
"RC02661",
"RC03282"
]
},
{
"compound_ID": "D1019",
"name": "nitroxoline",
"synonyms": "NITROXOLINE; 5-nitroquinolin-8-ol; 4008-48-4; 8-Hydroxy-5-nitroquinoline; 5-Nitro-8-hydroxyquinoline; 5-Nitro-8-quinolinol; Nitroxolin; 5-Nitrox; Noxibiol; 8-Quinolinol, 5-nitro-; 5-Nitroxine; 5-Nitroks; 5-NOK; Nibiol; Noxin; 5-Nitro-8-oxyquinoline; 5NOK; Nitroxolinum; 5-Nitro-8-oxychinoline; Nitroxolina; Galinok; Isinok; Nicene Forte; Nitroxolinum [INN-Latin]; Nitroxolina [INN-Spanish]; Uro-Coli; A-82; BAS 58; NSC 74947; Nitroxoline [INN:BAN:DCF]; MLS000069750; UNII-A8M33244M6; EINECS 223-662-4; BRN 0166146; SMR000059036; CHEBI:67121; RJIWZDNTCBHXAL-UHFFFAOYSA-N; MFCD00006791; A8M33244M6; NCGC00160664-01; DSSTox_CID_26284; DSSTox_RID_81510; DSSTox_GSID_46284; Notroxoline; CAS-4008-48-4; Nitroxoline (TN); HNQ; Nitrohydroxyquinoline; Nitroxoline (INN); PubChem7565; 3ai8; 5-Nitroquinoline-8-ol; ACMC-209jar; Opera_ID_204; 5-Nitro-quinolin-8-ol; 5-Nitro-8hydroxyquinoline; Quinolin-8-ol, 5-nitro-; Oprea1_594857; 8-Hydroxy-5-nitro-chinoline; 5-21-03-00297 (Beilstein Handbook Reference); cid_19910; MLS001148594; SCHEMBL151248; REGID_for_CID_19910; 5-Nitroquinolin-8-ol, 96%; WLN: T66 BNJ GNW JQ; CHEMBL1454910; DTXSID4046284; BDBM64987; CTK1D5867; HMS2230I14; HMS3264C05; HMS3374D08; KUC105356N; Pharmakon1600-01506173; 8-Hydroxy-5-nitroquinoline, 96%; HY-B1159; NSC74947; Tox21_111969; ANW-29281; BBL023366; KSC-8-140; NSC-74947; NSC760393; s4591; SBB037944; STK099582; ZINC15831592; AKOS001053242; Tox21_111969_1; AC-7828; CCG-213981; CS-4761; DB01422; LS20671; MCULE-8622459990; NSC-760393; PS-5547; RTR-015997; VQ10269; NCGC00160664-03; SC-04243; ST086486; AB0010831; AB1003427; DB-049530; LS-142569; TR-015997; A6696; FT-0621541; ST24029546; T7793; 08N484; D07245; 5-Nitro-8-quinolinol|5-Nitro-8-hydroxyquinoline; AB00572598_14; AG-205/04556035; Q304570; SR-01000721863; SR-01000721863-4; W-106391; Z56922155; InChI=1/C9H6N2O3/c12-8-4-3-7(11(13)14)6-2-1-5-10-9(6)8/h1-5,12;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C9H6N2O3",
"molecular_weight": "190.16",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "19910",
"classification": "J",
"indications": "",
"side_effects": "",
"atc_codes": "J01XX07",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02041",
"RC02662",
"RC03283"
]
},
{
"compound_ID": "D1020",
"name": "n-methyl-n,n-dioctyloctan-1-aminium chloride",
"synonyms": "Methyltrioctylammonium chloride; 5137-55-3; Aliquat 336; Trioctylmethylammonium chloride; Methyltricaprylylammonium chloride; TOMAC; 63393-96-4; Capriquat; Tricaprylmethylammonium chloride; Methyl trioctyl ammonium chloride; Trioctyl methyl ammonium chloride; Adogen(R) 464; Tricaprylylmethylammonium chloride; N-Methyl-N,N-dioctyloctan-1-aminium chloride; Methyltri-n-octylammonium Chloride; Trioctylmonomethylammonium chloride; N-Methyl-N,N-dioctyl-1-octanaminium chloride; 1-Octanaminium, N-methyl-N,N-dioctyl-, chloride; UNII-07Q8S2MJ6A; aliquat-336; Tricaprylyl methyl ammonium chloride; EINECS 225-896-2; NSC 61369; methyltrioctylammoniumchloride; AMMONIUM, METHYLTRIOCTYL-, CHLORIDE; 07Q8S2MJ6A; trioctylmethyl ammonium chloride; CHEBI:75286; Tri-n-octylmethylammonium Chloride; methyltrioctylamine, chloride; 1-Octanaminium, N-methyl-N,N-dioctyl-, chloride (1:1); Adogen 464; Aliquat(R) 336; Starks catalyst; methyl(trioctyl)azanium chloride; Aliquart 336; AliquatTM 336; Adogen-464; methyl-trioctyl-azanium; ACMC-1BKYG; trioctylmethylammoniumchloride; DSSTox_CID_24487; DSSTox_RID_80263; DSSTox_GSID_44487; N-METHYL-N, CHLORIDE; KSC491C0D; SCHEMBL108549; methyl trioctylammonium chloride; methyl-trioctylammonium chloride; trioctyl methylammonium chloride; tricapryl-methylammonium chloride; CHEMBL3188519; DTXSID1044487; methyl(trioctyl)ammonium chloride; methyl-tri-octylammonium chloride; CTK3J1101; methyl -trioctyl-ammonium chloride; XKBGEWXEAPTVCK-UHFFFAOYSA-M; KS-000001ZE; NSC61369; Tox21_302198; 1-Octanaminium,N-dioctyl-, chloride; ANW-31248; MFCD00011862; NSC-61369; SBB073021; WLN: 8K8&8&1 &G; AKOS015902686; CS-W020733; MCULE-4914333032; RTR-018303; TRA0068610; NCGC00255776-01; AK308459; CS-17393; DA-17487; LS-18704; N-methyl-N,N-dioctyl octanaminiumchloride; SC-26883; SC-91616; CAS-5137-55-3; AB1001993; DB-050397; TR-018303; FT-0621928; FT-0635557; ST45255433; 74350-EP2298828A1; 74350-EP2308857A1; 93810-EP2305625A1; Methyltrioctylammonium chloride, >=97.0% (AT); N--methyl-N,N--dioctyl-1-octanaminium chloride; 102055-EP2275469A1; 102055-EP2289965A1; 102055-EP2301983A1; A828561; C-36719; Q4726852; F0001-1342; Tricaprylylmethylammonium chloride, mixture of C8-C10 C8 is dominant;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C25H54ClN",
"molecular_weight": "404.2",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "21218",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02042",
"RC02663",
"RC03284"
]
},
{
"compound_ID": "D1021",
"name": "n-nitroso-n-methyl-4-nitroaniline",
"synonyms": "N-Nitroso-N-methyl-4-nitroaniline; N-methyl-4-nitro-N-nitrosoaniline; 943-41-9; N-Methyl-p-nitro-N-nitrosoaniline; N-Methyl-4-nitro-N-nitrosobenzenamine; NSC 528438; BRN 0912232; Benzenamine, N-methyl-4-nitro-N-nitroso-; ANILINE, N-METHYL-p-NITRO-N-NITROSO-; C7H7N3O3; NSC528438; DSSTox_CID_1002; DSSTox_RID_75908; DSSTox_GSID_21002; SCHEMBL8290211; CHEMBL3186468; DTXSID4021002; CTK5H6425; AMTRFSFECFPSHF-UHFFFAOYSA-N; 4-Nitro-N-methyl-N-nitrosoaniline; ZINC5319600; 4-nitro-N-nitroso-N-methyl-aniline; Tox21_302256; AKOS006272805; LS-7574; MCULE-3006954232; NSC-528438; Benzenamine,n-methyl-4-nitro-n-nitroso-; NCGC00255212-01; CAS-943-41-9; DS-006657; Benzenamine, N-methyl-4-nitro-N-nitroso- (9CI); 1-METHYL-1-(4-NITROPHENYL)-2-OXOHYDRAZINE;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C7H7N3O3",
"molecular_weight": "181.15",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "13671",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02043",
"RC02664",
"RC03285"
]
},
{
"compound_ID": "D1022",
"name": "nocodazole",
"synonyms": "nocodazole; 31430-18-9; Oncodazole; R 17934; Nocodazolum; Nocidazole; Nocodazol; NSC 238159; C14H11N3O3S; Nocodazole [USAN:INN]; Nocodazol [INN-Spanish]; Nocodazolum [INN-Latin]; R 17,934; UNII-SH1WY3R615; Methyl 5-(2-thenoyl)-2-benzimidazolecarbamate; Methyl N-(5-thenoyl-2-benzimidazolyl)carbamate; R17934; NSC-238159; Methyl [5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]carbamate; R-17934; Methyl N-[6-(thiophene-2-carbonyl)-1H-benzimidazol-2-yl]carbamate; EINECS 250-626-5; N-(5-(2-Thenoyl)-2-benzimidazolyl)carbamic acid methyl ester; NSC238159; Methyl (5-(2-thienylcarbonyl))-1H-benzimidazole-2-ylcarbamate; 2-Benzimidazolecarbamic acid, 5-(2-thienylcarbonyl)-, methyl ester; methyl (5-(thiophene-2-carbonyl)-1H-benzo[d]imidazol-2-yl)carbamate; NSC 238 159; CHEMBL9514; MLS001164242; SH1WY3R615; 2-Benzimidazolecarbamic acid, 5-(2-thenoyl)-, methyl ester; CHEBI:34892; Methyl (5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl)carbamate; Nocodazole, 98%; Carbamic acid, (5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl)-, methyl ester; API0003615; NCGC00015647-05; SMR000326904; CAS-31430-18-9; [5-(2-Thienylcarbonyl)-1H-benzimidazol-2-yl]-carbamic acid methyl ester; Carbamic acid, (5-(2-thienylcarbonyl)-1H-benzimidazole-2-yl)-, methyl ester; Carbamic acid, [5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]-, methyl ester; Methyl 5-(2-thienoyl)-2-benzimidazolecarbamate; DSSTox_CID_11800; DSSTox_RID_78890; DSSTox_GSID_31800; W-202288; 2-Benzimidazolecarbamic acid, 5-(2-thienoyl)-, methyl ester; Methyl [5-(2-thienylcarbonyl)-1H- benzimidazol-2-yl]carbamate; methyl [6-(thiophen-2-ylcarbonyl)-1H-benzimidazol-2-yl]carbamate; N-(5-(2-Thienoyl)-2-benzimidazolyl)carbamic acid methyl ester; SR-01000075979; Nococazole; Methyl(5-(2-thienylcarbonyl))-1H-benzimidazole-2-yl carbamate; Methyl[5-(2-thienylcarbonyl)]-1H-benzimidazole-2-yl carbamate; N-[5-(2-Thenoyl)-2-benzimidazolyl]carbamic acid methyl ester; N-[5-(2-Thienoyl)-2-benzimidazolyl]carbamic acid methyl ester; (5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl)-carbamic acid methyl ester; Carbamic acid, (5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl)-, methyl ester (9CI); Carbamic acid, [5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]-, methyl ester (9CI); NZO; Prestwick_359; Tocris-1228; 3ee2; Nocodazole (USAN/INN); Prestwick0_000100; Prestwick1_000100; Prestwick2_000100; Prestwick3_000100; Spectrum3_001768; Spectrum4_001060; Lopac-M-1404; ChemDiv1_000089; Probes1_000012; Probes1_000176; Probes2_000086; Probes2_000148; UPCMLD-DP111; Cambridge id 5175348; cid_4122; SCHEMBL9477; Lopac0_000733; Oprea1_483899; Oprea1_741554; BSPBio_000060; BSPBio_000982; BSPBio_003235; CBDivE_004971; CBDivE_008428; KBioGR_000322; KBioGR_001360; KBioSS_000322; MLS000860046; BIDD:GT0494; SPECTRUM1503266; SPBio_001999; BPBio1_000066; DTXSID9031800; UPCMLD-DP111:001; BCBcMAP01_000161; BDBM97233; CTK8G1974; HMS587E01; KBio2_000322; KBio2_002890; KBio2_005458; KBio3_000643; KBio3_000644; KBio3_002735; ZINC56509; AOB6196; KYRVNWMVYQXFEU-UHFFFAOYSA-N; Bio1_000461; Bio1_000950; Bio1_001439; Bio2_000331; Bio2_000811; HMS1362B03; HMS1568C22; HMS1792B03; HMS1922O09; HMS1990B03; HMS2094G13; HMS2095C22; HMS2235E18; HMS3262C08; HMS3267F03; HMS3403B03; HMS3412A10; HMS3604E13; HMS3656J06; HMS3676A10; HMS3712C22; Pharmakon1600-01503266; BCP07558; KS-00000XH0; Methyl-[5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]-carbamate; Tox21_110189; Tox21_500733; 2593AH; BN0389; GP8428; MFCD00005588; NSC759882; s2775; STK832483; Nocodazole, >=99% (TLC), powder; AKOS000538825; AKOS015901529; Tox21_110189_1; CCG-101240; CCG-208075; CP-0076; CS-1893; DB08313; LP00733; LS-1178; MCULE-3133043736; NSC-759882; SB19455; IDI1_002086; QTL1_000062; SMP2_000261; NCGC00015647-01; NCGC00015647-02; NCGC00015647-03; NCGC00015647-04; NCGC00015647-06; NCGC00015647-07; NCGC00015647-08; NCGC00015647-09; NCGC00015647-10; NCGC00015647-11; NCGC00015647-12; NCGC00015647-13; NCGC00015647-14; NCGC00015647-15; NCGC00015647-18; NCGC00025058-01; NCGC00025058-02; NCGC00025058-03; NCGC00025058-04; NCGC00025058-05; NCGC00025058-06; NCGC00025058-07; NCGC00025058-08; NCGC00025058-09; NCGC00025058-10; NCGC00261418-01; AC-25615; AK326024; AM807900; HY-13520; NCI60_001911; SC-21129; ST078193; SBI-0050711.P002; AB0109635; EU-0100733; FT-0660415; SW102861-5; C13719; D05197; M 1404; R17,934; Q2506092; SR-01000075979-1; SR-01000075979-3; SR-01000075979-6; SR-01000075979-9; BRD-K12539581-001-06-2; BRD-K12539581-001-14-6; methoxy-N-[6-(2-thienylcarbonyl)benzimidazol-2-yl]carboxamide; methyl 6-(thien-2-ylcarbonyl)-1H-benzimidazol-2-ylcarbamate; 2-Benzimidazolecarbamic acid, 5-(2-thenoyl)-, methyl ester (8CI); methyl N-(6-thiophen-2-ylcarbonyl-1H-benzimidazol-2-yl)carbamate; methyl N-[5-(thiophene-2-carbonyl)-1H-benzimidazol-2-yl]carbamate; N-[6-(2-thenoyl)-1H-benzimidazol-2-yl]carbamic acid methyl ester; [[5-(2-Thienylcarbonyl)-1H-benzimidazol-2-yl]]carbamic acid methyl ester; [5-(2-Thienylcarbonyl)-1H-benzimidazol-2-yl]carbonic acid, methyl ester; carbamic acid, [6-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]-, methyl ester; Carbamic acid, N-[5-(2-thenoyl)-1H-benzimidazol-2-yl]-, methyl ester; methyl (6-(thiophene-2-carbonyl)-1H-benzo[d]imidazol-2-yl)carbamate; [5-(Thiophene-2-carbonyl)-1H-benzoimidazol-2-yl]-carbamic acid methyl ester; Carbamic acid, N-[6-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]-, methyl ester; N-[6-[oxo(thiophen-2-yl)methyl]-1H-benzimidazol-2-yl]carbamic acid methyl ester;",
"trade_name": "",
"abbrev_name": "",
"description": "antineoplastic agent; prevents microtubule polymerization; synthetic tubulin-binding agent; Nocodazole is frequently used in cell biology laboratories to synchronize the cell division cycle(arrest with a G2- or M-phase DNA content )",
"molecular_formula": "C14H11N3O3S",
"molecular_weight": "301.32",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "4122",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0108",
"F0703"
],
"references": [
"RC02044",
"RC02665",
"RC03286",
"RC03789"
]
},
{
"compound_ID": "D1023",
"name": "nonylparaben",
"synonyms": "Nonyl 4-hydroxybenzoate; 38713-56-3; Nonylparaben; Nonyl p-hydroxybenzoate; 4-HYDROXYBENZOIC ACID N-NONYL ESTER; 4-Hydroxybenzoic Acid Nonyl Ester; Benzoic acid,4-hydroxy-, nonyl ester; Benzoic acid, 4-hydroxy-, nonyl ester; Nonyl4-Hydroxybenzoate; ACMC-209j1n; Nonyl 4-hydroxybenzoate #; DSSTox_CID_27861; DSSTox_RID_82614; DSSTox_GSID_47885; SCHEMBL187991; CHEMBL2271362; DTXSID9047885; CTK4I0366; MBNSKHJDYXPONL-UHFFFAOYSA-N; p-Hydroxybenzoic acid n-nonyl ester; ZINC2566003; Tox21_200548; ANW-28953; ACM38713563; KS-000013T7; NCGC00248693-01; NCGC00258102-01; AS-57964; AX8097875; CAS-38713-56-3; TC-117698; FT-0757780; C-52778;",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C16H24O3",
"molecular_weight": "264.36",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "586708",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02045",
"RC02666",
"RC03287"
]
},
{
"compound_ID": "D1024",
"name": "norelgestromin",
"synonyms": "Norelgestromin; Norgestimate metabolite Norelgestromin; 53016-31-2; Evra; Ortho Evra; RWJ-10553; Deacetylnorgestimate; 17-Desacetyl Norgestimate; NCGC00168787-01; DSSTox_CID_26788; DSSTox_RID_81906; Norelgestromin (USAN/INN); DSSTox_GSID_46788; SCHEMBL3163347; CHEMBL1200807; DTXSID9046788; CHEBI:135398; HY-G0018; Tox21_112647; 3046AH; BDBM50103633; AKOS015917579; NCGC00485891-01; CAS-53016-31-2; 17-Deacetyl norgestimate;17-Deacylnorgestimate; D05205; DEACETYLNORGESTIMATE (25 MG) ((E)- AND (Z)-17-DEACETYL NORGESTIMATE MIXTURE);",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C21H29NO2",
"molecular_weight": "327.5",
"state": "solid",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "9568628",
"classification": "G",
"indications": "",
"side_effects": "",
"atc_codes": "G03AA13",
"group": "Drug",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02046",
"RC02667",
"RC03288"
]
},
{
"compound_ID": "D1025",
"name": "noristerat",
"synonyms": "Norethisterone enanthate; 3836-23-5; Noristerat; Norethisterone enantate; NORETHINDRONE ENANTHATE; Norethisterone oenanthate; Norlutin enanthate; UNII-HY3S2K0J0F; Norigest; SH 393; HY3S2K0J0F; Sovel; 17alpha-Ethynyl-19-nortestosterone enanthate; CHEBI:34894; 17alpha-Ethynyl-17beta-heptanoyloxy-4-estren-3-one; CCRIS 6526; NEE; NSC 9564; EINECS 223-326-7; LG 202; BRN 3176529; 17alpha-Ethinyl-19-nortestosterone enanthate; 17-alpha-Ethinyl-19-nortestosterone enanthate; 17alpha-Ethynyl-19-nortestosterone 17-heptanoate; 17-alpha-Ethynyl-17-beta-heptanoyloxy-4-estren-3-one; 17-beta-Heptanoyloxy-17-alpha-ethynyl-4-oestren-3-one; 19-nor-17alpha-Pregnen-20-ynone, 17beta-heptanoyloxy-; 3-oxo-19-nor-17alpha-pregn-4-en-20-in-17-yl-heptanot; 19-Nor-17alpha-pregn-4-en-20-yn-3-one, 17-hydroxy-, heptanate; Noristerat (TN); NCGC00182712-01; norethindrone heptanoate; norethisterone enantate;; 19-Nor-17-alpha-pregnen-20-ynone, 17-beta-heptanoyloxy-; DSSTox_CID_28590; DSSTox_RID_82861; DSSTox_GSID_48664; [(8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] heptanoate; SCHEMBL354296; (17alpha)-17-((1-Oxoheptyl)oxy)-19-norpregn-4-en-20-yn-3-one; CHEMBL3187229; DTXSID2048664; BCP10922; EBD15536; NSC22846; ZINC4217172; Tox21_113027; NSC-22846; s6589; AKOS015896289; AC-6835; DB14678; AS-13385; I041; CAS-3836-23-5; ST24048794; 17.alpha.-Ethinyl-19-nortestosterone enanthate; 17.alpha.-Ethynyl-19-nortestosterone enanthate; C14486; D08285; Norethisterone Enantate (Norethindrone Enanthate); 836N235; 17.alpha.-Ethynyl-19-nortestosterone 17-heptanoate; Q7050956; WLN: L E5 B666 OV MUTJ E1 FOV6 F1UU1; 19-Nor-17.alpha.-pregn-4-en-20-yn-3-one, heptanate; 19-Nor-17.alpha.-pregn-4-en-20-yn-3-one, heptanoate; 17.alpha.-Ethynyl-17.beta.-heptanoyloxy-4-estren-3-one; 19-nor-17.alpha.-Pregnen-20-ynone, 17.beta.-heptanoyloxy-; 19-Nor-17alpha-pregn-4-en-20-yn-3-one, 17-hydroxy-, heptanoate (8CI); 19-Norpregn-4-en-20-yn-3-one, 17-[(1-oxoheptyl)oxy]-, (17a)-; 19-Norpregn-4-en-20-yn-3-one, 17-((1-oxoheptyl)oxy)-, (17alpha)- (9CI);",
"trade_name": "",
"abbrev_name": "",
"description": "",
"molecular_formula": "C27H38O3",
"molecular_weight": "410.6",
"state": "",
"clearance": "",
"volume_of_distribution": "",
"route_of_elimination": "",
"protein_binding": "",
"half_life": "",
"absorption": "",
"cid": "229295",
"classification": "Others",
"indications": "",
"side_effects": "",
"atc_codes": "",
"group": "Compound",
"drug_type": "",
"target": [],
"function": [
"F0108"
],
"references": [
"RC02047",
"RC02668",
"RC03289"
]
}
]
}
